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Abstract    I 
 
 
 
Abstract 
Latent membrane proteins (LMP) 2A and LMP2B are expressed in a wide variety of Epstein-
Barr virus (EBV) associated malignancies. The exact function of the proteins remains to be 
elucidated although it has been shown that in B-cells, LMP2A functions as a surrogate B-cell 
receptor, preventing BCR signalling to ensure persistence of viral latency. Less is known about 
the function of both proteins in epithelial cells but they have been shown to modulate 
signalling through MAPK, PI3K and Akt, to promote cell motility and to alter the turnover of 
certain classes of immunogenic receptors. Upon viral infection of a host cell the innate immune 
system is activated to promote and sustain initiation of an anti-viral state. Viruses have 
developed immune evasion strategies to counteract the effects of this immune response and 
also to prevent recognition of viral antigens by the adaptive response. Here novel functions are 
described for LMP2A and LMP2B in modulation of innate immunity, which have implications 
for the role of these proteins in contributing to oncogenesis. The first wave of the innate 
immune response is mediated by Toll-like receptor (TLR) signalling that initialises the type I 
interferon response. Findings presented here display attenuation of signalling from these 
receptors upon expression of LMP2A. These data were observed only in LMP2A expressing 
cells while those expressing LMP2B showed little or no alteration of the TLR signalling 
network, indicating that these functions are controlled by the unique N-terminal signalling 
domain of LMP2A. Examination of the putative role of LMP2A and LMP2B in intra-cellular 
traffic was also undertaken and revealed a shared role for both proteins in increasing 
endosomal-lysosomal trafficking and lysosomal acidification, important for degradation and 
turnover of receptors. These data present novel mechanisms by which EBV may evade 
immune responses and in doing so, contribute to the progression of the EBV-associated 
epithelial cell malignancy, NPC. 
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MPV Murine papillomavirus 
MuV Mumps virus 
MVB Multivesicular body 
MVE Multivesicular endosome 
MYXV Myxoma virus 
NBP1 Nef binding protein 1 
NDV Newcastle disease virus 
NEMO NFκB essential modifier 
NFKB Nuclear factor kappa B 
NiV Nipah virus 
NK Natural Killer 
NLPHL Nodular lymphocyte-predominant Hodgkins lymphoma  
NPC Nasopharyngeal carcinoma 
NPC1 Niemann-Pick disease protein 1 
OHL Oral hairy leukoplakia 
OV Orf virus 
PCR Polymerase Chain Reaction 
PI3K Phophoinositide 3 kinase 
PI3P Phosphatidylinositol 3-phosphate 
PKC Protein Kinase C 
PKR Protein Kinase Receptor 
PML Promyelocytic leukaemia  
PRD Positive Regulatory Domain 
PRR Pattern Recognition Receptor 
PTLD Post-transplant lymphoproliferative disorder 
RABV Rabies Virus 
Abbreviation   _ 
RBP-JK Recombination Signal-Binding protein J kappa 
RE Recycling endosome 
RIG1 Retinoic acid inducible gene 1 
RIP1 Receptor interacting protein 1 
RLH RIG-1 like helicases 
RPV Rinderpest virus 
RSV Respiratory syncytial virus 
RTK Receptor tyrosine kinases 
SeV Sendai Virus 
SH2 Src homology 2 
SNARES Soluble NSF Attachment Protein Receptors 
SOCS Suppressors of Cytokine Signalling 
STAT Signalling Transducers and Activators of Transcription 
SV40 Simian virus 40 
TAB TAK1 binding protein 
TAK Tat-associated kinase 
TANK TRAF family member associated NFκB activator 
TBK TANK-binding kinase 
TCR T-cell Receptor 
TERT Telomerase Reverse Transcriptase 
TGFB Transforming growth factor beta 
TGN Trans-Golgi Network 
THOV Thogoto virus 
TIR Toll/IL-1 receptor 
TLR Toll-like receptor 
TNF-R Tumour Necrosis Factor Receptor 
TR Terminal Repeat 
TRADD 
Tumor necrosis factor receptor type 1-associated death 
domain 
TRAF TNF receptor associated factor 
TRAM TRIF-related adapter molecule 
TRIF TIR domain containing adaptor inducing IFNβ 
TTV TT virus 
TYK Tyrosine kinase 
VACV Vaccina virus 
VCA Viral capsid antigen 
VSV Vesicular stomatatis virys 
VZV Varicella Zoster Virus 
XAP-1 X associated protein 1 
XLA X-Linked Agammaglobulinemia 
XLP X-linked lymphoproliferative syndrome  
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       CHAPTER 1 
INTRODUCTION 
1.1 Biology of Cancer 
Cancer accounted for 7.9 million or 13% of worldwide deaths in 2007 and it is 
estimated that 30% of all cancer is preventable (WHO). Cancer is a complex multi-step group 
of diseases, characterised by progression or regression of cell types, many of which have 
unique pathogenesis, aetiology and treatment prognosis. Ten years ago, Hanahan and 
Weinberg (Hanahan and Weinberg 2000), attempted to simplify the transformation of normal 
cells into malignant cancers in a robust “six-hit” model, which reflected the common cellular 
machinery used across all cell types to control, cell differentiation, growth and death.  
 These six hallmarks represent tenets of the transformation to the malignant state and it 
is understood that mechanisms controlling progression towards malignancy can be, and are, 
vastly different between different tumour types. Briefly the hallmarks include, self-sufficiency 
in growth stimulation, resistance or insensitivity to anti-growth signals, evasion of apoptosis, 
unlimited proliferative potential, localised angiogenesis and tissue invasion or metastasis 
(Hanahan and Weinberg 2000).  Accumulation of abnormal genetic and epigenetic signals that 
control these areas of the cellular life-cycle results in progression to a malignant phenotype, 
with tumours displaying most, if not all of these hallmarks. These genetic anomalies can be the 
result of errors in DNA replication during cell division or inherited mutations. Environmental 
factors, including exposure to carcinogens, have also been shown to play a role in development 
of these mutations and an increase in human proximity and exposure to such agents has been 
postulated to account for increases in cancer incidence (Belpomme, Irigaray et al. 2007; 
Irigaray, Newby et al. 2007). Environmental carcinogens include forms of radiation, (UV, 
pulsed electromagnetic fields and radioactivity), chemicals (benzene) and microorganisms 
 1
Chapter 1    Introduction 
 
 
(bacteria and viruses). Lifestyle choices such as bad diet, lack of exercise, smoking and alcohol 
consumption are other risk factors associated with cancer.  
 
1.2 Viruses and cancer 
The International Agency for research on cancer (IARC) estimates that approximately 
15% of cancer worldwide have a viral aetiology (Liao 2006). Historically the association of 
viral particles with malignancy and disease is well characterised: M’Faydean and Hobday 
described the cell free transmission of oral dog warts with cell free extracts in 1898 
(M'Faydean and Hodbay 1898). Human warts showed similar transmission capabilities (Ciuffo 
1907). In 1910, Peyton Rous described the transmission capabilities of Rous sarcoma in 
chickens (Rous 1910). It wasn’t until 1958 when Denis Burkitt described a novel West African 
endemic tumour known as Burkitt’s Lymphoma (BL) (Burkitt 1958), that the possibilities of a 
transmissible agent in human disease emerged. A transmissible herpesvirus-like particle was 
isolated from BL biopsies by Anthony Epstein, Bert Achong, and Yvonne Barr (Epstein, 
Achong et al. 1964), and was identified as Epstein-Barr virus (EBV), the first virus to be 
associated with a human tumour.  
The association between a virus and a given cancer cannot be readily assumed and various 
criteria have been suggested to allow clearer delineation of this relationship. In 1965, Hill 
described the criteria he thought necessary for a causative association to be placed between the 
environment and cancer. Briefly this included: strength of the association; consistency; 
specificity of association; temporal relevance; biological product; biological plausibility; 
coherence and experimental evidence (Hill 1965). More specifically tailored to viral 
association with cancer were the criteria set down by Evans and Mueller in 1990 (Evans and 
Mueller 1990), which were spilt into two sections, one comprising the epidemiological 
elements of the association and the other the virological. With respect to epidemiology, that the 
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geographical distribution of the tumour is the same as the virus, that viral markers are 
increased in cases compared to matched controls, that these markers precede tumour 
development and that there is a higher incidence of tumours with markers. Finally that tumour 
incidence decreases by prevention of viral infection. In terms of virology it must be shown that 
the virus can transform cells in vitro, that the viral genome is present in tumour and not in 
normal controls and that virus-induced tumours can be recapitulated in an experimental model 
(McLaughlin-Drubin and Munger 2008). 
More recently, zur Hausen put forward four criteria to enable establishment of a causal role 
for infection in cancer as opposed to an association between virus and malignancy (zur Hausen 
1999). These include plausibility and evidence that an infection is a risk factor for tumour 
development, presence and persistence of the genome of the microbe in cells of the tumour, the 
stimulation of cell proliferation in tissue culture cells by the viral genome in vitro, and 
induction of proliferation and phenotypic changes (Damania 2006). These criteria give an 
insight into the difficulty of definitively establishing causal links between infecting viruses and 
malignancy. 
 Thus far, members of three families of double stranded DNA viruses, the 
Hepadnaviridae, Herpesviridae and Papillomaviridae, and also members of two families of 
RNA viruses, the Flaviviridae and Retroviridae, have been identified as tumour viruses and the 
relationships described above are well established. Members from three additional families 
have been implicated as having the potential for oncogenic transformation and these include 
the Circoviridae, Polyomaviridae and additional members of the Retroviridae. In these cases, 
research is ongoing to increases the strength of association between viral infection and 
malignancy.  
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1.2.1  Hepadnavirinae 
Hepatitis B virus (HBV) is associated with non-malignant hepatitis, cirrhosis and 
heptocellular carcinoma (HCC), which exhibits a 60-90% association in adults and 100% 
association in children (McLaughlin-Drubin and Munger 2008). HBV is a partially double 
stranded DNA virus with four identified open reading frames and respective proteins, C, P, S 
and X (Dayaram and Marriott 2008). HBVx protein is the major transforming viral oncoprotein 
and has been shown to exert its effects via proteasomal degradation, disruption of the activator 
protein 1 (AP-1) transcription factor (Masucci 2004), distortion of centriole formation and 
XAP-1-mediated DNA repair (de Oliveira 2007). HBV is a prime example of the efficacy of 
immunisation against a virus causing a marked decrease in both chronic carrier rates and 
incidence of the associated malignancy (Ni, Chang et al. 2001; Chang 2009).  
  
1.2.2  Papillomaviridae 
Human papilloma virus (HPV) is a non-enveloped double stranded DNA virus with 
around 100 types. Different types have been associated with both mucosal and cutaneous 
lesions with varying associated risk of malignancy. HPV 5 and 8 are associated with high-risk 
cutaneous skin cancers, in patients with the autosomal recessive disorder, Epidermodysplasia 
verruciformis (EV) (McLaughlin-Drubin and Munger 2008). Low risk viruses associated with 
non-malignant mucosal disease, e.g. genital warts, include HPV 6 and 11. HPV 16 and 18 are 
high-risk viruses that are commonly associated with squamous intraepithelial lesions such as 
cervical intraepithelial neoplasia, (CIN) and invasive cervical cancer (de Oliveira 2007). 
HPV16 proteins E6 and E7 have been shown to have oncogenic potential and can transform 
infected keratinocytes and are more effective when co-expressed than when expressed alone 
(Dayaram and Marriott 2008). E6 has been shown to disrupt growth by inducing p53 
degradation and cell immortalisation via upregultaion of hTERT (de Oliveira 2007). E7 has 
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been shown to interact with the pRb family of proteins and modulates E2F regulated cell 
growth (Damania 2006). A vaccine is now available against the L1 capsid protein and affords 
protection against both high-risk HPV16 and HPV18, where infection is associated with 70% 
of all cervical cancers. It remains to be seen whether vaccination programmes can reduce 
incidence of cervical cancer, (Galani and Christodoulou 2009).  
 
1.2.3  Retroviridae 
Human T lymphtrophic virus-1 (HTLV-1) is a delta type complex retrovirus that is 
associated with adult T cell leukaemia (ATL) (Dayaram and Marriott 2008). It has been studied 
extensively in Japanese populations where it was first discovered in the late seventies. It is 
estimated that 10-20 million people are infected by the retrovirus with only 5% developing 
disease (Liao 2006), including tropic spastic paraperesis. It is endemic in Japan, South Africa 
and parts of the Caribbean. Tax is the major oncogenic protein of the virus and is shown to act 
via mechanisms including ubiquitin reprogramming (Rousset, Desbois et al. 1996) interacting 
with p300/CBP to inactivate p53 and alteration of chromosomal segregation via TAXIBP2 and 
RANBP1 (McLaughlin-Drubin and Munger 2008).  
 
1.2.4  Flaviviridae 
Hepatitis C virus (HCV), is an enveloped single stranded RNA virus with a genome of 
9.4kb coding for approximately 9 open reading frames. HCV is causally linked to hepatitis, 
cirrhosis and malignant HCC (McLaughlin-Drubin and Munger 2008). It is estimated the 3% 
of the population is infected with the virus, for which there is no vaccine due to its highly 
mutagenic nature (Liao 2006). It establishes a persistent lifelong infection in its host and 
evades the immune system through a variety of mechanisms including PKR receptor 
inactivation by viral proteins E2 and NS3 (McLaughlin-Drubin and Munger 2008).   
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1.2.5  Viruses with oncogenic potential 
A variety of viruses have been identified that have been implicated in malignant 
transformation. These include members of the double stranded DNA Polyomoviridae, BK virus 
(BKV) associated with prostate cancer, JC virus (JCV) with brain tumours (Damania 2006) 
and merkel cell virus (MCV) associated with merkel cell carcinoma (MCC)  (Becker, Schrama 
et al. 2009). Simian virus 40 (SV40) is a controversial polyoma virus that has also been 
implicated in human oncogenesis; in particular, its ability to transform pleural mesotheliomas 
(de Oliveira 2007). Members of the Retroviridae with oncogenic potential include, Human 
Endogenous Retrovirus (HERVs) associated with seminomas, breast cancer and melanoma and 
the Human Mammary Tumour Virus (HTMV), which is implicated in breast cancer. Finally 
the single stranded DNA, Circoviridae family member, Torque Teno Virus (TTV) is 
implicated in gastrointestinal, lung and breast cancers (McLaughlin-Drubin and Munger 2008). 
 
1.2.6  Herpesviridae 
The herpesviridae family of viruses are large double stranded DNA viruses of which 8 
have been identified in humans, designated the human herpes viruses 1-8 (HHV1-8).  The 
typical herpesvirus virion is similar in architecture across the family and the human viruses are 
morphologically indistinguishable, consisting of a core with liner double stranded DNA 
surrounded by an icosahedral capsid 100-110nm in diameter with 162 capsomeres, an 
amorphous tegument and an envelope. Many of the family members also exhibit dual-tissue 
tropism, effectively replicating via the lytic cycle in one cell type and establishing a lifelong 
persistent latent infection in another. Family members differ in terms of gene content (70 to 
100 genes), genome size (100-250 kb), arrangement of genes, host range, maintenance of 
latency and length of replicative cycle. Lytic reactivation can occur resulting in virion release 
and re-establishment of latency. Three further subfamily classifications, the 
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alphaherpesvirinae, betaherpesvirinae and gammaherpesvirinae further divide the family 
based on biological properties.  
Alphaherpesvirinae are grouped by host range, are relatively short cycling, exhibit 
rapid spread in culture, efficiently destroy infected cells and persist by latent infection in glial 
or neuronal cells. Genera include: Herpes simplex virus types 1 and 2 (HSV-1, HSV-2) causing 
the common “cold sore” and genital herpes, and the Varicellovirus (VZV) responsible for 
chickenpox in children and shingles in adults.  
 Betaherpesvirinae generally exhibit a restricted host range, with long reproductive 
cycling, slow spread in culture and infection often results in enlargement of infected cells or 
cytomeglia. Persistence occurs in secretory glands, lymphoreticular cells, kidneys and other 
tissues. Genera include: Human cytomegalovirus (HCMV), and human herpes virus 6 (HHV-6) 
and 7 (HHV-7). HCMV establishes latency in haematopoietic progenitor cells and is thought to 
persistently infect epithelial and glandular cells (Roizman and Baines 1991).  Although 
asymptomatic in the majority of hosts, lytic reactivation in the immunocompromised can be 
fatal. 
 Gammaherpesvirinae exhibit a narrow host range and can be further subdivided into two 
genera, the gamma-1-herpesviruses or lymphocryptoviruses, of which EBV is the prototypic 
member and the gamma-2-herpesviruses or rhadinoviruses, of which HHV-8 or Kaposi’s 
sarcoma-associated human herpesvirus (KSHV) is a member. Viruses in this group are specific 
to T cells or B cells and replicate in vitro in lymphoblastoid cells, with some lytic infection of 
epithelial cells and fibroblasts. 
 
1.2.7  KSHV as an oncogenic virus 
KSHV or HHV-8, a member of the rhadinovirus subfamily of gammaherpesvirinae, is a 
double stranded DNA virus with a genome length of 165kb containing approximately 90 open 
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reading frames (McLaughlin-Drubin and Munger 2008). It is associated with the non-
malignant Multicentric Castleman’s Disease (MCD), malignant primary effusion lymphoma 
(PEL) and Kaposi’s Sarcoma (KS). HIV is a cofactor of HHV-8-associated malignancy with 
disease occurring in immunocompromised AIDS patients. Classic, endemic and transplant-
related KS have been described, as well as the epidemic AIDS-related cases (Damania 2006). 
The KSHV latency-associated nuclear antigen 1 (LANA1) has been shown to contribute to 
oncogenesis by modulation of p53 activity and attenuation of Fas-mediated apoptosis. KSHV 
also expresses viral homologues of human genes which act to prevent apoptosis, such as v-
Flip, and evade the immune system, for example the secreted cytokines vCCL1(K6), 
vCCL2(K4), vCCL3(K4.1) (Damania 2006).  
 
1.3  Epstein-Barr Virus 
EBV was the first human tumour using electron microscopy from in vitro cultures 
derived from fresh BL biopsies when “herpesvirus like” particles were observed in a subset of 
cells. The virus was shown to be biologically distinct from the previously characterised 
herpesvirus family members and was named Epstein-Barr virus, (EBV) (Epstein, Achong et al. 
1964). The first major experimental evidence highlighting the oncogenic potential of the virus 
was its ability to infect and transform normal resting B-cells into immortalised lymphoblastoid 
cell lines (LCLs) in vitro. It was found that when lymphocytes from EBV-positive donors were 
placed in culture and the T lymphocytes either removed or inhibited by cyclosporin-A 
treatment, spontaneous outgrowth of immortalised LCLs occurred. This can also be replicated 
upon direct infection of resting B lymphocytes with EBV (Rickinson, Rowe et al. 1984).  
 EBV is a widespread virus infecting over 95% of the world’s population. Primary 
infection is also usually asymptomatic and generally occurs during early childhood. When 
primary infection occurs during late adolescence it often results in infectious mononucleosis, a 
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self-limiting lymphoproliferative disease. Fever, weight loss, malaise, pharyngeal 
inflammation and a haematological increase in numbers of lymphoblasts, mainly CD8 positive 
T cells, are classical symptoms (Henle, Henle et al. 1968; Henle and Henle 1969). From the 
first association between EBV and BL experimental evidence has amassed that implicates a 
link between the virus and other malignancies. These include, undifferentiated nasopharyngeal 
carcinoma (uNPC), a mucosal epithelial cell-derived tumour that is endemic in parts of South 
East China (Canton region) and with increased incidence in Greenland and North Africa 
(Henle, Henle et al. 1968; Henle, Henle et al. 1970; zur Hausen, Schulte-Holthausen et al. 
1970). EBV is also associated with approximately 10% of lymphoepithelioma-like gastric 
carcinoma (Takada 2000), a subset of Hodgkins lymphoma, post-transplant 
lymphoproliferative disorder (PTLD), and rare T cell lymphomas (Pagano, Blaser et al. 2004).  
 
1.3.1 EBV: Mode of infection 
 The dual-tissue tropism of EBV is borne out by its interactions with and infective 
capacity of B lymphocytes and epithelial cells. EBV persists latently as an extrachromosomal 
episome in a small percentage of B-lymphocytes (Rezk and Weiss 2007). Production of virion 
particles occurs via the lytic cycle in another cell type, most likely a specialised epithelial cell, 
given EBV’s oral mode of transmission (Sixbey, Nedrud et al. 1984). Primary uptake of the 
virus is believed to occur by direct binding of the virus by these epithelial cells or by transfer 
from neighbouring B cells (Shannon-Lowe, Neuhierl et al. 2006). EBV replicates in these cells 
and lytic cycle results in release of the virus into the throat where it is capable of infecting 
mucosal B cells and establishing latency. This latent state facilitates growth-transformation that 
results in the expansion of LCL-like cells in the lymphoid tissue of the tonsil, particularly at 
extrafollicular areas, and the emergence of infected cells in the peripheral blood (Hislop, 
Taylor et al. 2007). EBV then persists in a subset of resting memory B cells, which are capable 
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of proliferating indefinitely and at a frequency of infection of approximately 1 in 1x105 to 
1x106 cells (Thompson and Kurzrock 2004). 
 
1.3.2  Viral entry to B-cells and epithelial cells 
The EBV viral envelope consists of a complement of glycoproteins that are involved in 
viral cell entry, of which gp350/220 is one. Primary B-lymphocytes express the high affinity 
complement receptor 2 (CR2/CD21), which facilitates attachment of the virus via this 
gp350/220 glycoprotein (Fingeroth, Weis et al. 1984; Nemerow, Wolfert et al. 1985; 
Nemerow, Mold et al. 1987; Tanner, Weis et al. 1987). Upon this initial interaction, three 
additional envelope glycoproteins (gH/gp85, gL/gp25 and gp42) associate together, and in 
conjunction with the MHC class II cellular molecules, HLA-DR, DP and DQ, facilitate 
endocytosis of the virus and release into the cytoplasm (Li, Turk et al. 1995; Borza and Hutt-
Fletcher 2002).  EBV can enter normal B cells by endocytosis into large non-clathrin-coated 
vesicles; subsequently, the viral envelope fuses with the vesicular membrane and the 
nucleocapsid is released into the cytoplasm (Miller and Hutt-Fletcher 1992). 
Although it is believed that the primary site for viral replication upon transmission of 
the virus is a specialised epithelial cell, this environment does not appear to be amenable to 
establishment of latency or lytic replication. Detection of EBV in epithelia has proved 
problematic and studies of tonsillar and desquamated epithelial cells from EBV-positive 
patients have failed to detect the virus. Virus has not been identified in epithelial cells in close 
proximity to uNPCs or gastric carcinomas (Niedobitek, Meru et al. 2001). However, the virus 
can be detected in pre-invasive NPC lesions (Pathmanathan, Prasad et al. 1995) and some 
gastric dysplasia (Gulley, Pulitzer et al. 1996).  
In order to ensure dual-tissue tropism the virus has two mechanisms of infection, a 
complex of three glycoproteins as described above and a complex of two glycoproteins without 
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gp42 (Borza and Hutt-Fletcher 2002). It has been proposed that primary infection occurs in B-
lymphocytes through interactions between CR2 and gp350/220 and HLA class II and gp42. 
gp42 is thought to be retained by intracellular HLA class II, and virus is then produced which 
lacks gp42. This virus is then capable of infecting epithelial cells via the gH and gL proteins, 
where it replicates, shedding gp42 positive virus which can then latently infect B-lymphocytes 
(Borza and Hutt-Fletcher 2002). This is intriguing when taken into account with a study by 
Molesworth et al. in 2000 (Molesworth, Lake et al. 2000) who showed that virus produced by 
epithelial cells contained more gp42 and was up to ten times more efficient at infecting B-cells 
than virus produced by B-cells, thus facilitating latent infection following primary infection of 
an epithelial cell. 
CR2 is only expressed at a very low level on the surface of epithelial cells (Fingeroth, 
Diamond et al. 1999), and very low rates of infection are recorded upon exposure of epithelial 
cells to virus in vitro (Imai, Nishikawa et al. 1998). Artificial systems have been developed to 
allow infection of epithelia in vitro (Rickinson 2001), since the occurrence of EBV-positive 
epithelial-derived neoplasia is suggestive of in vivo infection. These systems incorporated the 
use of CR2 over-expression or bypassing its necessity for viral entry (Li, Young et al. 1992; 
Knox, Li et al. 1996; Gan, Chodosh et al. 1997). Spontaneous lytic reactivation can occur in 
these cases and this is thought to be linked to the differentiation status of the cell (Knox, Li et 
al. 1996). In vitro, co-cultivation of a monolayer of epithelial cells with the recombinant EBV-
producing BL-derived cell line, Akata, have resulted in experimental systems which allow 
better study of viral interaction of epithelial cells (Takada and Ono 1989; Shimizu, Yoshiyama 
et al. 1996). This recombinant EBV has a selectable antibiotic resistance marker which allows 
for positive selection of infected cells (Chang, Tung et al. 1999). 
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1.3.3  Virion structure 
EBV contains a double stranded DNA core surrounding a toroid shaped protein core. 
This is surrounded by an outer nucleocapsid comprising 162 capsomeres, an amorphous 
tegument and a viral envelope studded with glycoproteins (Rickinson 2001). The most 
abundant of these glycoproteins is gp350/220, which is necessary for virion binding to the CR2 
receptor to facilitate infection and viral entry. The genome itself is approximately 172kb and 
was the first human herpesvirus genome to be fully sequenced using the B95.8 strain of the 
virus isolated from an IM patient and sequenced upon cloning the overlapping restriction 
endonuclease fragments of EcoR1 and BamH1 (Baer, Bankier et al. 1984). Nomenclature of 
the open reading frames was designated based on these fragments with a four letter and number 
acronym relating to their position and the direction of cloning, e.g. BZLF1, first fragment of 
the Z fragment, leftward reading (Figure 1.1). 
 The genome is divided into two unique regions by tandem repeats: Ul (unique long); 
and Us (unique short) (Hayward, Nogee et al. 1980). Internal repeat sequences are also found 
throughout the genome and include: IR1, comprising the glycine alanine repeat of the EBNA1 
protein; the internal IR2-IR4 repeats within the Ul region; and the 500bp terminal repeat (TR), 
of which there are between 4-12 repeats (Kintner and Sugden 1979) and which can be used as 
an indicator of clonality (Raab-Traub and Flynn 1986). The origin of replication of the viral 
episome (oriP) consists of two EBNA1-binding elements, the family of repeats (FR) with 20 
EBNA1-binding sites, and the dyad symmetry elements with only 4 binding sites (Wysokenski 
and Yates 1989; Frappier, Goldsmith et al. 1994). FR is involved in retention of the episome in 
the nucleus and the DS is the origin of replication. Replication from oriP occurs once during S-
phase following EBNA1-binding and recruitment of cellular enzymes. The FR element blocks 
leftward replication, so genome replication only propagates in a rightward direction, therefore  
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Figure 1.1  Structure of the EBV genome 
(A) Viral Episome  
Here a schematic of the EBV viral episome is displayed which is approximately 
172kbp in length and codes for ~85 genes. The location of each of the latent ORFs are 
indicated including the various promoters controlling their expression. The 
nomenclature of the episome is designated from the BamHI fragments created during 
sequence of the EBV genome. Circularisation is facilitated by fusion of the 0.5kb TR 
(Terminal repeats) across which the LMP2 genes are transcribed. Maintenance of the 
episome is controlled by the OriP, which is also indicated. 
 
(B) Linearised viral genome 
Displayed here is a schematic of the linearised ORFs of the latent genes of EBV, the 
nomenclature designated by the BamHI restriction endonuclease map of the genome 
of  the B95.8 EBV strain. Each region is named based according to size, wit A being 
the largest. The TR elements here are positioned at either end of the linearised 
genome. The W repeat element of EBNA-LP is also indicated. Both Figures are 
adapted from those in (Young and Rickinson 2004). 
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beginning and ending at oriP (Dhar and Schildkraut 1991). Figure 1.1 depicts a schematic 
representation of the EBV genome.  
1.3.4  Strain Variation 
Variation between EBV strains was originally identified on the basis of polymorphism 
in the EBNA2 gene, and subsequent identification of variation between EBNA3A, 3B and 3C 
facilitated division of EBV into two types: type 1 (EBV1) and type 2 (EBV2) (Dambaugh, 
Hennessy et al. 1984; Rowe, Young et al. 1989; Sample, Young et al. 1990). These two types 
show sequence homology of 50-80% (depending on the locus) with some allelic polymorphism 
amongst the aforementioned genes. Thus far, full sequences are available for two type 1 
viruses, B95.8 and GD1 (Baer, Bankier et al. 1984; Zeng, Li et al. 2005), and one type 2 virus, 
AG876 (Dolan, Addison et al. 2006). Type 1 viruses (B95.8-like) have been shown to 
transform B-lymphocytes more efficiently in vitro than their type 2 (AG876-like) counterparts 
(Rickinson, Young et al. 1987). These EBNA2 polymorphisms appear to be the major 
determinant of the virus’s transforming abilities (Cohen, Wang et al. 1989). 
 Epidemiological, serological and DNA sequencing studies reveal that both types are 
widespread in equatorial Africa and New Guinea and that type 1 is predominant in the West 
and South East Asia (Zimber, Adldinger et al. 1986). Other strain variants have been identified 
including the “f” polymorphism, which may protect against a predisposition to tumour 
development (Lung, Chang et al. 1990; Lung, Lam et al. 1991), and isolates carrying a 30bp 
deletion of the LMP1 gene, which is endemic in parts of south-east Asia. This particular LMP1 
isolate displays increased transforming abilities in rodent fibroblasts, findings which have led 
to speculation that EBV isolates carrying this particular LMP1 isolate may predispose 
individuals to malignant disease (Li, Chang et al. 1996). EBV strain variation and comparisons 
between three strains, lineage and tree building based on differences within the EBNA proteins 
are reviewed elsewhere (McGeoch and Gatherer 2007). 
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1.3.5  Lytic cycle 
 The bi-phasic lifecycle of herpesviruses is divided into the latent cycle during persistent 
infection and productive lytic reactivation, during which viral replication occurs. Lytic 
replication is reliant on more EBV-encoded genes than the restricted number expressed during 
latency (Fixman, Hayward et al. 1995), is initiated from the oriLyt and multiple rounds of 
replication are usually involved (Hammerschmidt and Sugden 1988). The proteins involved are 
divided into three categories and are expressed sequentially: the immediate early genes (IE), 
mainly transsactivating proteins that control early gene expression; the early genes (E), which 
include components of viral DNA replication; and the late genes (L), including structural 
proteins (Hislop, Taylor et al. 2007). 
 
1.3.5.1  Immediate early genes (IE) 
 Induction of the lytic cycle begins with transcription of two genes: BZLF1 and Rta; the 
latter of which is transcribed from the BRFL1 locus. These are both transcribed from the Rp 
promoter, whilst BZLF1 can also be transcribed from the Zp promoter, and both can be 
activated by the BZLF1/ZEBRA protein itself (Flemington and Speck 1990). BZLF1 is a 
DNA-binding protein of approximately 36kDa and transactivates gene expression by binding 
to specific promoter elements, termed ZREs. These proteins can operate alone but it has been 
shown that maximal transactivation occurs when they act synergistically (Feederle, Kost et al. 
2000). Lytic reactivation in latently infected cells is believed to be driven by BZLF1 
expression and it has been shown that its transfection into the latently infected EBV-positive 
Raji BL cell line results in lytic gene expression (Chevallier-Greco, Manet et al. 1986; Biggin, 
Bodescot et al. 1987). Furthermore, Rta has been implicated in reactivation of the lytic cycle in 
epithelial cells in vitro (Zalani, Holley-Guthrie et al. 1996).  
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1.3.5.2  Early genes 
 BZLF1 and Rta act together to transactivate a number of genes including the thymidine 
kinase BXLF1, which acts via c-fos to downregulate the latent Cp promoter activity 
(Flemington and Speck 1990; Sinclair, Jacquemin et al. 1994; Zalani, Holley-Guthrie et al. 
1996), and the DNA replication genes which comprise the core of the replication machinery. 
BMRF1, BALF2, BALF5, BSLF1, BBLF4 and BBLF2/3. BSLF1 and BMRF1 are 
transcriptional activators and induce other lytic cycle-associated genes. BHRF1 is a conserved 
17kDa membrane protein that is related to Bcl-2 family of cellular proteins and may function 
to prevent apoptosis (Dawson, Eliopoulos et al. 1995). 
 
1.3.5.2  Late genes 
The late genes are transcribed following replication and encode viral structural proteins, 
including 11 glycoproteins. The classical membrane antigen complex (MA) consists of the 
BLLF1-encoded gp350 and the BXLF2-encoded gH/g85; these are involved in virus-cell 
interactions mediated by the CR2 cellular receptor. BZLF2 encodes the gp42 glycoprotein, 
which is important for viral entry into B-lymphocytes. Other structural proteins include p160 
(BCLF1), three capsid proteins, p18, p23 and p40 (BFRF3, BLRF2 and BLRF1), and the 
tegument proteins, BNRF1 and BPLF1. The lytic cycle is reviewed extensively elsewhere 
(Tsurumi, Fujita et al. 2005). 
 
1.3.6  Latent cycle 
EBV establishes persistent latent infection in B-lymphocytes, which constitutes the 
second phase of its bi-phasic lifecycle. The B-lymphocyte is believed to be the site of viral 
persistence in vivo and this has been substantiated by analysis of the EBV strain of allogeneic 
bone marrow recipients prior to and post-transplant. Here it was shown that the recipient strain 
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was replaced with that of the donor, suggestive of a B-lympocytic reservoir for EBV (Gratama, 
Oosterveer et al. 1988). XLA (X-linked agammaglobulinaemia) patients cannot produce 
mature B-lymphocytes, are EBV-negative and are incapable of persistent EBV infection, 
further implicating these cells as the site of persistence (Young, Dawson et al. 1999). The 
pattern of gene expression during latency can change, which is heavily dependent on the 
differentiation status of the infected B-lymphocyte. Upon infection, B-cells become 
proliferating B-blasts characterised by the “growth programme” or latency III type pattern of 
EBV gene expression. This antigen activated B-blast can then enter the follicle, expand and 
undergo a germinal centre reaction. The latency programme is then switched to the “default” or 
latency II programme. Following this the B-cells leave the follicle and enter peripheral 
circulation as resting B-cells, entering the memory pool with a “latency programme” or latency 
0 type pattern of expression, where expression of all viral proteins is restricted (Thorley-
Lawson 2001). The pattern of viral gene expression is dependent on both the location of the 
infected B-cell and its differentiation status.  
Examination of both EBV-associated malignancies and EBV-positive cell lines has lead 
to a greater understanding of these latency programmes and whilst these classifications are 
useful they are also fluid, and the virus has been shown to adapt to its cellular environment. BL 
cells displaying a classical latency I pattern of gene expression have been shown to drift 
overtime in culture to a latency III programme (Rowe, Lear et al. 1992). EBNA3 expression 
has also been identified in rare cases of an EBNA2-deleted BL, representing an unclassified 
latency programme (Kelly, Bell et al. 2002).  
 
1.3.6.1  The growth programme/latency III 
As mentioned previously, EBV infection has the ability to transform resting B-cells into 
proliferating LCLs, which are characterised by expression of a latency III pattern of gene 
 18
Chapter 1    Introduction 
 
 
expression. Here, as in post-transplant lymphoproliferative disease (PTLD), all of the nine 
latent proteins are expressed, the six EBV nuclear antigens, EBNAs 1, 2, 3A, 3B, 3C and LP 
(leader protein), spliced from a single polycistronic transcript driven from the Cp/Wp promoter 
and the three latent membrane proteins, LMPs 1, 2A and 2B. In addition to these proteins, the 
virus also expresses two small non-polyadenylated RNAs, EBERs 1 and 2, and the 
differentially spliced RNAs from the Bam H1-A region of the genome, the BARTs, BARF0, 
BARF1 and the more recently described microRNAs (miRNAs). Three BHRF1 miRNAs have 
been shown to be expressed only in latency III (Cai, Schäfer et al. 2006). This pattern of gene 
expression activates the B-cell to becoming a proliferating B-blast (Thorley-Lawson 2001).  
 
1.3.6.2  The default programme/latency II 
This pattern of gene expression is observed in malignancies including NPC, EBV-
positive Hodgkins lymphoma, T-cell lymphoma and NK-cell lymphoma (Young and Rickinson 
2004). Gene expression here is restricted to Qp-driven EBNA1, LMP1, LMP2A, the EBERs, 
BARTs and BARF1 (Young and Rickinson 2004). A twenty member cluster of BART 
miRNAs is also expressed during latency II (Cai, Schäfer et al. 2006). A subdivision of latency 
II has been identified (IIb) in both lymphoid tissues of IM patients and EBV infected B-chronic 
lymphocytic leukaemia (B-CLL) cells in vitro. In these instances, LMP1 and LMP2A are not 
detected, but the six EBNA proteins are expressed (Klein, Kis et al. 2007). It is believed that 
this pattern of gene expression permits differentiation of B-cells into memory and enables 
maintenance of infection. 
 
1.3.6.2  The restricted default programme/Latency I 
Burkitt’s lymphoma is characterised by a latency I pattern of gene expression which 
includes expression of the EBERs, BARTs and Qp promoter-driven EBNA1 (Rickinson and 
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Kieff 2001). The remaining five EBNA proteins and the LMPs are not detected. This 
expression programme often drifts to that of latency III in BL cells in culture (Blum, Lozanski 
et al. 2004).  
 
1.3.6.4  The latency programme/Latency 0 
This programme of viral latency is believed to allow persistence of infected B-cells in 
the memory pool and avoidance of immune surveillance (Thorley-Lawson 2001). As such, 
usually no proteins are detectable, although LMP2A is sometimes expressed. The EBER and 
BART transcripts are readily detected in these cells (Tierney, Steven et al. 1994), and EBNA1 
may be expressed during division of these cells (Hochberg, Middeldorp et al. 2004). 
 
1.4  EBV latent genes 
1.4.1  EBNA1 
EBV nuclear antigen I (EBNA1) is the most consistently expressed of all the EBV 
latent proteins. It is expressed in all forms of latency with the exception of the latency 0 gene 
expression programme and is detectable in all malignancies associated with viral infection 
(Lee, Diamond et al. 1999; Rickinson 2001). Analyses of the EBNA1 protein have focused on 
its role in episomal maintenance. It is a DNA-binding protein of approximately 75kDa-encoded 
by the BamH1-K region of the viral genome, and comprises an 89 amino acid domain, a short 
basic residue-rich domain, a long hydrophilic carboxy terminus and a long Gly-Ala repeat 
element, which can be deleted without affecting EBNA1 function but may be detrimental to 
host immune evasion due to its role in the blockade of ubiquitin-mediated antigen presentation 
as demonstrated by domain swapping experiments (Levitskaya, Sharipo et al. 1997). It binds to 
elements within the oriP of the viral genome and facilitates synchronous replication with the 
host genome (Yates, Warren et al. 1985). EBNA1 can also modulate transcription of the viral 
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latent promoters (Lupton and Levine 1985), including that of LMP1 and the Cp promoter 
(Rickinson 2001), and may participate in cell growth transformation. This latter function is 
implicated by EBNA1’s ability to form B-cell lymphomas when targeted to lymphoid cells in 
transgenic mice (Wilson, Bell et al. 1996), and this role may be extended to epithelial cells in 
vitro, where EBNA1 transformation of the NPC-derived HONE-1 cell line has been reported 
(Sheu, Chen et al. 1996). Cellular tolerance to EBNA1 in epithelial cells appears to be context-
dependent (Jone et al., 2003), and whilst undifferentiated cells can tolerate EBNA1, its 
expression is associated with cellular toxicity in differentiation competent squamous epithelial 
cell lines (Jones, Smith et al. 2003). Differential promoter usage is a tenet of EBNA1 
expression and these are utilised during the different latency programmes described above. The 
Cp/Wp promoter is silenced via methylation in latency I and II (Schaefer, Strominger et al. 
1997) and EBNA1 expression is Qp promoter driven. During latency III, the Cp/Wp promoter 
is activated and the Qp promoter is silenced by EBNA1-binding (Nonkwelo, Skinner et al. 
1996). The Fp promoter is believed to regulate EBNA1 expression during lytic cycle induction 
(Tsai, Liu et al. 1995). 
 
1.4.2  EBNA2 
EBV nuclear antigen 2 (EBNA2) is transcribed as part of the long polycistronic mRNA 
driven by the Cp/Wp promoter. Similar to EBNA1, EBNA2 is a nuclear phosphoprotein that 
transactivates transcription via interactions with the cellular DNA-binding protein CBF-1/RBP-
Jκ. It has been shown to regulate viral latent promoters including those of LMP1, LMP2 and 
the Cp promoter, inducing Wp to Cp switching early in infection (Young and Rickinson 2004). 
EBNA2 expression is necessary for immortalisation of B-cells as demonstrated by the inability 
of the EBNA2-deleted P3HR1 EBV strain to transform B-lymphocytes and the restoration of 
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this upon EBNA2 reintroduction (Hammerschmidt and Sugden 1989; Rickinson 2001). 
EBNA2 has also been shown to mimic Notch (Zimber-Strobl and Strobl 2001).  
 
1.4.3  EBNA-LP, 3A, B, C 
EBV nuclear antigen leader protein (EBNA-LP) is not essential for transformation of 
B-lymphocytes but has been shown to be a coactivator of EBNA2 activity (Rickinson 2001) 
and is also involved in the progression of B-lymphocytes into the G1 phase of the cell cycle 
through interactions with p53 and the pRb tumour suppressor genes (Sinclair, Palmero et al. 
1994). EBNA3A, 3B and 3C are transcriptional regulators that have been shown to target both 
cellular and viral latent genes including CD21, CD40, EBNA2 and LMP1. EBNA3A and 3C 
are essential for growth transformation of B-lymphocytes, whilst EBNA3B is dispensable 
(Robertson, Lin et al. 1996). The EBNA3 proteins negatively regulate EBNA2 function by 
interacting with the cellular transcriptional regulator protein CBF-1/RBP-Jκ (Robertson, Lin et 
al. 1996). EBNA3C can co-activate the LMP1 promoter in tandem with EBNA2 (Zhao and 
Sample 2000), and is also involved in cell cycle checkpoint deregulation (Radkov, Touitou et 
al. 1999). 
 
1.4.4  Latent Membrane Protein 1 (LMP1) 
Latent membrane protein 1 (LMP1) is the major transforming oncoprotein-encoded by 
EBV. It is transcribed from the BamH1-N region of the viral genome and codes for a 63kDa 
integral membrane protein, and is under the transcriptional control of either of two promoters: 
the L1-TR, activated in epithelial cells; and ED-L1, activated during infection of B-cells (Tsai, 
Lee et al. 1999). The oncogenic potential of LMP1 is borne out by its ability to induce 
transformation in the rodent fibroblast cell line, Rat-1, allowing anchorage-independent growth 
and tumour formation in athymic nude mice (Wang, Liebowitz et al. 1985). It is essential for 
 22
Chapter 1    Introduction 
 
 
B-cell transformation in vitro (Kaye, Izumi et al. 1993) and acts as a constitutively active 
signalling molecule mimicking the activity of the tumour necrosis factor receptor (TNF-R) 
family member, CD40, engaging a variety of signalling pathways, mainly via the two domains 
of its cytosolic C-terminus, C-terminal activation regions 1 and 2 (CTAR1 and CTAR2). 
Through binding of members of both the TNF receptor associated factors (TRAFs) and 
TNFR1-associated death domain protein (TRADD) to these domains, LMP1 can mediate 
activation of various signalling pathways including Nuclear Factor kappa B (NFκB), c-Jun-N-
terminal kinase (JNK), p38 MAPK, phosphatidylinositol-3-kinase (PI3-K), extra cellular 
signal-regulated kinase (ERK) and signal transducer activator of transcription (STAT). 
Activation of these pathways contributes to B-lymphocyte transformation, and fit well with 
LMP1’s role as an activated CD40 receptor, given its role in B-lymphocyte development. 
LMP1 has also been shown to enhance epithelial motility and invasiveness in vitro (Dawson, 
Laverick et al. 2008) and to induce expression of genes involved in hyperproliferation and 
inflammation of in vitro keratinocytes (Morris, Dawson et al. 2008). LMP1 signalling and 
functions are reviewed extensively elsewhere (Eliopoulos and Young 2001; Morris, Dawson et 
al. 2009 ). 
 
1.4.5  The EBV-encoded RNAs (EBERs) 
The small non-polyadenylated RNAs, EBER1 and EBER2, are the most abundantly and 
consistently expressed EBV latent gene products. They are expressed in all EBV-associated 
malignancies and their abundance allows their use as a diagnostic marker for latent infection. 
The role of the EBERs in onocogenesis still remains unclear, although it has been shown that 
they are not essential for EBV-induced B-cell immortalisation (Swaminathan, Tomkinson et al. 
1991) and that EBER2, but not EBER1, plays a role in B-cell transformation (Wu, Maro et al. 
2007). It is likely that the EBERs play a role in viral immune evasion: they are recognised by 
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the cytosolic pattern recognition receptor (PRR), retenoic acid inducible gene 1 (RIG-1) 
(Samanta, Iwakiri et al. 2006), and have recently been shown to activate interferon (IFN) 
induction via toll-like receptor-3 (TLR3) activation in lymphocytes (Iwakiri, Zhou et al. 2009). 
An important role for the EBERs has been uncovered in the blockade of protein kinase R 
(PKR)-induced IFN responses. This is mediated by binding of the EBERs to PKR, and thus 
prevention of the phosphorylation and activation of the protein synthesis initiation factor, eIF2a 
(Nanbo and Takada 2002).  
 
 1.4.6  Bam-A Rightward Transcripts (BARTs) 
The BamHI-A-encoded rightward transcripts (BARTs) were identified in 1989 (Hitt, 
Allday et al. 1989) and are set apart from the lytic cycle-associated transcripts encoded in this 
region by their direction of transcription. BARTs have been detected in NPC biopsies, EBV-
positive BL and LCLs, suggestive of ubiquitous expression in latently infected epithelial cells 
and B-lymphocytes (Brooks, Lear et al. 1993). Although several open reading frames have 
been identified: BARF0, RK-BARF0, RPMS1 and A73 (Kusano and Raab-Traub 2001), the 
existence of putative protein products has been called into question and remains controversial. 
The BART intronic regions have been shown to generate the miRNAs and investigations into 
their role and the role of the BARTs is ongoing.  
 
1.5  Latent membrane Protein 2 (LMP2)
1.5.1  Structure and transcription 
The LMP2 genes are transcribed from across the terminal repeats of the viral episome 
and two mRNA species are generated: LMP2A and LMP2B (Laux, Perricaudet et al. 1988; 
Sample, Liebowitz et al. 1989; Salamon, Takacs et al. 2003). With the exception of the first 
exon, the genes share 100% identity. The unique exon of LMP2A encodes a 119 hydrophilic 
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amino acid sequence that constitutes the N-terminal signalling domain of the protein. The first 
exon of LMP2B is non-coding and translation is initiated at the ATG start codon located within 
the second exon. The proteins have molecular weights of 54kDa and 40Kda respectively. The 
LMP2A promoter is upstream of the gene, whilst LMP2B shares a bi-directional promoter with 
LMP1. It has been shown that the activity of the LMP2A promoter is regulated by DNA 
methylation and histone acetylation, with inactivation by methylation most pronounced in 
NPC-derived epithelial cell lines (Salamon, Takacs et al. 2003; Gerle, Korokani et al. 2007). 
Previous investigations have revealed that LMP2A promoter activity can be regulated by 
EBNA2 via CBF1 activity and the promoter has two consensus sequences, which are believed 
to mediate CBF1-binding (Zimber-Strobl, Suentzenich et al. 1991; Laux, Dugrillon et al. 1994; 
Zimber-Strobl, Strobl et al. 1994). In the absence of EBNA2 it is thought that LMP2A can 
autoregulate its own expression through manipulation of Notch signalling (Anderson and 
Longnecker 2008). Here it was also shown that LMP2B fails to regulate this activity and that 
point mutations within the N-terminal domain abrogated LMP2A promoter auto-activation by 
Notch.  
The common regions of LMP2A and LMP2B encode the 12 hydrophobic 
transmembrane domains and the C-terminal cytoplasmic tails, which consist of 27 amino acids. 
Given the highly hydrophobic nature of the proteins it was postulated that they were multi-pass 
integral membrane proteins (Laux, Perricaudet et al. 1988; Longnecker and Kieff 1990). Some 
disparity exists in their exact localisation in B-lymphocytes compared to that observed in 
epithelial cells. LMP2A and LMP2B expression in B-cells is localised to the plasma membrane 
(Longnecker, Druker et al. 1991), but the proteins appear to be bound to internal membranes in 
epithelial cells, in endosomal perinuclear aggregates (Dawson, George et al. 2001; Lynch, 
Zimmerman et al. 2002; Allen, Young et al. 2005). The localisation of the proteins in both 
NPC-derived and HNSCC (Head and neck squamous cell carcinoma)-derived epithelial cells is 
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investigated in this thesis (results Chapter 5). The C-terminus of the proteins is believed to 
promote self-aggregation at the membrane and also to mediate LMP2B interference of LMP2A 
activity in B-lymphocytes (Rovedo and Longnecker 2007). Due to the extent of homology 
between the proteins it is likely that they possess similar functions, another aspect of LMP2A 
and LMP2B, which is investigated in this thesis (results Chapters 3 and 5). 
 
1.5.2  N-terminal signalling domain  
The 119 N-terminal signalling domain of the LMP2A protein is the most extensively 
studied region of both proteins. The region itself contains eight tyrosine (Y) residues, some of 
which become phosphorylated in B-cells (Longnecker, Druker et al. 1991) and epithelial cells 
(Scholle et al., 2001). Three of these residues have been identified as essential in the binding of 
non-receptor tyrosine kinases (non-RTKs) to the LMP2A protein. Two of these residues, Y74 
and Y85, constitute the immunoreceptor tyrosine kinase activation motif  (ITAM) and, upon 
phosphorylation, in concert with the Y112 residue, have been shown to bind to the Src 
homology (SH2) domain containing Syk tyrosine kinase. Syk is a member of the Src family of 
tyrosine kinases, of which Lyn is also a member. It has also been shown that Lyn can bind to 
the Y112 residue of LMP2A and mediate phosphorylation of the ITAM motif, and that all 
three of these residues are essential for LMP2A blockade of B-cell receptor signalling (BCR) 
(Miller, Lee et al. 1994; Fruehling, Lee et al. 1996 
; Fruehling and Longnecker 1997). The five remaining tyrosine residues have been 
shown to be dispensable for LMP2A’s effect on the BCR, but it has also been shown that the 
Y60 residue may bind Abl (Swart, Fruehling et al. 1999). The N-terminal tail of LMP2A also 
contains multiple serine/threonine residues, of which two (S15 and S102) can be 
phosphorylated by mitogen activated protein kinase (MAPK) in vitro, whilst LMP2A is 
identified a substrate for MAPK in vivo (Panousis and Rowe 1997). Finally, proline-rich motifs 
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are also found within the N-terminus and have been shown to interact with a number of WW 
domain containing, Nedd4-like E3 ubiquitin ligases, including AIP4/Ithcy, WWP2, Nedd4, and 
Nedd4-2 (Ikeda, Ikeda et al. 2000; Winberg, Matskova et al. 2000). These interactions result in 
targeting of LMP2A and LMP2A-bound proteins, such as Lyn, for ubiquitin-mediated 
degradation, thereby contributing to modulation of cell signalling. Ubiquitination has also been 
shown to be important for LMP2A activity and cellular localisation, possibly regulating its 
association with lipid rafts, via endocytosis and endosomal sorting to cholesterol-rich 
membrane regions (Ikeda and Longnecker 2007). It has also been shown that LMP2A may 
hijack the ubiquitin pathway to modulate cellular signalling from the Notch and Wnt (Portis, 
Ikeda et al. 2004).   
 
1.5.3  LMP2 modulation of cell signalling 
 Although expressed in many of the viral latency programmes, both LMP2A and 
LMP2B been shown to be dispensable for EBV-induced transformation of B-lymphocytes 
(Longnecker, CL et al. 1992). However, LMP2A has been shown to contribute to the 
maintenance of latency via blockade of BCR signalling. This is achieved through physical 
exclusion of the BCR from lipid rafts and ubiquitin-mediated degradation of BCR-associated 
tyrosine kinases such as Lyn. Activation of the B-cell receptor results in recruitment of Src and 
Syk family tyrosine kinases to lipid rafts where signalling events can be initiated. In tandem 
with blocking normal B-cell signalling and thus B-cell development, LMP2A has also been 
shown to provide a “tonic” signal to protect B-lymphocytes from apoptosis. This allows 
development and persistence of B-cells in the absence of a normal BCR signal (Caldwell, 
Wilson et al. 1998; Caldwell, Brown et al. 2000; Longnecker and Portis 2003). LMP2A is 
constitutively active in non-transformed B-cells and can redirect B-cell development, as B-
cells cannot progress through development checkpoints without PTK activity. Expression of 
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genes associated with B-cell development have also been shown to be downregulated in 
LMP2A-expressing cells when compared with their control counterparts. Microarray analysis 
has identified LMP2A-mediated downregulation of E2A, a transcription factor induced as a 
consequence of BCR activation and upregulation of Id2 and SCL, inhibitors of E2A. 
(Longnecker and Portis 2003). 
 
1.5.3.1  MAPK signalling 
MAPKs are serine/threonine kinases that under normal cellular controls are activated 
and signal via three distinct pathways: ERK-MAPK, JNK/SAPK and p38-MAPK, and are 
known to be modulated by LMP2A. MAPK signalling controls cellular events such as 
apoptosis, differentiation, migration and proliferation. Deregulation of these mechanisms by 
LMP2A may contribute to the onset and/or pathogenesis of EBV-associated malignancies. It 
has been demonstrated that LMP2A can regulate phosphorylation and activation of the MAPK-
activated transcription factor, c-Jun and that this is prevented by inhibition of ERK signalling 
(Chen, Lu et al. 2002). Conversely, LMP2A is also a substrate for MAPK phosphorylation and 
is thought to be phosphorylated by ERK1 (Panousis and Rowe 1997). More recently it has 
been shown that LMP2A provides pre-B-cell receptor signalling via activation of ERK-MAPK 
(Anderson and Longnecker 2008).   
 
 
1.5.3.2  PI3-K signalling  
The surrogate BCR signal provided by LMP2A can be extended to include activation of 
phosphoinositide-3 kinase (PI3-K)/Akt signalling, which is responsible for cell growth, 
differentiation, motility, survival and intracellular trafficking under normal cellular conditions. 
It has been shown that upon expression of LMP2A, the PI3-K-activated serine/threonine 
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kinase, Akt, is constitutively phosphorylated (Swart, Ruf et al. 2000); however, this does not 
result in a concomitant increase in Akt-linked cell survival of B-lymphyocytes. Akt regulates 
the cell cycle proteins, glycogen synthase kinase 3 (GSK-3) and cyclin D. During normal 
epithelial cell differentiation, cells move up from layers of proliferating cells as they 
differentiate, and in doing so, lose contact with the extra-cellular matrix proteins. The activity 
of LMP2A in epithelial cells is dependent on tyrosine phosphorylation upon adhesion to these 
proteins (Scholle, Longnecker et al. 1999; Scholle, Longnecker et al. 2001). LMP2A has been 
shown to transform established epithelial cell lines and block the differentiation process in a 
PI3-K/Akt-dependent fashion (Scholle, Bendt et al. 2000). More recently it has been shown 
LMP2A-induced activation of PI3-K is mediated via Ras and that LMP2A expression is 
important for the clonal outgrowth of infected cells (Fukada and Longnecker 2007). Another 
indication of LMP2A’s effect on PI3-K signalling is its ability to partially attenuate TGFβ1-
mediated apoptosis, a phenomenon that is alleviated by the addition of PI3-K inhibitors 
(Fukada and Longnecker 2004).  
 
1.5.3.3  NFκB signalling  
LMP2A has been shown to modulate the NFκB signalling pathway in epithelial cells, and this 
modulation is another putative mechanism of its contribution to oncogenesis. The NFκB family 
of transcription factors control a variety of cellular pathways including cytokine release, cell 
growth and the inflammatory response. In 2004, Stewart and colleagues demonstrated 
modulation of NFκB activity by LMP2A in epithelial cell lines stably infected with a 
recombinant LMP2A-deleted EBV (Stewart, Dawson et al. 2004). Cells stably infected with an 
LMP2A-deleted EBV showed a reversal of NFκB inhibition, as demonstrated by production of 
the IL-6 cytokine, and a concomitant induction of STAT-mediated L1-TR promoter-driven 
LMP1 expression. These defects could be repaired by transient re-expression of LMP2A which 
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resulted in down-regulation of NF-kB and STAT activity and a concomitant repression of 
LMP1 promoter activity, (Stewart, Dawson et al. 2004).  
 
Another investigation linking the effects of LMP1 and LMP2A demonstrated that co-
expression of both viral proteins in epithelial cells augmented LMP1’s ability to activate both 
the AP-1 and NFκB signalling pathways (Dawson, George et al. 2001). Moreover, LMP2A 
significantly increased the half-life of LMP1, possibly contributing to its dose-dependent effect 
in tumourigenesis. These events were mediated by the ITAM motif of the LMP2A protein 
since LMP2B co-expression with LMP1 did not yield the same results (Dawson, George et al. 
2001). Findings suggest that this may be attributed to the regulation of TRAF2 expression by 
LMP2A (Guasparri, Bubman et al. 2008). 
 
1.5.3.4  Cellular localisation 
LMP2A and LMP2B’s cellular localisation is believed to differ between epithelial cells 
and B-lymphocytes. Whereas LMP2A and LMP2B localise to the plasma membrane in B cells, 
they localise to perinuclear endosomes in epithelial cells (Allen, Young et al. 2005), with 
neither protein colocalising with the plasma membrane marker CD151 (Dawson, George et al. 
2001). This latter study also demonstrated that LMP2A and LMP2B could alter the adhesion 
and migration of epithelial cells in a manner that was independent of PI3-K/Akt, ERK-MAPK 
and protein kinase C (PKC) activation, highlighting a function for the transmembrane domains 
of both proteins in modulating cell signalling (Allen, Young et al. 2005). LMP2A-mediated 
migration and invasion has also been observed in primary epithelial cells, further implicating 
the protein in epithelial malignancy (Pegtel, Subramanian et al. 2005). Further investigations 
into the role of LMP2B in B-cells revealed its ability to prevent LMP2A phosphorylation, and 
thus ubiquitin-mediated degradation of Lyn. LMP2B prevented LMP2A aggregation in lipid 
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rafts through competitive binding to the C-terminus of LMP2A (Rovedo and Longnecker 
2007). Further investigations revealed that some, but not all of the membrane passes of 
LMP2A and LMP2B are necessary for membrane binding (Tomaszewski-Flick and Rowe 
2007).  
 
1.5.3.5  Other signalling cascades 
LMP2A has also been implicated in modulating other cellular pathways, for example 
telomerase reverse transcriptase (hTERT) expression and telomerase activity. Telomerase is 
important for stabilisation of telomere shortening after rounds of cell division and its activation 
is linked to cellular immortalisation. A comparison of LMP2A-expressing cells with their 
parental counterparts revealed that telomerase activity and hTERT expression was inhibited by 
LMP2A, which although paradoxical, was hypothesised to maintain viral latency and suppress 
B-cell activation (Chen, Liu et al. 2005). Other investigations have identified a role for LMP2A 
in modulation of the Wnt/β-catenin signalling pathway with resultant effects on epithelial cell 
differentiation (Morrison, Klingelhutz et al. 2003; Morrison and Raab-Traub 2005).  
 Finally a recent publication from our laboratory revealed a novel function for LMP2A 
and LMP2B, in the modulation of IFN signalling. Here,  type I IFN responses was attenuated 
when compared with their control counterparts, as demonstrated by a global downregulation of 
interferon stimulated genes (ISG) in NPC-derived epithelial cells in vitro (Shah, Stewart et al. 
2009). This was postulated to be a result of the increased turnover and degradation of the type I 
IFN receptors in these cells (Shah, Stewart et al. 2009). The modulation of immune signalling 
and the increased level of cellular trafficking/lysosomal acidification are investigated further in 
this thesis (results Chapters 4 and Chapter 5). 
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1.6  EBV-associated disease
EBV persists as a latent infection in over 95% of the world’s population. As mentioned 
previously EBV is associated with various diseases of both lymphoid and epithelial cell origin, 
an example of the dual-tissue tropism that characterises its lifecycle. These diseases, ranging 
from benign infections to the development of malignant tumours, are discussed below. 
 
1.6.1   Diseases of lymphoid origin 
1.6.1.1  Infectious mononucleosis 
Primary infection with EBV is usually asymptomatic and occurs in early childhood. In 
Western countries, and particularly in areas of higher socio-economic background, infection 
may be delayed until adolescence or early adulthood where viral infection manifests as 
infectious mononucleosis (IM). This is a benign self-limiting lymphoproliferative disease 
encompassing a wide variety of symptoms including fever, fatigue, malaise, sore throat and 
nausea (Henle 1979/1968). The tonsils become enlarged due to both mild ulceration and virus-
induced B-cell activation. Chronic mononucleosis can develop where disease symptoms persist 
for a prolonged period of time. IM is rarely fatal but in patients with the inherited condition X-
linked lymphoproliferative syndrome (XLP), who are extremely sensitive to EBV infection, 
death can occur as a result of liver failure induced by lymphocytic infiltration and hepatic 
necrosis (Rickinson 2001). 
  
1.6.1.2  Burkitt’s Lymphoma (BL) 
Historically, Burkitt’s lymphoma was first characterised by Denis Burkitt in 1958, as a 
childhood malignancy that displayed unusual clinical features and a specific geographical 
distribution whose prevalence coincided with holoendemic malaria (Burkitt 1958). In 1964, 
Epstein and colleagues discovered that EBV was the transmissible particle commonly found in 
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BL cell lines. Burkitt’s Lymphoma can be broadly divided into three categories based on 
geographical incidence: high incidence, classical or endemic Burkitt’s (eBL), as first described 
by Burkitt in 1958, is endemic to areas of equatorial Africa and Papua New Guinea; low 
incidence or sporadic Burkitt’s (sBL) found worldwide; and finally HIV-associated BL. The 
latter form of BL arises prior to severe immunosuppression by HIV and in tandem with the 
onset of full-blown AIDS (Powles, Matthews et al. 2000; Rochford, Cannon et al. 2005). It is 
estimated that approximately 30% of these tumours in adult AIDS patients are EBV-positive 
(Rickinson 2001). 
 The geographical incidence of eBL is limited to areas of Africa and Papua New Guinea 
that are also holoendemic for malaria. It is believed that co-infection of individuals in these 
regions with both the malaria causing parasite, Plasmodium falciparum, and EBV contributes 
to disease incidence and progression by the immunosuppression precipitated by malarial 
infection. eBL is the most commonly occurring childhood malignancy in these regions with 
incidence rates of 5-10 cases/100,000 (Murray and Young 2002), and although 95% of eBL are 
EBV-associated a definitive role for the virus in the pathogenesis and aetiology of the disease 
remains unclear (De-Thé 1979; Blum, Lozanski et al. 2004; Ferry 2006; Pattle and Farrell 
2006). However, the clonal nature of viral isolates from eBL is well established, which implies 
that the malignant clone originated from a single virally infected cell (Raab-Traub and Flynn 
1986). The sBL form of the disease shows no such geographical limitations and is detected 
worldwide; however, its association with EBV is much weaker than eBL with EBV positivity 
rates of approximately 20% in sBL (Lenoir, Vuillaume et al. 1985). BL has also been detected 
in areas of Brazil and North Africa with up to 87% EBV association (Anwar, Kingma et al. 
1995; Araujo, Foss et al. 1999; Klumb, Hassan et al. 2004). Histologically, both forms are 
indistinguishable from one another expressing a similar pattern of cell surface markers, 
including decreased levels of cell adhesion molecules (ICAM-1, CD58), germinal centre 
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markers (CD77, CD10) and B-cell activation markers (CD21, CD23, CD40) (Rowe, Rooney et 
al. 1985; Gregory, Edwards et al. 1988). 
 MYC translocation is a genetic alteration that is present in all forms of BL regardless of 
geographical distribution or EBV status. This translocation places the c-myc proto-oncogene in 
close proximity to an immunoglobulin gene, a region of the B-cell genome that has high 
transcriptional activity (Klein and Klein 1985). This accounts for the high level of c-myc 
expression in BL tumours compared to the levels observed in resting B-cells (Nishikura, ar-
Rushdi et al. 1983). The most frequently detected chromosomal abnormality is the reciprocal 
translocation between the long arm of chromosome 8, 8q24, and the long arm of chromosome 
14, 14q32, occurring in 80% of cases. Alternative translocations occur at t(2:8) and t(8:22) 
(Zech, Haglund et al. 1976; Dalla-Favera, Bregni et al. 1982). This increased activation of 
MYC deregulates the cell cycle of affected cells, pushing them toward either proliferation or 
apoptosis depending on the presence or absence of growth-stimulating cytokines. Both HIV 
infection and malaria display high levels of B-cell stimulatory cytokines driving cells to 
proliferate and contributing to disease pathogenesis.  
 The role played by EBV in endemic BL remains under investigation, although some 
studies show that loss of EBV in BL results in a concomitant loss in its tumourigenic 
phenotype in vitro, which is restored upon re-infection with EBV (Ruf, Rhyne et al. 2000). In 
terms of EBV gene expression, BL typically displays a highly restricted pattern of viral gene 
expression termed latency I, where only Qp-driven EBNA1, the EBERs and the BARTs are 
expressed. In vitro, BL cell lines undergo phenotypic drift, with viral gene expression 
switching to the latency III programme of expression in tandem with an alteration of cell 
surface markers and a concomitant phenotypic alteration to a more lymphoblastoid-like one. 
Such switching may occur in vivo, with rare cases of EBNA2 and LMP1-positive BL 
documented also (Kennedy, Komano et al. 2003).  
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1.6.1.3  Hodgkin’s disease 
Hodgkin’s disease (HD/HL) is the most common lymphoma in the Western world with 
a worldwide incidence of 2-3 cases/100,000. The most recent classification of the disease has 
divided it into classical and non-classical types with further subdivision of the classical type 
into four subtypes, based on morphological, phenotypic and molecular criteria (Harris 1999). 
Classical HL (cHL) includes the nodular-sclerosis (NS), mixed cellularity (MC), lymphocyte-
rich classical (LRC) and lymphocyte-depleted (LD) subtypes; whilst nodular lymphocyte-
predominant Hodgkin’s lymphoma (NLPHL) represents the non-classical types. Although 
most HL is B-cell in origin some rare T-cell-derived HL has been described (Trümper, Brady 
et al. 1993; Kanzler, Küppers et al. 1996). The tumour itself is characterised by the presence of 
malignant multinucleate Reed-Sternberg (HRS) cells contained within hyperplastic lymph 
nodes and constitute only about 2% of the total tumour mass, the remainder consisting of a 
benign cellular infiltrate of lymphocytes, granulocytes and fibroblasts. HRS cells of cHL differ 
from their non-classical counterparts in that the former express CD15 or CD30 markers while 
the latter express the B-cell antigens CD20 or CD19 (Buettner, Greiner et al. 2005).  
EBV is associated with approximately 50% of HL in the Western world: a rate that 
increases to 100% in the developing world (Jarrett, Gallagher et al. 1991), and also appears to 
be age dependent, with a higher frequency amongst patients under 10 and over 55 years of age 
(Ambinder, Browning et al. 1993). The clonal nature of the disease is well established 
implying progression of disease from a single virally infected cell (Anagnostopoulos, Herbst et 
al. 1989). The exact role of EBV in the pathogenesis of HL remains to be fully elucidated, but 
a direct role for EBV has been implicated in the MC subtype of cHL (Murray, Young et al. 
1992; Young and Murray 2003). Increased antibody titres for EBV-associated antigens are 
detectable in HL patients, suggestive of lytic reactivation prior to symptom development 
(Johansson, Klein et al. 1970; Mueller, Evans et al. 1989). It has also been suggested that IM 
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patients are at an increased risk of HL (Bernard, Cartwright et al. 1987). EBV gene expression 
in HL is restricted to latency type II, and both immunohistochemistry and PCR analyses have 
confirmed expression of the EBERs, BARTs, Qp-EBNA1, LMP2A and surprisingly high 
levels of LMP1, given the absence of EBNA2 and its variable level in NPC (Pallesen, Sandvej 
et al. 1991; Deacon, Pallesen et al. 1993; Herbst, Samol et al. 1997). The level of LMP1 is 
thought to contribute to pathogenesis and has been the subject of investigations demonstrating 
that increased levels of IL-6 may be a result of LMP1-mediated modulation of NFκB signalling 
(Herbst, Samol et al. 1997). It has also been postulated that EBV contributes to B-lymphocyte 
survival of HL via LMP1 and LMP2A mimicking CD40 and BCR signalling, respectively 
(Rickinson 2001). Phenotypic differences associated with EBV status are also currently under 
investigation (Baumforth, Flavell et al. 2005). 
 
1.6.1.4  Immunoblastic lymphomas 
EBV-associated lymphoblastic B-cell lymphomas are lymphoproliferative diseases that 
become malignant as a result of chronic immunosuppression following organ transplantation or 
in immunocompromised patients, such as those suffering from AIDS or with the hereditary 
XLP syndrome (Thomas, Allday et al. 1991). These lymphomas are thought to arise as a result 
of a lack of T-cell control in these immunocompromised or immunosuppressed individuals 
(Carbone, Tirelli et al. 1993; Ambinder 2003). Post-transplant lymphoproliferative disorder 
(PTLD) includes diseases such as non-Hodgkins lymphoma, and both EBV-positive and 
negative cases have been documented. AIDS-related EBV-associated lymphomas develop 
predominantly in the central nervous system (CNS), but arise relatively rarely among AIDS 
patients (1-4%) (Niedobitek, Meru et al. 2001). A latency type III gene expression programme 
is displayed in EBV-associated forms, with all nine latent proteins being expressed, together 
with the BARTs and EBERs, comparable with EBV-transformed LCLs in vitro. Tumours of 
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this type are predominantly polyclonal but occasionally monoclonal tumours are identified, as 
defined by their immunoglobulin rearrangements. Monoclonal lesions have been shown to 
switch towards a latency II or latency I pattern of gene expression (Niedobitek, Mutimer et al. 
1997), but the majority of tumours retain an LCL-like phenotype in terms of EBV gene 
expression and cell surface markers (Young, Alfieri et al. 1989; Gratama, Zutter et al. 1991). 
 
1.6.1.5  T-Cell/NK-cell Lymphoma 
Although the majority of EBV-associated lymphoid malignancies are of B-cell origin, 
rare infection of CD4 and CD8 positive T-cells and natural killer (NK) cells has been 
demonstrated in IM patients (Mitarnun, Suwiwat et al. 2002). Lymphoproliferative disorders 
with T-cell origin that have been identified as having an association with EBV include nasal T-
cell lymphoma in patients with lethal midline granuloma (Harabuchi, Yamanaka et al. 1990), 
aggressive peripheral T-cell lymphoma (Dupuis, Emile et al. 2006), extranodal nasal type 
NK/T cell lymphoma, enteropathy-type T cell lymphoma, γδ T-cell lymphomas, (Arnulf, 
Copie-Bergman et al. 1998), and aggressive NK cell lymphoma (Rezk and Weiss 2007). 
Although extensive analyses of the pattern of latent gene expression has not been undertaken, 
evidence does suggest that nasal T-cell lymphoma displays a latency II pattern of expression, 
with peripheral T-cell lymphomas displaying a more restricted latency pattern (Young and 
Rickinson 2004). Given the lack of evidence surrounding the expression of the latent EBV 
proteins in these malignancies, it is unsurprising that the role for EBV in pathogenesis of these 
lymphomas remains to be elucidated.  
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1.6.2  Epithelial cell disease 
1.6.2.1  Oral hairy leukoplakia 
First described and characterised from HIV-positive patients in the 1980s, oral hairy 
leukoplakia (OHL) is a hyperkeratotic lesion of the tongue, which presents as white, poorly 
demarcated ridges on the lateral borders of the tongue that cannot be scraped off (Greenspan, 
Greenspan et al. 1985; Reichart, Langford et al. 1989). It is thought that emergence of the 
benign lesion is an indicator of progression to AIDS from HIV-positivity, which is suggestive 
of an association with immunosuppression as a contributing factor in this disease (Epstein, 
Sherlock et al. 1991). This is further highlighted by the fact that EBV shows little or no ability 
to replicate in the epithelia of the tongue in immunocompetent hosts. Histologically, little or no 
inflammatory infiltrate is detected in the underlying connective tissue, but the squamous 
epithelium of the tongue is notably hyperplastic (Greenspan, Greenspan et al. 1985). 
Reappearance of the lesion after treatment with the antiviral drug, acyclovir, is indicative of 
association with both productive and nonproductive EBV infection (Resnick, Herbst et al. 
1988; Greenspan, De Souza et al. 1990), which is further evidence of the link between 
epithelial cell differentiation and viral replication (Sixbey, Nedrud et al. 1984; Walling, Brown 
et al. 2003). It would appear that OHL is the result of repeated re-infection of tongue 
epithelium rather than uncontrolled expansion  of latently infected basal epithelial cells. The 
presence of multiple EBV strains are indicative of superinfection of EBV infected cells within 
the differentiating layers (Sandvej, Krenács et al. 1992; Webster-Cyriaque, Middeldorp et al. 
2000). Given the inability to identify EBV infection in normal healthy oral mucosa, it is likely 
that immunosuppression is causally linked to the onset of OHL (Pegtel, Middeldorp et al. 
2004; Frangou, Buettner et al. 2005).  
Although analyses have revealed expression of the viral markers EBNA1, EBNA2, 
EBNA-LP and LMP1 in the suprabasal epithelium of these lesions (Murray, Niedobitek et al. 
 38
Chapter 1    Introduction 
 
 
1996; Webster-Cyriaque and Raab-Traub 1998; Walling, Flaitz et al. 2001), these are shown to 
be localised to this layer and the consensus is that latent infection is not established. This is 
reinforced by the detection of immediate early (BZLF1, EA-D, BHRF1), and late (VCA, MA) 
proteins in terminally differentiating cells (Thomas, Felix et al. 1991; Young, Lau et al. 1991; 
Webster-Cyriaque and Raab-Traub 1998; Hayes, Brink et al. 1999). The exact role of EBV in 
this disease remains unclear. However the presence of LMP1 and EBNA2 in OHL lesions and 
the overexpression of cyclin B1 and IL-10 suggests that these may act to deregulate the cell 
cycle and increase cytokine production (Hayes, Brink et al. 1999),. 
 
1.6.2.1  Gastric Carcinoma 
Gastric carcinoma is one of the most common forms of cancer, with approximately 
930,000 cases diagnosed in 2002 (Pisani, Bray et al. 2002), of which between 6 to 16 % were 
found to be EBV-positive (Takada 2000). A comprehensive review of EBV and its role in 
gastric carcinoma has been published recently (Fukayama, Hino et al. 2008). EBV is detected 
in 100% of the tumour cells of EBV-positive gastric carcinoma, and analyses have shown that 
tumour expansion occurs after infection with EBV and arises from a single virally infected cell. 
Two histologically distinct forms of EBV-associated GC have been identified and these vary 
substantially in incidence rate. Lymphoepithelioma-like GC is the rarer of the two, with over 
80% of tumour cells detected as EBV-positive (Osato and Imai 1996; Takada 2000; Fukayama, 
Chong et al. 2001). It is characterised as a poorly differentiated carcinoma with a high level of 
lymphocytic infiltrate. The more common type of EBV-positive GC is an ordinary gastric 
adenocarcinoma, which is characterised as a moderately to poorly differentiated 
adenocarcinoma with varying levels of lymphocytic infiltrate. EBV is not detected in the tissue 
surrounding the tumour but is found in the dysplastic cells located at its periphery (Yuen, 
Chung et al. 1994). This may be indicative of dysplastic cells behaving in a more permissive 
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manner to EBV infection and allowing further development of the malignancy. This mode of 
late infection of cells by EBV is underlined by the fact that EBV is absent from pre-malignant 
lesions (Zur Hausen, van Rees et al. 2004).  
 A restricted pattern of viral gene expression is observed in EBV-positive gastric 
carcinoma, and is most similar to that displayed in HL and NPC, whereby Qp-driven EBNA1, 
the EBERs and BARF1 are all consistently detected and occasionally LMP2A (Takada 2000; 
Fukayama, Chong et al. 2001; Fukayama, Hino et al. 2008). Other latent proteins including 
EBNA2, the EBNA3s and LMP1 are not detected (Luo, Wang et al. 2005), and although these 
cells are latently infected, lytic reactivation can occur via expression of BZLF1 (Niedobitek, 
Herbst et al. 1992). BARF1 has been shown to control apoptosis and promote cell survival via 
modulation of the Bcl-2 family of anti-apoptotic proteins (Wang, Tsao et al. 2006). The BART 
microRNAs have been implicated in the pathogenesis of EBV-positive GC given their frequent 
detection both in vitro, in EBV associated GC (EBVaGC) cell lines, and in vivo, in tumour 
tissue samples (Chang, Lee et al. 2007). More recently the role of LMP2A in the pathogenesis 
of EBVaGC has been investigated: this was performed by cloning LMP2A from the EBV-
positive SNU-719 cell line and stably expressing it in the EBV-negative AGS cell line. Upon 
stable and detectable expression, no differences were observed in the ability of LMP2A to 
effect colony formation of these cells in soft agar, compared to control counterparts. This is 
suggestive of a minor role for LMP2A in tumourigenesis (Seo, Jun et al. 2010), and could 
explain why it is not detected in some cases of EBVaGC. Finally the tumour suppressor gene, 
p53, is found to be frequently mutated in many EBV-negative GCs. In EBVaGC this is not the 
case: rather, p53 shows weak expression indicating a role for EBV in the blockade of p53 
expression and function (Ojima, Fukuda et al. 1997; Leung, Chau et al. 1998). 
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1.6.3  Nasopharyngeal carcinoma (NPC) 
EBV positive Nasopharyngeal carcinoma (NPC) is a lymphoepithelioma of the 
nasopharynx and is classified as a specific subtype of head and neck squamous carcinoma 
(HNSCC). Histologically, the world health organisation classifies the tumour into three types 
based on differentiation status. Type I is a differentiated keratinising squamous cell carcinoma; 
type II is a non-keratinising carcinoma; and type III is an undifferentiated carcinoma. EBV is 
most commonly associated with type II and III NPC, which are commonly grouped together as 
undifferentiated carcinomas (Shanmugaratnam 1978). Type I is the most rare and accounts for 
approximately 20% of all cases and does not have a consistent association with EBV 
(Desgranges, Wolf et al. 1975). Histologically, undifferentiated NPC is characterised by the 
presence of an EBV-negative non-malignant lymphocytic infiltrate, which surrounds latently 
infected, malignant epithelial cells (Chan, Teo et al. 2002; Chan and Lo 2002). The function of 
the infiltrate remains unclear although several investigations reveal that its presence may be 
due to EBV-induced antigen presentation, or perhaps that the lymphocytic tumour environment 
controls tumour growth and progression (Agathanggelou, Niedobitek et al. 1995; Tang, 
Rohwäder et al. 2007). It has been demonstrated that cells of the infiltrate express ligands that 
bind to receptors commonly found on the surface of the tumour cells (Tang, Rohwäder et al. 
2007). 
 In a similar manner to endemic Burkitt’s lymphoma, NPC shows a specific 
geographical distribution: it is the most common tumour in Southern China, particularly in 
Guangdong province, with incidence rates of between 25-30/100,000. In contrast, incidence 
rates of less than 1 in 100,000 occur in Europe and North America. Higher rates of incidence of 
3-8/100,000 are also reported in areas of North Africa and among the Inuit populations of 
Alaska and Greenland (Busson, Keryer et al. 2004). Although strong familial correlation exists 
in endemic Chinese NPC, this is not displayed amongst North African cases (Busson, Keryer et 
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al. 2004). EBV’s association with the disease and its role in the progression of oncogenesis 
have been studied since serological analyses in the late 60s and 70s revealed a putative link 
between the virus and the malignancy (Henle, Henle et al. 1970; zur Hausen, Schulte-
Holthausen et al. 1970). Subsequent investigations demonstrated that EBV viral DNA, 
specifically EBNA1, was present in all tumour cells examined (Huang, Ho et al. 1974; Klein, 
Giovanella et al. 1974), regardless of the geographical origin of the tumour (Desgranges, Wolf 
et al. 1975).  
In tandem with EBV infection, environmental and genetic factors are believed to play 
an important role in oncogenesis (Chan, Teo et al. 2002; Goldsmith, West et al. 2002). Various 
environmental factors have been implicated including phorbol esters in the drinking water, 
which can reactivate EBV, (Shao, Poirier et al. 1988; Raab-Traub 2002); ingestion of 
Cantonese salted fish which contains a high amount of the EBV lytic activator, nitrosamine 
(Mirvish 1995); ingestion of preserved vegetables and certain Chinese herbs; ingestion of 
badly preserved meat and rancid butter (North Africa) (Feng, Jalbout et al. 2007); and 
occupational exposure to pollutants. These factors have all been linked to increased levels of 
NPC (Li, Man et al. 2006). The rate of NPC in endemic areas of China does appear to be on the 
decline and this is attributed, at least in part, to the removal of salted fish from the diet of 
children in the region (Chan, Teo et al. 2004). Studies into the genetic susceptibility of the 
disease have highlighted potential genetic links. The association of various HLA types with the 
development and progression of NPC is reviewed elsewhere (Li, Fasano et al. 2009 ). In 
addition, a variant of the cytochrome P450 CYP2E1 gene also shows strong correlation with 
NPC among Chinese populations (Hildesheim, Anderson et al. 1997). 
 Analyses of genetic changes revealed a putative stepwise mechanism of disease 
development whereby it is hypothesised that accumulation of genetic alterations renders cells 
more permissive to latent EBV infection (Lo and Huang 2002). NPC tumours frequently 
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harbour chromosomal losses at multiple sites including: 3p, 9p, 9q, 11q, 14q and 16q, or 
chromosomal gains at 1q, 3q, 8q, 12p and 12q. Amongst these alterations, higher frequencies 
of loss at 3p/9p were observed in individuals from the high-risk region of China compared to 
control counterparts (Chan, To et al. 2000; Wong, Hui et al. 2003). These deletions are present 
in 80-100% of NPC, which is similar to the level of EBV infection, and is thus suggestive that 
EBV infection may not be the initiating event in NPC pathogenesis, but rather, occurs before 
the initiation of invasive growth (Niedobitek, Meru et al. 2001). NPC tumours are clonal in 
nature thereby supporting the notion that viral infection occurs prior to malignant proliferation 
(Raab-Traub and Flynn 1986). The exact nature of EBV’s role in NPC pathogenesis remains 
unclear, with disease: development attributable to both genetic and epigenetic changes that can 
alter the function of genes involved in proliferation, growth, differentiation and latent EBV 
infection (Niedobitek, Meru et al. 2001). Nasopharyngeal intraepithelial lesion (NPIL), a 
preinvasive lesion with malignant potential, has been shown to be EBER-positive and BZLF1-
negative, indicative of EBV infection prior to initiation of invasive carcinoma; however, it is 
rarely diagnosed since the disease is often presented at later stages (Cheung, Pang et al. 2004). 
The vast majority of NPC tumours display a type II latency programme, with 
expression of Qp-driven EBNA1, the EBER and BART RNAs and variable expression of 
LMP1 and LMP2 (Brooks, Yao et al. 1992; Chen, Hu et al. 1995). Although LMP2A RNA is 
detectable in 100% of cases by RT-PCR, expression of LMP2A protein has been documented 
in approximately 50% of cases (Heussinger, Büttner et al. 2004). A similar situation is 
observed with LMP1 where protein expression varies widely between tumour samples; ranging 
anywhere between 15% and 60% (Niedobitek, Young et al. 1992). Although the majority of 
EBV positive tumour cells adopt a latent gene expression programme, a small proportion of 
NPC tumour cells have been reported to express immediate-early proteins, suggesting that a 
fraction of cells are semi-permissive for lytic reactivation (Cochet, Martel-Renoir et al. 1993). 
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The IE-protein BARF1 has been shown to increase the survival and proliferative ability of 
primary epithelial cells upon infection with an NPC-derived EBV strain (Danve, Decaussin et 
al. 2001). More recently it has been demonstrated that exogenous expression of SV40 
promoter-driven BARF1 in the NPC-derived cell lines CNE-1 and HONE-1 results in cellular 
resistance to apoptosis and growth at high density as compared to their control counterparts 
(Seto, Ooka et al. 2008).  
 
1.7  Innate Immunity 
1.7.1  The TLRs 
The innate immune system is “the first line of defence” against infection by 
microorganisms. Multiple signalling pathways are involved in its regulation and their 
activation results in a variety of cellular phenomena including inflammation, cell clearance by 
apoptosis, and NK cell killing (.A, Yanai et al. 2005; Kawai and Akira 2005; Uematsu and 
Akira 2007). In terms of viral infection, the host cells have a variety of responses to prevent the 
spread of infectious virus and to maintain the integrity of normal cellular function. Pattern 
recognition receptors (PRR) are cellular receptors that are responsible for mounting immune 
responses against invading pathogens (Takeda, Kaisho et al. 2003). These are divided into two 
classes: the toll-like receptors (TLRs) and the RIG-I-like helicases (RLHs) (Kawai and Akira 
2008). The TLRs are members of the interleukin-1 receptor (IL-1R) superfamily and share 
homology within their cytoplasmic regions, specifically within the Toll/IL-1R (TIR) domain 
(Kawai and Akira 2006). The extracellular domain contains a characteristic leucine-rich repeat 
(LRR) and is the site of ligand recognition (Kawai and Akira 2005). Exhibiting high levels of 
evolutionary conservation, TLRs were first identified in Drosophila melanogaster (Lemaitre, 
Nicolas et al. 1996) and, to date, ten receptors have been identified in humans (TLRs 1-10) 
(Takeda, Kaisho et al. 2003).  
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Genetic analyses have revealed their respective ligands include bacterial components 
such as lipopeptide, peptidoglycan and lipoprotein (TLR1, TLR2 and TLR6, respectively), 
bacterial flagellin (TLR5), bacterial lipopolysaccharide (LPS – TLR4), and viral products and 
components including dsRNA (TLR3), ssRNA and imidazoquinoline-like molecules (TLR7/8) 
and microbial unmethylated CpG DNA (TLR9). However, as yet no ligand has been identified 
for TLR10 (Kawai and Akira 2006; West, Koblansky et al. 2006). Activation of TLR 
signalling results in induction of type I interferons, chemokines and inflammatory cytokines. 
TLR signalling links innate and adaptive immunity by initialising maturation of dendritic cells 
(DC), cells which are important for antigen presentation (Iwasaki and Medzhitov 2004; 
Blander and Medzhitov 2006; Husebye, Halass et al. 2006). In the context of viral infection, 
five TLRs have been shown to initiate innate immunity: TLR3, TLR4, TLR7/8 and TLR9 
(Uematsu and Akira 2007; Randall and Goodbourn 2008.). Upon ligand recognition, signalling 
is initiated within endosomal compartments for all of these receptors, with the exception of 
TLR4, which can also signal from the plasma membrane (Fitzgerald, Palsson-McDermott et al. 
2001; Kagan, Su et al. 2008).  
 
1.7.2  TLR3 signalling 
TLR3 signalling is initiated within the endosome (West, Koblansky et al. 2006), 
although the receptor has also been identified in alternative locations such as the plasma 
membrane (Matsumoto, Funami et al. 2003). Findings suggest that for signalling to occur, 
activation of adaptor molecules must occur within an acidified or partially acidified endosome 
compartments (Johnsen, Nguyen et al. 2006). The receptor recognises extra-cellular viral 
dsRNA which is internalised into endosomes via endocytosis (Alexopoulou, Czopik Holt et al. 
2001; Marshall-Clarke, Downes et al. 2007). Upon ligand binding (poly(rI).poly(rC), TLR3 
dimerises and becomes phosphorylated (Sarkar, Peters et al. 2004; Sen and Sarkar 2005) 
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through its TIR domain, subsequently recruiting the adaptor proteins TIR domain containing 
adaptor inducing IFNβ (TRIF) and PI3-K (Kawai and Akira 2005; Kawai and Akira 2006). 
These adaptor proteins mediate the signal through two distinct pathways of interferon 
induction: IRF3 and NFκB (O'Neill and Bowie 2007). The IRF3 pathway is the less well 
understood of the two but it is known that TRIF interacts with TNF receptor associated factor 3 
(TRAF3) (Sato, Sugiyama et al. 2003; Häcker, Redecke et al. 2006), which subsequently 
recruits TRAF family member associated NFκB activator (TANK) (Sato, Sugiyama et al. 
2003). The exact role of TANK is, as yet ill-defined, although it has been shown to associate 
with TANK-binding kinase (TBK1), which in addition to IκB kinase epsilon (IKKε – a 
member of the kinase complex involved in the control of NFκB) is responsible for directly 
phosphorylating IRF3 (Dragan, Hargreaves et al. 2007). Once phosphorylated, IRF3 forms 
homo/heterodimers with itself or IRF7, translocates to the nucleus and activates the 
transcription and production of IFNβ (Honda and Taniguchi 2006). 
Activation of NFκB by TLR3 has been better characterised: TRIF recruits TRAF6 
which initiates its ubiquitin ligase activity, enabling it to poly-ubiquitinate both itself and the 
receptor interacting protein 1 (RIP1) (Sato, Sugiyama et al. 2003; Häcker, Redecke et al. 
2006). Once ubiquitinated, these proteins are recognised by and interact with TAK1-binding 
proteins 2 and 3 (TAB2 and TAB3), which leads to the recruitment of transforming growth 
factor B-activated kinase 1 (TAK1) to the complex (Sato, Sugiyama et al. 2003; Randall and 
Goodbourn 2008.). Recognition of poly-ubiquitinated RIP1 by the NFκB essential modifier 
(NEMO) component of the IKK complex brings it into close proximity with the TRIF-RIP1-
TRAF6-TAB2-TAB3-TAK1 complex and facilitates phosphorylation of the IKKβ subunit by 
TAK1 (Kawai and Akira 2006; Sarkar, Elco et al. 2007). This leads to the downstream 
phosphorylation and ubiquitin-mediated degradation of IκBα, resulting in NFκB release, 
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processing and translocation of the transcriptional activators, usually p65 and p50, to the 
nucleus (Deng, Wang et al. 2000; Hayden and Ghosh 2004).  
 
1.7.3  TLR7/8 and TLR9 signalling 
TLRs 7 and 8 recognise endosomal viral ssRNA and the imidazoquinoline molecules 
which include imiquimod and R848; both signal from internal endosomes (Hemmi, Kaisho et 
al. 2002; Diebold, Kaisho et al. 2004; Nishiya, Kajita et al. 2005). These ssRNA products are 
commonly produced during the replication of Vesicular stomatitis virus (VSV), Sendai virus 
(SeV) (Kawai and Akira 2006), and activation of signalling from these TLRs can also occur 
upon infection and RNA release in the endosome of RNA viruses such as influenza A virus, 
without replication (Hemmi, Kaisho et al. 2002; Kawai and Akira 2008). Due to the restricted 
pattern of cellular expression of these TLRs, their activity has been extensively but not 
exclusively studied in plasmacytoid dendritic cells (pDCs), which express high levels of TLR7 
(Cao and Liu 2007). TLR8 signalling is less well characterised, but it is widely thought that 
signalling activation is controlled in a similar manner to that of TLR7 given the similarities 
between their expression patterns and cognate ligands (Jurk, Heil et al. 2002). In the case of 
TLR7, upon recognition and binding of ligand, the adaptor molecule myeloid differentiation 
factor 88 (MyD88) is recruited to the receptor (McGettrick and O'Neill 2004), which interacts 
with the interleukin-1 receptor associated kinase (IRAK) proteins, IRAK1 and IRAK4 (Li, 
Strelow et al. 2002; Gottipati, Rao et al. 2007; Kim, Staschke et al. 2007), which facilitate 
activation of TRAF6 (Kawai and Akira 2005; Martin, Lee et al. 2007; Randall and Goodbourn 
2008.). NFκB signalling is then initiated in a similar manner to the RIP1-TAB-TAK 
mechanism described for TLR3 signalling (Kawai and Akira 2006; Wullaert, Heyninck et al. 
2006).  
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While the pathway to induction of IFN initiated from TLR3 depends heavily on 
phosphorylation and dimerisation of IRF3 in TLR7- and TLR8-expressing pDCs there are also 
high levels of endogenous IRF7 (Sato, Suemori et al. 2000). Here TLR7 engages the MyD88-
IRAK-TRAF6 complex, described above, and binds directly to IRF7 (Kawai, Sato et al. 2004). 
IRF7 then becomes ubquitinated by TRAF6 in a RIP1-dependent manner, and is subsequently 
phosphorylated by IRAK1 (Caillaud, Hovanessian et al. 2005; Kawai and Akira 2005; Randall 
and Goodbourn 2008.). The complex then translocates to the nucleus where it can bind to 
promoter elements to activate transcription. IRF7 has been shown to be responsible for 
transcriptional activation of members of the IFNα cytokine (Au, Moore et al. 1998; Barnes, 
Richards et al. 2004; Honda, Yanai et al. 2005; Honda and Taniguchi 2006). Signalling 
downstream of TLR9 is identical to that of TLR7, although the ligand for this receptor is 
unmethylated microbial DNA (CpG DNA) which is derived from a variety of infective sources 
and is delivered to the receptor by retention in the endosome (Uematsu and Akira 2007; Kawai 
and Akira 2008).  
 
1.7.4  TLR4 signalling 
TLR4 is the PRR responsible for recognition of LPS, a component of the bacterial cell 
wall. In terms of viral infection it has also been shown to be involved in signalling by 
recognition of the F protein of Respiratory Syncitial Virus (RSV) (Kurt-Jones, Popova et al. 
2000) and the gG protein of Vesicular Stomatitis Virus (VSV) (Georgel, Jiang et al. 2007). 
TLR4 is unique among the type I IFN-inducing TLRs in that it can signal through both 
MyD88-dependent and independent mechanisms (Takeda, Kaisho et al. 2003; Shen, Tesar et 
al. 2008). It does so through activation of a variety of signalling cascades but, unlike the 
previously described pathways, which demonstrate direct interaction between the activated 
receptor and the relevant adaptor molecule (TRIF or MyD88), signalling through TLR4 
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requires additional interacting proteins. Activation of IRF3 is mediated initially by binding of 
the TRIF-related adaptor molecule (TRAM) protein to TLR4 (Kagan, Su et al. 2008). This 
adaptor has been shown to be necessary for activation of TRIF-dependent induction of IRF3 
and has dual localisation capabilities, shuttling between the endosomal and the plasma 
membrane. Upon interaction of TRAM with TRIF, signalling continues in a similar manner to 
that of TLR3, activating IRF3 via TBK1 and IKKε, and activating NFκB via RIP1 and TRAF6 
(Kawai and Akira 2006). The second MyD88-dependent mode of signalling from this receptor 
occurs via the Mal protein (MyD88-adaptor like) (Fitzgerald, Palsson-McDermott et al. 2001). 
This protein interacts directly with the receptor and recruits the MyD88-IRAK-TRAF6 
complex, thus facilitating signalling to proceed in manner to that observed upon activation of 
TLR7 (Randall and Goodbourn 2008.). Figure 1.2 shows a schematic of TLR signalling.  
 
1.7.5  The RIG-I-like helicases (RLHs) 
The RIG-I-like helicases (RLHs), retinoic acid-inducible gene 1 (RIG-1) and melanoma 
differentiation-associated gene 5 (MDA5) are cytoplasmic sensory proteins that have been 
shown to recognise and bind cytosolic dsRNA (Yoneyama, Kikuchi et al. 2004; Kawai and 
Akira 2008). While detection of endocytosed dsRNA is performed by TLR3, the 
aforementioned sensory proteins are responsible for mediating an immune response upon viral 
replication within the cytosol of infected cells that may otherwise remain undetected by the 
endosomally located TLR3. Structurally these proteins share three common domains, two 
caspase-recruiting domains (CARD domains) and one DexD/helicase domain. The dsRNA is 
recognised by the helicase domain, whilst signalling is initiated from the CARD domains 
(Yoneyama, Kikuchi et al. 2004). In a manner similar to signalling from TLR3, stimulation of 
a response results in activation of the nuclear transcription factors, IRF3 and NFκB. In both 
cases, analyses have revealed that the adaptor protein involved in the initiation of these signals 
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is the interferon promoter stimulator-1 protein (IPS-1) also known as mitochondrial anti-viral 
signalling protein (MAVS) or virus-induced signalling adaptor (VISA) (Sun, Sun et al. 2006). 
Interactions between IPS-1, RIG-1 or MDA5 occur via their CARD domains and downstream 
signalling is thought to proceed in a manner similar to the TRIF-mediated pathways of 
TLR3/4, thereby leading to the formation of the enhanceosome and production of IFNβ, 
although these mechanisms remain to be fully elucidated (Randall and Goodbourn 2008.).  
 
Whilst RIG-1 and MDA5 share significant structural homology, they appear to recognise 
infection by different virus types. RIG-1 is essential for ssRNA virus recognition, such as 
paramyxoviruses, influenza virus, VSV and Japanese encephalitis virus (JEV). MDA5 is also 
involved in recognising other RNA viruses, such as Encephalomyocarditis virus (EMCV), 
amongst others (Kawai and Akira 2008). A third member of the family has been identified: 
LGP2, which contains the helicase domain but not the signalling activatory CARD domains, 
therefore initially implicating it in the negative regulation of the two IFN-inducing receptors 
(Rothenfusser, Goutagny et al. 2005; Yoneyama, Kikuchi et al. 2005). A more recent 
investigation has proposed a role for LGP2 in the positive regulation of immune responses to 
viral infection (Satoh, Kato et al. 2010).  
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Figure 1.2  Innate immune signalling network. 
 
 
Displayed is a schematic representation of the signalling from the type I interferon inducing 
Toll-like receptors (TLRs) and the RIG-1-like helicases (RLHs). (1) TLR3 signalling is 
initiated upon binding of dsRNA or poly (I:C) to the receptor, which dimerises, phosphorylates 
and recruits TRIF via its TIR domain. The adaptor protein TRIF then recruits either TRAF3 or 
TRAF6 to initiate activation of IRF3 or NFκB subunits. IRF3 is activated recruitment of 
TRAF3 by TRIF and subsequent interaction with TANK, TBK1 and IKKε. Phosphorylation of 
IRF3 occurs upon interaction with one of these proteins but an exact mechanism for this 
remains to be elucidated. P-IRF3 can then homo- or hetero-dimerise with IRF7, translocate to 
the nucleus and exert its effect. NFκB subunit activation is effected by interaction of TRIF with 
TRAF6, the IKK complex and phosphorylation and degradation of IκBα, which releases NFκB 
subunits.  (2) TLR4 signalling is initiated upon binding of LPS to the receptor and recruitment 
of the TRAM and Mal intermediate proteins, TRAM activates signalling through interaction 
with TRIF as for TLR3. The Mal adaptor protein interacts with MyD88, facilitating 
recruitment of TRAF3 the IRAK proteins and subsequent phosphorylation, polyubiquitination 
and activation of IRF7. This complex can then move to the nucleus to activate transcription. 
NFκB activation id mediated through TRAF3 phosphorylation of TRAF6 and its interaction 
with the IKK complex. (3) TLR 7 8 and 9 signalling is initiated by binding of RNA and DNA 
molecules and proceeds in a MyD88 dependent manner as described for TLR4. (4) Signalling 
through the RLHs is initiated upon cytoplasmic recognition of RNA molecules which activate 
the receptor and facilitates recruitment of IPS1/VISA adapter protein. This intermediate 
interacts with TRAF3 and facilitates IRF3 activation in a similar manner to TLR3 signalling 
and with TRAF6 to activate NFκB subunits. Adapted from, (Kawai and Akira 2006; Randall 
and Goodbourn 2008.) 
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1.7.6  The IFNβ enhanceosome 
Type I interferon induction, inflammatory cytokine release, and initialisation of the 
anti-viral state are all consequences of activated TLR signalling (Kawai and Akira 2006). One 
important feature is the production of IFNβ, a cytokine which is controlled through formation 
of the IFNβ “enhanceosome” (Yie, Senger et al. 1999). This is a multiprotein activator of 
transcription that binds to four distinct binding sites of the IFNβ promoter element: positive 
regulatory domains (PRD) I, II, III and IV, each of which has been shown to interact with a 
dimer of transcription factors (Panne 2008). The IRF homo/heterodimers bind to PRDI and 
PRDIII, whilst the AP-1 subunits bind to PRDIV, and the NFκB dimers bind to PRDII (Panne 
2008). Translocation to the nucleus of the IRF and NFκB subunits is described in detail above. 
AP-1 is a dimeric transcription factor composed of two subunits of the Fos and Jun families, of 
which c-Jun and ATF-2 are thought to be responsible for mediating inflammatory responses 
(Vesely, Staber et al.; Ozanne, Spence et al. 2006). Activation of AP-1 upon TLR stimulation 
is controlled by the MAPK signalling pathways, which include the ERK, JNK and p38 
signalling cascades. Signalling through these cascades is controlled by TAK1, which has been 
shown to phosphorylate MAPK kinase family members including, MKK3 and MKK6 (Sato, 
Sanjo et al. 2005).  
 Formation of the enhanceosome complex results in the recruitment of cellular co-
activating molecules including CBP/p300 (Yoneyama, Suhara et al. 1998), and the subsequent 
transcriptional activation of the IFNβ promoter. In terms of IFNβ production, it has been 
shown that IRF3/IRF7-binding is indispensable whereas type I IFN induction has been 
documented in the absence of NFκB and AP-1 activity (Peters, Smith et al. 2002). 
Furthermore, it has also been reported that cooperative binding of NFκB subunits and IRF 
subunits to ISRE elements can result in the transcriptional activation of some chemokines 
involved in the inflammatory response (Honda and Taniguchi 2006). However, the correct 
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binding of the IRF components of the enhanceosome complex is fundamental to the production 
of IFNβ.  
 
1.7.7  The IRF proteins 
Activation of the IRF proteins is a fundamental component of the induction of the type 
I IFN response (Honda and Taniguchi 2006; Colonna 2007). As described above, there are 
multiple mechanisms that facilitate phosphorylation, dimerisation and translocation of these 
proteins to the nucleus where they can exert their effects. In TLR3 signalling, IRF3 is 
detrimental to the early phase of type I IFN induction, particularly IFNβ (Hiscott 2007). 
Although it shares a binding site with IRF7 within the IFNβ promoter and has been shown to 
form heterodimers with IRF7; this usually occurs after an initial wave of the innate immune 
response (Sato, Suemori et al. 2000). IRF3 expression is constitutive and in most cell types it is 
expressed at levels much higher than that of IRF7 (Wang, Zhang et al. 2008). Activation of 
TLR3 by dsRNA molecules is initially facilitated by utilisation of this intracellular pool of 
IRF3 and, following the initial wave, a positive feedback loop results in an increase of IRF7 
expression (Honda, Yanai et al. 2005). This can then be phosphorylated and activated in a 
TBK1/IKKε-mediated manner and can contribute to or replace IRF3 activity in further IFN 
production. IRF5 has also been shown to be involved in inflammatory cytokine induction as a 
result of signalling from TLR3, 4, 7 and 9. This is mediated by binding of the protein to the 
interferon stimulated response element (ISRE) in the promoter region of activated genes 
(Barnes, Richards et al. 2004; Takaoka, Yanai et al. 2005; Balkhi, Fitzgerald et al. 2010). 
Furthermore, IRF8 has been implicated in TLR9-driven NFκB activity (Tsujimura, Tamura et 
al. 2004). Both IRF9 and IRF1 have been shown to be involved in controlling signalling from 
the IFNAR, which is activated para/autocrinely upon release of the IFNβ or IFNα cytokines.  
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1.7.8  The SOCS proteins 
The suppressors of cytokine signalling (SOCS) family of proteins are involved in the 
negative regulation of interferon induction (Yoshimura, Naka et al. 2007), functioning to 
attenuate or limit IFN production in response to TLR or RIG-I/MDA-5 activation. The 
complex network of signalling cascades initiated by invading pathogens requires tight and 
rigorous control, which is mediated in part by these proteins. The family consists of eight 
members, Cytokine Inducible SH2 containing protein (CIS) and SOCS1-7 and roles have been 
defined for them in both innate and adaptive immunity, including inhibition of TLR and IFN 
signalling (Alexander and Hilton 2004). Structurally the proteins contain an SH2-interacting 
domain; a conserved carboxy-terminal domain (the SOCS-box) through which it is thought to 
mediate its effects in an E3 ligase-dependent fashion; and a kinase inhibitory domain (KIR), 
which is also important for attenuation of signalling responses (Zhang, Farley et al. 1999; 
Kobayashi, Takaesu et al. 2006). SOCS1 has been shown to inhibit TLR signalling through 
interactions with the NFκB subunit, p65, and the Mal adaptor protein, facilitating their 
ubiquitin-mediated degradation (Gingras, Parganas et al. 2004; Kobayashi, Takaesu et al. 
2006). Type I interferon signalling is inhibited through direct interaction of the SOCS1 protein 
with the JAK tyrosine kinases (Yoshimura, Naka et al. 2007). Additionally the SOCS3 protein 
interacts with STAT3, which has been shown to control signalling from the pro-inflammatory 
IL-6 receptor (IL6R) and the anti-inflammatory IL-10R as well as the IL-12 receptor (IL-12R) 
(Yamamoto, Yamaguchi et al. 2003). It is thought that STAT3 activation of IL-6R is transient 
and operates mainly to promote an anti-inflammatory response through attenuation of TLR 
signalling through an indirect interaction with SOCS3 (Andrea, Frey et al. 2004). It has also 
been reported that SOCS3 can inhibit activation of both TRAF6 and TAK1 to modulate TLR 
signalling. Expression of both of these proteins is induced by TLR receptor signalling – an 
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example of the complex feedback loops utilised by innate immunity to regulate responses (Kile 
and Alexander 2001; Yoshimura, Naka et al. 2007).  
 
1.7.9  Interferon signalling 
The term “interferon” was first coined by Issacs in 1957 (Isaacs and Lindenmann 1957) 
to characterise a secreted cytokine that demonstrably “interfered” with viral replication. They 
are grouped into three types, which contribute to formation of the ant-viral state (Goodsell 
2001; Randall and Goodbourn 2008.). Type I IFNs, which are induced by TLR, RIG-I and 
mda-5 activation, as described above, include IFNβ and the IFNα family, of which 13 have 
been identified in humans (Garcia-Sastre and Biron 2006). Type II has one member, IFNγ, 
which is secreted by activated T-cells and NK-cells as an indirect consequence of viral 
infection and serves to further promote the inflammatory response (Platanias 2005). The role of 
the type III interferons is less well characterised but they are known to be released as a result of 
viral infection and include IL-26, IL-28A and IL-28B (Uzé and Monneron 2007).  
The type I interferons are recognised by the dimeric IFNα/β receptor which is 
composed of two subunits: IFNAR1 and IFNAR2, and signal through their respective 
associated tyrosine kinases, Tyk2 and Jak1 (Randall and Goodbourn 2008.). Upon ligand 
binding to the receptor, the two subunits dimerise enabling Tyk2-mediated phosphorylation of 
both STAT2 at tyrosine 690, which is associated with IFNAR2 prior to activation, and 
IFNAR1 at tyrosine 466. Jak1 phosphorylates STAT1 at tyrosine 701 and the phosphorylated 
STATs form a stable heterodimer, which can then interact and bind to IRF9/p48 to form the 
ISGF3 heterotrimeric transcription factor (Samuel 2001; Garcia-Sastre and Biron 2006; 
Murray 2007). The location of this IRF9 binding to STAT heterodimers was thought to be 
nuclear, given the nuclear localisation signal (NLS) that is revealed upon STAT dimerisation 
and the reversal of inhibition of STAT2 nuclear retention (Randall and Goodbourn 2008.). 
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However, recent evidence demonstrating that acetylation is necessary for IRF9 DNA-binding 
and that IFNAR2 also becomes acetylated thus recruiting the CBP cofactor, alludes to the 
formation of ISGF3 in the cytosolic compartment (Tang, Gao et al. 2007). The ISGF3 
transcription factor binds to the ISRE element to activate transcription of over one hundred 
genes involved in the maintenance of an ant-viral state, including members of the IRFs, PKR, 
2’5’-oligoadenylate synthase (OAS) and promyelocytic leukaemia nuclear bodies (PMLs). 
Upon activation by interaction with dsRNA, PKR can induce autophagy, which disrupts viral 
replication and initiates further immune responses. 2’5’OAS is also activated by dsRNA and is 
involved in production of RnaseL, and agent that degrades viral RNA (Platanias 2005; Tang, 
Gao et al. 2007). PML bodies are also involved in the regulation of viral replication and 
depletion of these bodies has been shown to increase replication of HSV-1 (Herpes simplex 
virus-1) (Boutell, Orr et al. 2003). Their exact function remains to be further elucidated and is 
reviewed elsewhere (Everett and Chelbi-Alix 2007).  
IFNγ signalling is controlled in a similar manner: its cognate receptor becomes 
activated upon dimerisation of its two subunits, IFNGR1 and IFNGR2, which are associated 
with the tyrosine kinases JAK1 and JAK2, respectively (Goodbourn, Didcock et al. 2000). 
Once activated, JAK1 phosphorylates JAK2 and the IFNGR1 subunit, facilitating STAT1 
binding, which results in homodimer formation and activation via phosphorylation. This 
homodimer can then bind to gamma-activation sequence (GAS) elements in the promoters of 
relevant genes, activating their transcription (Samuel 2001; Platanias 2005). Various other 
STAT dimers have been identified and these include STAT1 homodimers, STAT2 
homodimers with IRF9, and STAT1-STAT2 heterodimers without IRF9, as a result of type I 
signalling. In response to type II interferon signalling, STAT1 homodimerises with IRF9 and 
the STAT molecules have also been found to be associated with various other proteins, 
including IRF1 (Honda and Taniguchi 2006).  
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1.8  Viral immune evasion
Viral infection triggers mechanisms, which serve to orchestrate host immune responses 
to initiate anti-viral responses, thereby limiting the spread of infectious virus. Viruses have 
developed strategies to circumvent these responses, be they short-term, as is the case for 
transient lytic infections, or more long-term, in the case of persistent viruses such as 
herpesviruses (Garcia-Sastre and Biron 2006). In addition to developing mechanisms to limit 
innate immune responses, viruses have also devised mechanisms to avoid detection by 
immunosurveillance. Such strategies include inhibition of interferon and TLR signalling, 
blockade of cytokine secretion, modulation of apoptosis and disruption of antigen presentation 
(Grandvaux, tenOever et al. 2002). In terms of the interferon response, viruses have acquired 
various methods of attenuating and blocking the establishment of an anti-viral state. Recent 
data highlighting a role of the EBV-encoded LMP2A/2B proteins have demonstrated that their 
expression leads to a downregulation of Type I interferon signalling and ISGF3 formation, 
which results in a global repression of ISG expression (Shah, Stewart et al. 2009). The 
importance of IRF3 in regulating these pathways has also been demonstrated in other viruses 
including the smallpox vaccinia virus and HCV which can both block IRF3 activation; the 
latter through the virally-encoded protein NS3/4A (Sen and Williams 2003). Blockade of IFR3 
results in an attenuated IFN response and facilitates viral infection. The extensive and wide-
ranging methods of viral disruption of interferon signalling are outlined in the Table below. 
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Table 1.1: Viral Inhibition of Interferon responses
 
Activity Virus Protein/Gene Mechanism 
HCV NS3/4a 
VACV A52, A46 
Inhibition of TLR response 
Paramyxo-viruses V 
Influenza A virus NS1 
Inhibition of RIG-1 and Mda5
HCV NS3/4a 
BDV P 
Inhibition of TLR/RIG-1  
signalling 
VACV N1 
Disruption of IPS-1 activity 
RABV P 
HTNV G1 
HHV6 E1 
Rotaviruses NSP1 
BVDV N Protein 
CSFV N Protein 
HPV16 E6 
HSV ICP0 
BHV1 BICP0 
Inhibition of IRF3 activity 
THOV ML 
Inhibition of IRF3 activity by 
alteration of phosphorylation 
or degradation 
HPV E7 
HCV Core 
VACV Unknown 
Adenovirus E3 
Disruption of IKK complex 
formation/activity 
ASFV A238L 
VACV N1 
Inhibition of NFκB signalling 
MYXV MNF 
Disruption of NFκB activity 
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Table 1.1: Viral Inhibition of Interferon responses
 
 
Activity Virus Protein/Gene Mechanism 
HHV8 K3 K5 Receptor retention 
HCMV Unknown 
HPV18 E6 
HSV U(L)41 
JEV NS5 
LGTV NS5 
MeV C, V proteins 
MPV T antigen 
Downregulation of 
IFN receptor  
activity 
MuV V protein 
Interference with JAK 
HPIV2 V protein 
HPIV5 V protein 
HSV U(L)41 
MuV V protein 
NDV V protein 
RSV NSP2 
SeV C protein 
SV41 V protein 
SV5 V Protein 
Degradation of STAT 
Adenovirus E1A 
EBOV VP24 
HBV Unknown 
HCMV IE1 
HCV Core 
HeV V protein 
HPIV3 Unknown 
MeV V protein 
MPRV V protein 
NiV V protein 
RABV P protein 
RPV P, V protein 
Disruption of STAT 
 activity 
VACV VH1 
STAT phosphorylation 
 /sequestration 
HSV UL41/UL13 
HCV Core 
Induction of SOCS proteins 
HHV8 vIRFs 1-3 
HBV Capsid protein
Adenovirus EIA 
Interference of ISG  
promoter activity 
HHV8 vIRFs 1-3 Interference of IFNβ promoter 
EBV EBNA2 Disruption of IFN  
induced transcription 
Inhibition of IFN 
 induction/ 
transcriptional activity 
HPV16 E7 IGSF3 formation 
Sequestration of  
IFN via soluble 
 receptors 
 
MYXV 
 
 
M-T7 
Bind IFNs and prevent  
signalling from cellular  
receptors 
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Table 1.1: Viral Inhibition of Interferon responses
Activity Virus Protein/Gene Mechanism 
Reovirus Omega3 
Rotavirus NSP3 
VACV E3L 
OV OV20.0L 
Influenza virus NS1 
HSV US11 
HCMV TRS1 
MCMV m142/143 
EBOV VP35 
EBV SM 
Binds and sequesters dsRNA  
preventing activation 
Adenovirus VAI RNA 
EBV EBER RNA 
HIV TAR RNA 
Binds to PKR without activation 
Baculovirus PK2 
HCV NS5A, E2 
HSV US11 
HIV Tat 
Binds to and inhibits PKR 
Poliovirus Unknown Degrades PKR 
Inhibition of PKR  
activity 
Influenza virus Unknown Induction of p58IPK, inhibitor 
VACV K3L Inhibition of eIF2a 
phosphorylation  HSV ICP34.5 
Inhibition of eIF2a phosphorylation
Reovirus Omega3 
Rotavirus NSP3 
VACV E3L 
OV OV20.0L 
Influenza virus NS1 
HSV US11 
HCMV TRS1 
MCMV m142/143 
EBOV VP35 
EBV SM 
Binds and sequesters dsRNA  
preventing activation 
EMCV Unknown 
HIV Unknown 
RnaseL inhibitor induction 
Inhibition of  
2’5’OAS activity 
RnaseL 
HSV Unknown 2’5’OAS antagonist expression 
 
 
 
The above Table is adapted from the following review articles (Alcami and Koszinowski 2000; 
Randall and Goodbourn 2008.), and demonstrates the wide variety of mechanisms of ant-viral 
immune evasion, highlighting the evolution of viral genes tailored to disrupt normal cellular 
defences. In addition to modulation of the interferon response, viruses have evolved 
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mechanisms to disrupt apoptosis, cytokine production and release; these have been reviewed 
extensively elsewhere (Levy and Garcia-Sastre 2001). Importantly in the context of this thesis, 
viruses have been shown to modify normal cellular trafficking to disrupt antigen presentation 
by MHC molecules. The following Table highlights some of the viral proteins that have been 
shown to exert such effects.  
Table 1.2: Viral inhibition of MHC antigen presentation.  
 
Activity Virus Protein/Gene Mechanism 
Adenovirus E3/19K 
US3 
Retention of MHC I molecules in 
(endoplasmic reticulum) 
US2, US11 Relocation of MHC I 
m4 MHC I binding 
HCMV 
m6 Lysosomal degradation of  
MHC I 
MCMV m152 Retention of MHC I in Golgi 
HHV8 K3, K5 
MHV68 K3, K5 
Downregulation of MHC from 
 surface 
Nef Endocytosis of MHC 
MHC class I 
 inhibition 
HIV 
Vpu Destabilisation of MHC 
Adenovirus E1A Prevents activation of MHCII  
expression 
HCMV US2 Degradation of MHC II 
HSV ORF14 MHC II binding 
HPV E5, E6 Acidification of endosomes 
BPV E5, E6 Disruption of AP complexes 
MHC class II  
inhibition 
HIV Nef Disruption of processing 
HSV ICP-47 Inhibits peptide:TAP binding Inhibition of TAP 
(transporters  
associated with 
 antigen processing) 
HCMV US6 Inhibits TAP transport 
Inhibition of antigen 
production 
EBV EBNA1 Inhibits proteasomal degradation
 (Gly-Ala repeat) 
 
The above Table is adapted from a selection of review articles (Bonnerot, Briken et al. 1997; 
Alcami and Koszinowski 2000; Donaldson and Williams 2009; Hansen and Bouvier 2009). In 
addition to demonstrating the ability of viral proteins to alter antigen presentation, this Table 
also highlights the mechanisms by which viruses can affect intracellular trafficking, a subject 
which is investigated in more detail later (Chapter 5). 
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1.9  Endosomal-lysosomal trafficking 
The endosomal-lysosomal trafficking network is involved in a variety of cellular 
processes including receptor signalling, immune surveillance and sensing of the extracellular 
milieu. Vast quantities of membrane are constantly endocytosed into the cell, along with 
tethered proteins. These are subject to membrane recycling, undergo degradation or participate 
in cell signalling responses. Due to the pleiomorphic and dynamic nature of the network, 
analysis has been problematic, although advances in cell imaging and isolation of markers for 
specific compartments are aiding increases in our level of understanding. It is known that the 
family of small Rho GTPases have a significant role to play in the regulation of intracellular 
traffic (Zerial and McBride 2001; Rodriguea-Boulan, Kreitzer et al. 2005). Figure 1.3 depicts a 
schematic representation of the trafficking network whereby invaginated clathrin-coated pits 
allow access of membrane and membrane-bound proteins into the cell, which can be 
transferred through early endosomes to the sorting multi-vesicular body, or sorting endosome, 
and from here they are targeted for recycling or degradation in the lysosome. Specific 
endosomal compartments involved in these various processes can be defined by molecular 
analysis of their membrane proteins (Deneka, Neeft et al. 2003). 
 
1.9.1  Endocytosis, clathrin and its effectors 
Endocytosis is a process by which cells uptake exogenous proteins from their 
immediate environment and in doing so internalises membrane and membrane-bound proteins. 
Much of the current research focuses on clathrin-dependent endocytosis (CDE), although 
clathrin-independent mechanisms have also been identified (CIE) (Donaldson, Porat-Shliom et 
al. 2009). CDE is a mechanism that involves complex protein-protein and protein-lipid 
interactions. These mechanisms include those dependent on caveolin-coated structures, which 
is linked to proteins localising to cholesterol-rich membrane regions, in addition to  
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Figure 1.3 Endosomal-Lysosomal Trafficking 
 
Schematic of endosomal to lysosomal intracellular trafficking network by which 
receptors are endocytosed, sorted and targeted for recycling or degradation in the 
lysosome. (1) Endocytosis is controlled in a clathrin dependent manner and results in 
internalisation of membrane and membrane bound receptors and proteins first in 
clathrin coated pits (CCP) and secondly in clathrin coated vesicles (CCV). These 
vesicles are then carried through the cell and interact with Rab5 to form Rab5 early 
vesicles (2), Rab5 is a small GTPase that controls both early and late stages of 
endosome and vesicle intracellular traffic. Upon recruitment of its effector proteins 
(GEFs) (3) including EEA1, Rabex-5 and Rabaptin-5, this activated Rab5 and 
facilitates vesicle to endosome fusion and homotypic early endosome (EE) fusion.  
 
The contents of the vesicle are passed to the EE and here through the interaction of 
GEFs, Rab5 and membrane bound phospholipids trafficking to the late endosome 
(LE) is effected (4). EE to LE switching is facilitating by changes in the membrane 
architecture of the compartments, including loss of Rab5 and the presence of Rab7. 
EE conversion events to LE conversion events occur more often than the reverse and 
from the LE compartmental contents are passed to the acidic lysosome for 
receptor:ligand detachment and degradation of content.(5) The lysosomal pH is 
maintained by presence of the v-ATPase holoenzyme and degradation is mediated by 
the presence of acid hydrolases including Cathespins. LAMP1 is a membrane bound 
lysosomal protein that is used a marker of this compartment and contributes to the 
highly carbohydrate component of the membrane via glycosylation events. (6) Rab9 
is responsible for shuttling, MPRs to the lysosome from the Trans Golgi Network 
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(TGN), which are bound to acid hydrolases. (7) Endocytosed content can also be 
recycled back to the membrane via the multi-vesicular body (MVB)/sorting 
endosome, Rab4 and Rab11 are localised here, Rab4 controlling short recycling, not 
via the TGN and Rab11 long recycling, through the GA (golgi apparatus) (8). 
Authophagy, exosome formation and synthesis and secretion of protein are controlled 
by the TGN/GA and are initiated here.  This Figure is adapted from a variety of 
sources, (Woodman 2000; Zerial and McBride 2001; Rodriguea-Boulan, Kreitzer et 
al. 2005) 
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phagocytosis and macropinocytosis (Mousavi, Malerod et al. 2004) which are both dependent 
on cellular cortical actin filaments. Other cascades of CIE have been identified and deal with a 
unique set of membrane components, regulatory factors and cargo (Brodsky 1988). The 
primary focus of this thesis pertains to CDE. A facet that was not investigated during this 
research, but which is of interest in light of the localisation of the LMP2A and LMP2B proteins 
to cholesterol-enriched lipid rafts, is the contribution of caveolin-driven endocytosis on the 
levels of cell surface receptor. It is therefore likely that this pathway could be modulated in the 
presence of LMP2 expression.  
It has been shown that clathrin-mediated endocytosis occurs in three main stages 
(Brodsky 1988). First, clathrin is assembled into polygonal lattices on the plasma membrane, 
which also involved re-organisation and complex formation of a variety of membrane-bound 
proteins and intracellular cytosolic effectors. These complexes concentrate receptors to distinct 
regions of the membranes, which increases the efficiency of sorting endocytosed vesicles by 
endosomes later on. Uncoated internalisation is not as efficient and is in no way specific, 
similar to the mode of entry of viruses and toxins. Accumulation of these clathrin complexes 
precedes formation of clathrin-coated pits and invaginations that internalise portions of the 
plasma membrane and allow infiltration of extra cellular fluid into these invaginations. Finally, 
vesicles are formed through clipping or pinching off of the invaginated membrane, and the 
subsequent loss of the clathrin coat (Mousavi, Malerod et al. 2004). These free vesicles are 
then targeted to the endosomal trafficking networks and sorted depending on the lipid and 
protein component of the internalised membrane. Many factors are involved in the regulation 
of this process, with two of the best characterised components being the adaptor protein 2 
(AP2) and Dynamin proteins (Shih, Gallusser et al. 1995). AP2 is a protein composed of four 
subunits and is thought to localise and facilitate the accumulation of clathrin at the plasma 
membrane, and in so doing, can contribute to lattice formation. Sorting of plasma membrane 
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proteins by APs into clathrin-coated pits or depressions leads to the formation of internalised 
clathrin-coated vesicles (Brodsky 1988; Hansen, Sandvig et al. 1993; Shih, Gallusser et al. 
1995; Wucherpfennig, Wilsch-Brauninger et al. 2008). Dynamin has an N-terminal domain 
responsible for the hydrolysis of GTP: its three forms are differentially expressed and their 
functions appear to overlap. It is thought that this GTPase activity mediates, either directly or 
indirectly, closing of the neck of the invaginated pit and subsequent vesicle fission. More 
recently it has been shown that dynamin may recruit actin filaments, and in doing so, can 
further facilitate vesicle scission (Wucherpfennig, Wilsch-Brauninger et al. 2008).  
In the case of receptor-mediated endocytosis, ligand binding to the receptors results in 
their activation and subsequent signal transduction. The receptor complex is endocytosed and 
internalised in a clathrin-dependent manner, and upon uncoating of the internalised vesicle, 
they are exposed to intracellular compartments, which serve to acidify the vesicle and its 
contents thus segregating the ligand from the receptor (Bananis, Murray et al. 2000). These 
then separate and enrich two separate populations of vesicles, one is of which is targeted for 
degradation and has a high ligand content, whilst the other is recycled to the membrane and 
contains a higher proportion of receptor. For this process to occur it is necessary for pre-
segregated vesicles to bind to, and move along, microtubules to undergo fission (Bananis, 
Murray et al. 2000). Early endocytic vesicles have the capacity to undergo fission and receptor-
ligand segregation is dependent on binding to microtubules, whilst their motility is dependent 
on ATP. Vesicles that undergo binding with kinesin have been shown to contain unsegregated 
receptor-ligand complexes. These vesicles are then capable of fusing with compartments of the 
early endosome trafficking network in a Rab5 dependent manner, (Woodman 2000). From here 
the fate of internalised molecules is decided, whether targeted for lysosomal degradation or 
recycled to the plasma membrane, as in the case of receptors whose signalling cascade has 
been initiated in earlier compartments upon interaction with signalling intermediate adaptor 
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molecules or activating ligands. This trafficking network is a small fraction of a much larger 
extensive intracellular dynamic membrane process, which can include the trans-golgi network 
(TGN), the endoplasmic reticulum, exosome secretion and autophagy (Woodman 2000; Zerial 
and McBride 2001).  
The transport of cargo between endocytosed vesicles and cellular compartments, or 
between compartments, involves the movement and subsequent tethering of the vesicle to its 
destination membrane, and finally fusion of the two membranes. Soluble N-ethylmaleimide 
sensitive fusion protein receptors (SNAREs) are integral membrane proteins that are localised 
to compartments throughout the trafficking network, and have been shown to be responsible 
for this fusion between the phospholipid bilayers of the target membrane and the incoming 
vesicle (Deneka, Neeft et al. 2003). SNAREs, are tightly regulated, and although expressed on 
a wide variety of organelles, are only active at specific membrane sites. These proteins are 
fundamental to vesicular transport, and have been shown to interact directly with another 
family of proteins, the Rab GTPases. Through these interactions it is thought that the Rab 
proteins regulate activation of SNARE machinery and provide cues as to the specific timing 
and location of fusion events. A significant level of cross talk exists between the SNARE 
fusion machinery and the Rab GTPases (Raiborg and Stenmark 2009). Specific examples of 
this include the interaction of EEA1 and Rabenosyn5 (effectors of Rab5 activity) with 
SNAREs, syntaxin 6, 7 and 13, and the interaction between Rabenosyn5 and the Sec1 family 
member, VPS45 (Christoforidis, McBride et al. 1999; Raiborg and Stenmark 2009). These 
interactions are integral to full endosomal trafficking but a detailed discussion of their 
mechanics is beyond the scope of this investigation. Experimental data in this thesis has 
focused on the Rab proteins and the effect of their impaired expression on trafficking networks 
as a result of LMP2A/2B expression. 
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1.9.2  The early endosome: Rab 5 
Rab 5 is one of the best characterised members of the Rab family of proteins, which 
constitute the largest family of monomeric small GTPases that function at specific sites of the 
endosome/lysosome pathway (Woodman 2000). In the early endocytic pathway Rab5 regulates 
vesicle and early endosome fusion, as well as homotypic endosome-to-endosome fusion. Rab5 
also acts as a chaperone to endocytosed vesicles, transporting them to the early endosome and 
facilitating the tethering of vesicles to endosomal membranes. These processes are mediated by 
a positive feedback loop between Rab5 and its guanine exchange factor (GEF), Rabex-5 
(Horiuchi, Lippe et al. 1997). Following membrane recruitment of Rab5, Rabex-5 activates 
Rab5 GTPase activity, allowing recruitment of its effector Rabapatin-5. This facilitates 
enhanced Rabex-5 activity and the subsequent enrichment of Rab5 levels at the membrane. 
Rab5 can also interact with PI3-K to form phosphatidylinositol-3-phosphate (PtdIns-3-P) 
(Deneka, Neeft et al. 2003). The co-localisation of Rab5 with newly formed PtdIns-3-P enables 
binding of the Rab5 effector proteins, EEA1 and Rabenosyn5, which function to stabilise the 
classical early endosome and promote its fusion with vesicles and other endosomal membranes 
(Simonsen, Lippe et al. 1998). EEA1, a classical marker of early endosomes, is a coiled protein 
that contains two Rab5 binding domains. It is thought to contribute to fusion by bridging two 
Rab5-positive membranes through these domains, and two FYVE Zn finger domains, which 
can interact specifically with PtdIns-3-P (Christoforidis, McBride et al. 1999). Rabenosyn5 is 
recruited in a similar FYVE-dependent manner and is involved in the docking and fusion of 
endosomal membranes, an example of the complex level of interactions occurring between 
lipids and proteins at the membrane, especially given that the enrichment of PtdIns-3-P on the 
membrane could instigate binding of additional effectors in a Rab5-independent manner 
(Barnekow, Thyrock et al. 2009). 
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The role of Rab5 and its importance in both the early and late stages of the network is 
highlighted in studies where a GTP-deficient Rab5 was expressed in normal rat kidney (NRK) 
cells (Hirota, Kuronita et al. 2007). This study uncovered the existence of 3 distinct classes or 
types of endosomes. Firstly, formation of type I endosomes occurs: these can undergo 
homotypic endosome fusion and also fusion with carrier vesicles from the TGN and 
endocytosed vesicles (homotypic fusion still occurs due to the endogenous pool of Rab5 
remaining in the cell, and as this is depleted, the rate of homotypic fusion is diminished). This 
is followed by the formation of type II endosomes, which are morphologically distinct from 
“classical early endosomes”. They are giant endosomes that display all the characteristics of 
the type I endosomes and late endosomes, yet appear to be a hybrid between these and 
intermediary cargo vesicles. Finally type III clustered endosomes form via the vesiculation of 
the type II giants, allowing reformation of late endosomes and lysosomes (Hirota, Kuronita et 
al. 2007). When cells expressing this defective form of Rab5 are treated with wortmannin, a 
specific inhibitor of PI3-K activity, the rate of vesiculation of the type II giants is accelerated, 
which is perhaps unsurprising given the role of PtdIns-3-P in mediating the function of Rab5 
and its effectors as described above. Early endosomes can fuse with late endosomes: an event 
that is promoted by, and dependent on, active forms of Rab5. The effect of expression of 
defective Rab5 on lysosomal formation as described below is indicative of a role for Rab5 in 
the late stages of endosomal trafficking, in tandem with its role in early endosome fusion, as 
described above (Hirota, Kuronita et al. 2007). 
Cells display distinct subpopulations of early endosomes, which are dynamic but do not 
necessarily intermix: early endosomes containing Rab5 only; Rab5- and Rab4-carrying 
endosomes; and finally Rab4- and Rab11-recycling endosomes (McCaffrey, Bielli et al. 2001; 
Stenmark and Olkkonen 2001). Rab4 can bind to Rab5 effectors and vice versa, indicative of 
the fluid nature of the Rab-controlled membrane network and the cross reactivity of their 
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machinery. Rab4 and Rab11 are the GTPases responsible for sorting membranes either for 
recycling or degradation, and are localised within recycling endosomes and the multi-vesicular 
body (MVB) (McCaffrey, Bielli et al. 2001). Rab4 is responsible for short loop recycling and 
Rab11 is responsible for long loop recycling (that which passes through the TGN) (Zerial and 
McBride 2001). Another Rab family member, Rab6, has been shown to have a role in 
microtubule development through interaction with Rabkinesin6, which has roles in vesicle 
motility and cytokinesis. Development of such intracellular structures enables endosomes and 
endosome-like compartments to traffic through the cell (Bananis, Murray et al. 2000). Plus 
end-directed kinesin binds Rab6 via KIF16B, which is recruited by PtdIns3, implicating Rab6 
further in the process of compartment movement (Barnekow, Thyrock et al. 2009). 
 
1.9.3  Early to late fusion: Rab7 
The endosome can fuse with additional intracellular compartments and it has been 
shown that loss of Rab5 from an intracellular compartment can induce Rab7 positivity (Rink, 
Ghigo et al. 2005). Rab7 is a marker of the late endosome and the lysosome. The numbers of 
Rab5-positive endosomes increases over time, with the loss of EEA1 from these compartments 
being observed as they become Rab7 positive. Loss of EEA1 enhances loss of Rab5 through 
destabilisation of Rab5 effector complexes (Rink, Ghigo et al. 2005). Inactivation of RabGAP-
5 results in the swelling of endosomes and a reduction in lysosomal conversion and trafficking 
(Hirota, Kuronita et al. 2007). Rab5 also regulates the attachment to, and movement of, early 
endosomes along microtubules, dynamically fluctuating on individual early endosomes. Via 
repetitive fusion events, degradative cargo becomes highly enriched in progressively fewer and 
larger compartments (Woodman 2000). These are then removed from the cell centre via loss of 
Rab5 and acquisition of Rab7, a process requiring the class c VPS/HOPS complex (a Rab7 
GEF) (Bucci, Thomsen et al. 2000). This is the most striking example of membrane identity 
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remodelling via exchange of Rab machinery, and is another example of SNARE regulation by 
the Rab domains on organelles that are not static, but rather merge and separate in a dynamic 
manner, changing the properties of their binding compartments (Markgraf, Peplowska et al. 
2007). This cyclical nature of Rab5 machinery means that endosomes are either stable for 
minutes or lose identity rapidly in conversion events. Early and late systems are thus separated; 
yet remain connected through Rab5-mediated control of these events. 
Rab7 is implicated in early endosome to late endosome trafficking. Expression of an 
activated Rab7 resulted in increased levels of perinuclear aggregates, as does overexpression of 
wild-type Rab7 (Bucci, Thomsen et al. 2000). Inactive dominant negative mutants showed the 
reverse, and localised to the cytosol, whilst lysosomal content also became increasingly 
dispersed. Rab7 is therefore essential for the maintenance of the perinuclear lysosomal 
compartments. Once structures begin to acquire Rab7 and lose Rab5, direction of movement of 
these late endocytic structures toward the perinuclear aggregate or lysosomes occurs, likely 
recruiting dynesin/kinesin to serve as tracks for this movement. Rab7b has been shown to 
negatively regulate TLR4 signalling through investigation of its role in LPS-induced 
production of TNFα, IL-6, nitrous oxide (NO) and IFNβ (Wang, Chen et al. 2007); and has 
also been shown to potentiate activation of MAPK, NFκB and IRF3 signalling through TLR4 
(Wang, Chen et al. 2007). Lack of Rab7b has been shown to increase IRF3 and NFκB activity 
and concomitantly increase the levels of their effector cytokines. This silencing of Rab7b also 
led to the upregulation of TLR4 expression, indicative of a possible role for Rab7b in TLR4 
degradation (Wang, Chen et al. 2007). 
 
1.9.4  The lysosome 
The lysosome is an acidified intracellular compartment responsible for the digestion of 
membranes and membrane-bound proteins by acid hydrolases, such as cathepsin D (Eskelinen, 
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Tanaka et al. 2003). These products undergo trafficking  to the lysosome by phagocytosis, 
autophagy, and also by the process of endocytosis and endosomal sorting described above. 
Structurally, the membrane of the lysosome is densely packed with carbohydrate and is 
spanned by a number of proteins including the highly glycosylated proteins, lysosome 
associated membrane protein 1 (LAMP1) and LAMP2; the tetraspannin, CD63; and Niemann 
Pick C1 protein (NPC1) (Eskelinen, Tanaka et al. 2003). Acidity is maintained through the 
action of the V-ATPase holoenzyme (Bucci, Thomsen et al. 2000). Lysosomes are conspicuous 
by their lack of mannose-6-phosphate receptors (MPRs), which bind lysosomal enzymes from 
the TGN and transport them to late endosomes in a Rab9-dependent manner. Rab9 is localised 
to late endosomes and the TGN and has been shown to control traffic between both 
compartments, specifically transporting newly synthesised MPRs bound to cathepsins via the 
Rab9 effector, TIP47 (Dodeller, Gottar et al. 2008). Due to the acidic conditions of the 
compartment, the cathepsins become activated; the ligands dissociate from their cognate 
receptors and are released into the late endosome. These lysosomal hydrolysis events facilitate 
both receptor recycling and degradation of receptors and ligands (Forgac 2007).  
 
1.9.5  Ubiquitination as a sorting signal 
While poly-ubiquitination is mainly responsible for directing proteins to the proteasome 
for degradation, additional forms of post-translational modification exist that require ubiquitin 
binding. Mono- or multi-ubiquitination has been shown to be largely involved in the stability 
and activity of a variety of proteins, and has also been linked to the maintenance and control of 
interactions that specify subcellular localisation of certain classes of membrane-bound 
receptors (Piper and Luzio 2007). In yeast, it has been shown that mono-ubiquitination is 
sufficient to induce internalisation of receptors and this hypothesis has been broadened to 
include the endocytosis and secretory networks of mammalian cells. The fate of TGFβ 
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receptors, for example, can be controlled by the extent of ubiquitination of the cytosolic 
domains of the receptor. When associated with Smad7/Smurf-2 complexes, the TGFβ receptor 
is endocytosed in a caveolin-dependent manner and targeted for proteaosomal degradation; 
however, when associated with Smad anchor proteins, it is internalised through clathrin-
mediated endocytosis and signalling is activated (Piper and Luzio 2007). Ubiquitin also has a 
role in the sorting of internalised proteins in the multi-vesicular body (MVB) or multi-vesicular 
endosome (MVE), whereby non-ubquitinated proteins are targeted for recycling to the plasma 
membrane and those ubiquitinated are cycled to late endosomes, and eventually the lysosome 
for degradation by acid hydrolases. LPS is endocytosed through receptor-mediated 
endocytosis, which is both clathrin- and dynamin-dependent. TLR4 is then ubiquitinated and 
targeted for recycling or degradation. Inhibition of endocytosis and sorting leads to increases in 
LPS-induced signalling (Wang, Chen et al. 2007). Trafficking of these receptor complexes is 
therefore essential for signal termination and optimal LPS-associated antigen presentation. 
Other receptors are internalised and activated in different ways. For example, the EGF receptor 
is internalised within minutes after ligand-binding by clathrin-mediated endocytosis (Keegan, 
Sheflin et al. 2000; Repetto, Yoon et al. 2007), whereas IL-2 receptor complexes are taken up 
in a raft-dependent manner that is reliant on caveolin.  
 
1.9.6  Viral proteins and cell traffic.  
1.9.6.1  The E5 protein of Papillomavirus 
The HPV-encoded E5 protein is a small hydrophobic protein that is expressed in virus 
infected keratinocytes. E5 has been implicated in interfering with a wide range of normal cell 
functions including signal transduction, receptor turnover and compartment pH regulation 
(Thomsen, Deurs et al. 2000; Ashby, Meagher et al. 2001). E5 is localised to the endoplasmic 
reticulum and can induce the anchorage-independent growth of immortalised fibroblasts but 
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not primary keratinocytes (Disbrow, Hanover et al. 2005). BPV E5 has been shown to interact 
with the V-ATPase complex, resulting in alkylation of the golgi which is partially responsible 
for MHC class I retention. Interacting with both V-ATPase and MHC in complexes, E5 retains 
newly assembled MHC complexes in the golgi apparatus (GA) by preventing GA acidification. 
By physical interaction these complexes are shunted into the lysosome for degradation 
(Disbrow, Hanover et al. 2005). HPV16 E5 transiently alters endosomal, but not GA, pH. It is 
possible that E5 sequesters V-ATPase regulators in the ER, thus inhibiting the function of the 
complex. Interaction of E5 and V-ATPase may be lost due to the removal of the bound protein 
during “turning” of the ATP-driven proton pump explaining the transient nature of this 
dysregulation (Ashby, Meagher et al. 2001; Marchetti, Ashrafi et al. 2006).  
 
1.9.6.2  The K3 and K5 proteins of KSHV 
Viral disruption of antigen presentation by MHC links both intracellular trafficking and 
immune responses. In the context of KSHV, the K3 and K5 proteins have been shown to 
downregulate MHC class I molecules from the cell surface (Hewitt, Duncan et al. 2002). These 
proteins remove HLA molecules from the surfaces of cells via rapid endocytosis of the 
molecules: K5 is responsible for downregulating HLA A and B, but has a weaker effect on 
HLA class C molecules; K3 downregulates cell surface expression of all HLA types (Ishido, 
Wang et al. 2000). K3 and K5 have also been shown to target IFNγR1 for increased 
endocytosis by ubiquitinating the receptor, thereby contributing to the viral mechanisms of 
immune evasion (Li, Means et al. 2006). Increased endocytosis is also responsible for 
decreased levels of B-72 and ICAM-1 (proteins involved in T-cell stimulation) in BJAB cells 
expressing K5 (Coscoy and Ganem 2001). These processes and additional immunomodulatory 
effects of KSHV are reviewed elsewhere (Means, Ishido et al. 2002; Lehner, Hoer et al. 2005; 
Rahim-Rezaee, Cunningham et al. 2006).  
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1.9.6.3  The Nef protein of HIV 
The HIV protein, Nef, internalises CD4, which functions to bind to the viral envelope 
glycoprotein, GP120, and permit viral entry. CD4 binds to the N-terminus of Nef, and 
increased internalisation of this molecule has three secondary effects: combating immune 
surveillance; preventing superinfection; yet allowing trafficking of ENV proteins. This occurs 
in a clathrin-dependent manner and it has been demonstrated that Nef expression induces pit 
formation, resulting in the accumulation of endosomes, and that the stability of CD4 is 
sensitive to lysosomal inhibitors (Foti, Mangasarian et al. 1997; Mangasarian, Foti et al. 1997; 
Sanfridson, Hester et al. 1997). Nef binding protein 1 (NBP1) can bind to the C-terminus of 
Nef and encodes a component of the V-ATPase holoenzyme. The V-ATPase complex can bind 
to AP2, which is complexed with clathrin at the cell surface, thus facilitating the increase of 
clathrin density, and consequently endocytosis (Lu, Yu et al. 1998). Nef has also been shown 
to promote actin filament remodelling to further disrupt intracellular signalling and T-cell 
immune responses (Haller, Rauch et al. 2007).  
These are examples by which viral proteins can interact with and disrupt intracellular 
trafficking mechanisms to evade detection by the immune system. Other examples include the 
role of the Tip protein of Herpes virus saimiri (HVS) in downregulating CD4 and T-cell 
receptor (TCR) from the cell surface (Cho, Kingston et al. 2005), an effect that is dependent on 
its localisation in lipid rafts, is important for this, which is significant given LMP2A/2B’s 
similar intracellular location. 
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1.10  Aims and Objectives 
The aim of this body of research was to elucidate the exact mechanisms by which, LMP2A and 
LMP2B contribute to EBV-associated epithelial malignancy through maintenance of viral 
latency by immune evasion. To perform such analysis comparisons were made between panels 
of epithelial cell-lines, CNE-2, H103 and H157, stably expressing LMP2A, LMP2B or a 
Neomycin control. Firstly comprehensive investigations were undertaken to characterise the 
effect of viral protein expression on the TLR signalling network, the first mediator of the host 
response to viral infection. This was performed at a variety of levels from basal and activated 
receptor expression to activation and read-out of signalling responses, including Ap-1 and 
NFκB activity and IFNβ production extended across nine of the TLRs. These analyses 
involved using standard techniques such as immunoblotting, immunofluorescent staining and 
luciferase assay. Secondly this study aimed to identify the exact effect of expression of the 
LMP2 proteins on endosomal-lysosomal trafficking network, identifying a putative mechanism 
for the reported modulation of type I interferon responses. Utilising both standard and live-cell 
confocal imaging allowed a comprehensive overview of intracellular trafficking to be 
performed in the cell-lines described above. Finally generation of attenuated forms of the 
LMP2 proteins through sequential deletion of the transmembrane domains was undertaken to 
highlight the importance of these protein regions in mediation of these effects and to ascertain, 
which of these loops is necessary for internal membrane localisation.  
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CHAPTER 2 
    Materials and Methods  
2.1  Tissue Culture 
2.1.1 Tissue culture media and solutions 
2.1.1.1  Media 
RPMI 1640: Gibco®, liquid in 500ml sterile bottles, supplemented with L-glutamine (0.2M) 
and stored at 4oC. 
DMEM-F12,1:1: Gibco®, liquid in 500ml sterile bottles, supplemented with L-glutamine 
(0.2M)  high glucose, phenol red and sodium pyruvate, pH 7.0 and stored at 4˚C. 
Opti-MEM® : Gibco®, liquid in 500ml sterile bottles with a reduced amount of phenol red. 
Freezing media: 70% normal growth media, 20% FCS and 10% Dimethyl sulfoxide (DMSO) 
(Sigma Aldrich).  
2.1.1.2  Other solutions and buffers 
Foetal Calf Serum (FCS): Gibco®, liquid in sterile 500ml bottles (mycoplasma/virus tested), 
stored in 25ml aliquots at -20 oC. 
Antibiotics: Sigma-Aldrich, Penicillin/streptomycin solution containing 10,000 units/ml 
penicillin and 10 mg/ml streptomycin in 0.9% sodium chloride. Sterilised by filtration and used 
at 5ml per 500ml media. 
Phosphate- Buffered Saline (PBS): Oxoid, supplied as tablets, containing NaCl 0.8g, KCL 
0.02g, Na2HPO4 0.115g, KH2PO4  0.02g.  100 tablets dissolved in 10 litres of SDW.  aliquoted 
into 500ml bottles and sterilised by autoclaving at 15psi and 120 oC for 20 minutes. 
Trypsin: Gibco®, Trypsin-EDTA (0.25% Trypsin with EDTA) 1X solution 100ml sterile 
bottles, Porcine parvovirus and mycoplasma treated. Solution contains 2.5 g/L of Trypsin 
(1:250), 0.38 g/L of EDTA and phenol red.  Stored at -20 oC, thawed and heated to 37°C prior 
to use and stored at 4°C thereafter. 
 79
Chapter 2    Materials and Methods 
 
Genticin (G418): Sigma-Aldrich, 5g of G418 powder dissolved in 100ml SDW for a stock 
solution of 50mg/ml. Sterilised by filtration and stored in 5ml aliquots at –20°C. 
Fibronectin: Sigma-Aldrich, pre-sterilised human plasma 0.1% (solution) derived fibronectin 
at a concentration of 1mg/ml, stock solutions are stored at 4oC. 
Hydrocortisone: Sigma Aldrich, 100ng hydrocortisone sodium-succinate powder dissolved in 
10ml SDW. 10ml of absolute ethanol was added to give a stock solution of 5mg/ml in 50% 
ethanol, which was subsequently filtered using a 0.2µm filter and stored at 4ºC.  
 
2.1.2  Cell lines  
The CNE-2 cell line is an immortalised nasopharyngeal carcinoma. CNE-2 Neo has been 
retrovirally transduced to express a neomycin resistance cassette and is used as a control, CNE-
2 WT rEBV is derived from parental CNE-2s that are stably infected with the recombinant 
Akata strain of EBV. CNE-2 LMP2A-rEBV is derived from parental CNE-2s that are stably 
infected with a recombinant Akata strain of EBV that carries a deletion for the EBV gene 
LMP2A. CNE-2 LMP2A has been retrovirally transduced to express a neomycin resistance 
cassette and the SV40 promoter driven EBV gene LMP2A.  CNE-2 LMP2B has been 
retrovirally transduced to express a neomycin resistance cassette and the SV40 promoter driven 
EBV gene LMP2B. Medium: RPMI-1640 supplemented with 5% FCS and antibiotics. 
The Ad/Ah cell line is an immortalised human adenocarcinoma derived from the 
nasopharynx. Ad/Ah Neo has been retrovirally transduced to express a neomycin resistance 
cassette and is used as a control, Ad/Ah WT rEBV is derived from parental Ad/Ahs that are 
stably infected with the recombinant Akata strain of EBV. Ad/Ah LMP2A-rEBV is derived 
from parental Ad/Ahs that are stably infected with a recombinant Akata strain of EBV that 
carries a deletion for the EBV gene LMP2A. Ad/Ah LMP2A has been retrovirally transduced to 
express a neomycin resistance cassette and the SV40 promoter driven EBV gene LMP2A.  
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Ad/Ah LMP2B has been retrovirally transduced to express a neomycin resistance cassette and 
the SV40 promoter driven EBV gene LMP2B. Medium: RPMI-1640 supplemented with 5% 
FCS and antibiotics. 
The H103 cell line is an immortalised human squamous oral carcinoma, H103 Neo has 
been retrovirally transduced to express a neomycin resistance cassette and is used as a control. 
H103 LMP2A has been retrovirally transduced to express a neomycin resistance cassette and 
the SV40 promoter driven EBV gene LMP2A.  H103 LMP2B has been retrovirally transduced 
to express a neomycin resistance cassette and the SV40 promoter driven EBV gene LMP2B. 
Medium: DMEM-F12 supplemented with 10% FCS, hydrocortisone (0.4mg/ml) and 
antibiotics. 
The H157 cell line is another immortalised human squamous oral carcinoma, H157 Neo 
has been retrovirally transduced to express a neomycin resistance cassette and is used as a 
control. H157 LMP2A has been retrovirally transduced to express a neomycin resistance 
cassette and the SV40 promoter driven EBV gene LMP2A.  H157 LMP2B has been retrovirally 
transduced to express a neomycin resistance cassette and the SV40 promoter driven EBV gene 
LMP2B. Medium: DMEM-F12 supplemented with 10% FCS, hydrocortisone (0.4mg/ml) and 
antibiotics.  
The C666-1 cell line is an EBV positive cell line derived from undifferentiated 
nasopharyngeal carcinoma (NPC).  C666-1 is a subclone of the parental cell line, C666, 
derived from a xenograft of Southern Chinese origin.  Medium: RPMI-1640 supplemented 
with 10% FCS and antibiotics.    
 
2.1.3  Maintenance of cell lines 
All cell lines were grown and maintained in culture in incubators at 37°C and 5% C02. Cells 
were grown on various treated plastic vessels (Iwaki, Corning, MatTek) depending on cell 
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number required for experimentation. All cell lines adhered readily to the plastic surface with 
the exception of the C666-1line, which required the flasks to be pre-coated in fibronectin at a 
concentration of 10µg/ml. Maintenance of stock cultures was performed in 75cm2 or 150cm2 
tissue culture treated flasks and passaged twice a week. Once cell stocks had reached 
approximately 90-95% confluency, medium was removed and the cells washed gently with 
5mls of PBS, this was subsequently removed and 5ml of trypsin added. Flasks were then 
incubated at 37°C until cells detached. Deactivation of the trypsin was performed by the 
addition of 10ml of normal growth medium. Cells were pelleted by centrifugation at 1500rpm 
for 5 minutes and the supernatant removed. Cell pellets were then resuspended in 10ml of 
growth medium and counted using a haemocytometer, depending on the experimental 
requirement cells were plated at varying densities onto various types of plastics. Stocks were 
typically maintained by adding 2ml of cell suspension into 13ml of normal growth Medium in 
fresh flasks. G418 was added to maintain expression of EBV genes at a concentration of 
400µg/ml.   
 
2.1.4  Cryopreservation of cell lines 
Cells were trypsinised and recovered as above. Cells were frozen at a usual density of 1 x 106 
in 1ml of freezing medium in sterile freezing ampoules (Nunc) and transferred to a 
cryopreservation box (Mr Frosty, Nalgene). This was then placed into -80oC freezer and the 
cells cooled by 1oC per minute.  Ampoules were left overnight at -80oC and for long-term 
storage transferred to the vapour phase of nitrogen (-140oC).  Recovery of frozen stocks was 
performed by thawing ampoules in a 37°C water bath and transferring the cell suspension 
slowly, in a drop-wise manner, into 5-10ml of warmed growth medium. Cells were allowed to 
recover for 10mins at 37°C before seeding in the normal manner.  
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2.2  DNA Transfection into mammalian cells 
2.2.1  Lipofectamine and Plus Reagent transfection 
Lipofectamine (Invitrogen) is a lipid-based system of successfully delivering DNA plasmids 
into cultured eukaryotic cells.  Its efficiency is greatly increased by first pre-complexing the 
DNA using Plus reagent (Invitrogen), optimisation of manufacturers instructions was carried 
out by altering DNA concentrations, cell numbers and reagent volumes. For transfection onto a 
six-well plate (Iwaki), the following amounts were deemed to be the most effective (Table 
2.2.1.1) 
Table 2.2.1.1: Optimum volumes for DNA transfection of cells in culture. 
DNA amount   
(µg) 
Plus reagent 
(µl) 
Dilution volume
(µl) 
Lipofectamine
Reagent  
(µl) 
Dilution 
Volume 
(µl) 
Transfection 
Volume 
(µl) 
0.5-2 6 100 4 100 800 
  
For a typical transfection using a 6-well plate, cells of interest were seeded at a density of 2.5 x 
105 and allowed to adhere to the surface by incubation overnight. The media was then removed 
and the dish washed with PBS followed by two washes with serum free Opti-Mem®. The 
DNA to be transfected was mixed with the appropriate volume of Opti-Mem® medium and 6µl 
Plus reagent per reaction added. This was incubated at room temperature for 15 minutes, 
following which, 4µl of Lipofectamine diluted in Opti-Mem® was added and allowed to mix 
for an additional 15 minutes. During the second incubation 800µl of serum free Opti-Mem® 
was added to each well of a 6-well plate. The appropriate volume of transfection mixture was 
then added in a drop-wise manner onto the six-well plate and the plate placed into the 
incubator for 3hours. Following this the reactions were supplemented with 2ml of 10% FCS-
Opti-Mem® per well, this was returned to the incubator overnight. The following day the 
medium was removed and either 2ml of normal growth medium added for 24hrs prior to 
harvesting or additional transfections/treatments were performed again using serum free Opti-
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Mem®. In order to assess transfection efficiency a plasmid expressing green fluorescent 
protein (p-eGFP) was used and a percentage of positivity determined by fluorescent 
microscopy. 
Table 2.2.1.2:List of plasmid DNA vectors 
Gene of Interest Plasmid Control 
LMP2A pSG5-LMP2A pSG5 
LMP2B pSG5-LMP2B pSG5 
LMP2A-HA pLXSN-LMP2A-HA pLXSN-Neo 
LMP2B-HA pLXSN-LMP2B-HA pLXSN-Neo 
GFP pLenti-6-GFP pLenti6 
LMP2A pLenti-6-LMP2A pLenti6 
LMP2B pLenti-6-LMP2B pLenti6 
LMP2-L1 pLenti-6-L1del pLenti6 
LMP2-L3 pLenti-6-L3del pLenti6 
LMP2-L4 pLenti-6-L4del pLenti6 
LMP2-L5 pLenti-6-L5del pLenti6 
LMP2-L6 pLenti-6-L6del pLenti6 
EBERS pBSAII-EBER pBSAII 
 
2.3  Tissue culture treatment of cells 
2.3.1  Stimulation of signalling responses 
In order to stimulate signalling responses of certain classes of immunological receptors, 
purified versions of their ligands are commercially available. Cells of interest were seeded at 
the required density depending on the experimental design and allowed to adhere overnight in 
the incubator at 37°C and 5% C02. Once adhered, the media was removed and the dishes 
washed with PBS followed by serum free Opti-Mem®. This removes any residual FCS, which 
could interfere with signalling responses. Cells were then incubated with Opti-Mem® 
containing the required concentration of treatment (Table 2.3.1.1) and incubated for a variety 
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of timepoints prior to harvesting and analysis. For treatment of cells with Poly (I:C) a synthetic 
double stranded RNA molecule (Invivogen), Lipofectamine 2000(Invitrogen) was used. This is 
a similar reagent to Lipofectamine (described in section 2.2.1) but does not require Plus 
reagent. It is specifically designed for the transfection of RNA molecules. Briefly, cells of 
interest were seeded at a density of 2.5 x 105 and allowed to adhere overnight at 37°C. 
Following this the cells were washed with PBS and serum free Opti-Mem®, the RNA to be 
transfected was diluted in Opti-Mem® and incubated for 30mins at room temperature. This 
was then added in a drop-wise manner to the 6-well plate and the reactions returned to the 
incubator. As Liopfectamine 2000 was only used to transfect P(I:C) it was not deemed 
necessary to supplement the media after 3hours with 10% FCS. 
 Table 2.3.1.1: Cell treatments and stimulations 
Signalling Pathway Treatment Concentration Timepoints 
 
TLR1 Pam3CSK4 0.5Μµg/ml 6 and 9 hours 
TLR2 HKLM 108 cells/ml 6 and 9 hours 
TLR3 Poly (I:C) 5µg/ml  6 and 9 hours 
TLR4 LPS 200ng/ml 6 and 9 hours 
TLR5 Flagellin 50ng/ml 6 and 9 hours 
TLR6 FSL-1 400ng/ml 6 and 9 hours 
TLR7 Imiquimod 2.5µg/ml 24 and 48 hours 
TLR8 ssRNA 1µg/ml 6 and 9 hours 
TLR9 CpG DNA 1µM 6 and 9 hours 
 
2.3.2  Dual luciferase reporter assay (Promega) 
The dual luciferase reporter assay system (Promega) is a method by which, the luciferase 
activities of both firefly (Phontinus pyralis) and Renilla (Renilla reinformis) can be quantified 
from the same sample effectively and efficiently. The firefly luciferase signal expressed by the 
promoter of interest is measured through quantitation of the luminescent signal emitted upon 
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addition of luciferase reagent II (LARII). This signal is quenched by the addition of the second, 
Stop and Glo’, reagent, which allows the constitutively active Renilla luciferase signal to then 
be measured. Cells were transfected with the reporter plasmid to be analysed, consisting of the 
promoter of the gene of interest cloned upstream of the firefly luciferase coding DNA 
sequence, or an appropriate negative control vector, in the manner described in section 2.2.1. In 
tandem with transfection with the reported construct the Renilla (pRL-TK) was co-transfected 
into all cell samples, including negative controls. For transfection into a 6-well plate, 0.5µg of 
each of the vectors were used, (see Table 2.3.2.1 for list of reporter plasmids and their control 
counterparts). Further stimulation of the reporter by receptor ligands was performed depending 
on experimental design as described in section 2.3.1.  
 
Table 2.3.2.1.:List of Luciferase reporter constructs and their control counterparts 
Reporter Control Counterpart 
pIFNβ-Luc pTAL-luc 
p-κBconA-Luc  pGL2-basic 
pAP1-Luc pGL3-basic 
 
The samples were harvested at the appropriate time point by removing all of the media and 
washing the wells gently with PBS. All PBS was removed on-ice and 500µl of 1 x Passive 
Lysis Buffer (Promega) per well of a 6-well plate was added. Samples were subjected to two 
cycles of freeze and homogenised by repetitive pipetting. 20µl of each sample was added to the 
wells of a 96-well microtitre plate in triplicate. 50µl of LARII reagent was added to each well, 
mixed gently and the firefly luminescence read using a Victor luminometer. 50µl of Stop and 
Glo’ reagent was then added to each sample, mixed and the Renilla values measured. Relative 
activity was calculated by normalising the firefly values to their Renilla counterparts. 
Standardisation was performed according to experimental design, usually using the control 
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vector as a baseline or the level of firefly activity prior to stimulation.  Histograms of these 
data were constructed using Excel™ and statistical significance assigned using an F-test 
followed by the relevant student’s T-test.  
 
2.4  Immunofluorescent  staining 
2.4.1  Solutions and Buffers 
4% Paraformaldehyde (PFA) 
20g PFA powder was dissolved by stirring overnight at 42oC in 500ml SDW.  Once in 
solution, 5 Dulbecco A tablets were added, the pH adjusted to 7.4 and the solution covered in 
foil, to protect from light. 
20% HINGS 
Heat inactivated normal goat serum, diluted to 20% (v/v) in PBS. 
Triton-X-100 
Triton-X-100 detergent, diluted to 0.5% (w/v) in PBS.  
1, 4 Diazabicyclo (2,2,2) octane triethylene diamine (DABCO) 
90ml of glycerol was added to 10ml PBS containing 2.5g of DABCO powder, the pH adjusted 
to 8.6 and the solution covered in foil, to protect from light. 
 
2.4.2  Immunofluorescent Staining 
12-well microdot Teflon coated slides (Henley) were seeded with cells of interest at a density 
of 2x104. Cell samples were supplemented with normal growth media up to a total volume of 
50-75µl per well. Slides were placed into 10cm2 dishes and grown overnight at 37°C and 5% 
C02. Media was then removed and slides washed in PBS for 2 minutes at room temperature. 
Extra PBS was removed using blotting paper and the cells fixed according to the primary 
antibody.  For PFA fixation slides were incubated with 4% PFA for 10 minutes, washed twice 
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for 5 minutes in PBS and permeabilised in 0.5% Triton-X for 10 minutes. Two, 5 minute 
washes were repeated and all excess PBS removed using blotting paper. Other methods of 
fixation included methanol, acetone and methanol/acetone. In these cases, slides were 
incubated in of the ice-cold solution for 8-10 minutes, removed and washed (2 x 5 minutes) in 
PBS. Once dry, cells were blocked in 50µl/well of 20% HINGS/PBS for one hour in a moist 
box. Primary antibodies were diluted in 20% HINGS/PBS (Table 2.4.2.1) and 50µl added to 
each well of interest, adding 20% HINGS/PBS with no antibody to negative controls. Upon 
incubation for 1 hour in a moist box, slides were then washed (2 x 5 minutes) in PBS and 
excess PBS removed using blotting paper. Secondary antibodies, one of either, Alexa 594, 
Alexa 546, Alexa 488 or Alexa 364 (Molecular Probes) (Table 2.4.2.2.) were diluted 1:1000 in 
20%HINGS/PBS and 50µl added in a species specific manner depending on primary antibody. 
Slides were washed, dried and coverslips mounted using DABCO.  
Co-staining for co-localisation experiments were performed in a similar manner, with 
primary antibodies added and incubated together and various labelled secondaries used 
depending on the species of the primary. For fixed staining of intracellular lysosomes, cells 
were seeded onto microdot slides and grown overnight at 37°C. Wells were then treated with 
serum free Gibco® Opti-Mem® media containing 150nM LysoTracker™ Dye (Invitrogen) for 
45mins-2hours, fixed and mounted as above. All slides were analysed using fluorescent and/or 
confocal laser microscopy.  
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Table 2.4.2.2: Primary Antibodies used for Immunofluorescent staining 
Primary antibody 
 
Species Dilution Supplier/ Reference 
A1- VTPase 
 
Rabbit 
 
1:500 
 
Sanata Cruz (sc-28801) 
CD63 
 
Mouse 1:25 Gift from R.Sadej 
EEA1 
 
Mouse 1:50 AbCam (ab 18175) 
Ductin Rabbit 1:50 Chemicon (AB5469) 
 
Dynamin 
 
Mouse 1:1000 BS Transduction 
 
HA  
 
Rat 1:1000 Roche (3f10) 
 
HA(Y112) 
 
Rabbit 1:1000 Santa Cruz (sc-805) 
IRF1 
 
Rabbit 1:100 Santa Cruz (sc-497) 
IRF2 
 
Rabbit 1:100 Santa Cruz (sc-498) 
 
IRF3 
 
Rabbit 1:100 Santa Cruz (sc-9082) 
 
IRF7 
 
Rabbit 1:100 Santa Cruz (sc-9083) 
 
LAMP1 
 
Rabbit 1:200 Abcam (ab 24170) 
 
LMP2 
 
Human Sera 1:50 Gift from C. Dawson 
 
MyD88 
 
Rabbit 1:300 Imgenex IMG 5519 
 
Rab5 Rabbit 
 
1:100 
 
Santa cruz (sc-28570) 
 
Rab5 Mouse 
 
1:50 
 
Santa cruz (sc-46692) 
 
Rab7 Rabbit 
 
1:100 
 
Santa cruz (sc-10767) 
 
SOCS2 Rabbit 
 
1:100 
 
Santa Cruz (sc-9022) 
 
SOCS3 
 
Rabbit 
 
1:200 
 
Santa Cruz (sc-9023) 
 
SOCS6 Rabbit 
 
1:200 
 
Santa Cruz (sc-5608) 
 
TLR3 Mouse 
 1:500 
Imgenex 
 
TLR3 Goat 
 1:50 
Santa Cruz (sc8691) 
 
TLR4 Mouse 
 1:500 
Imgenex  
 
TLR4 Rabbit 
 1:50 
Santa Cruz (sc-10741) 
 
TLR7 Rabbit 
 
1:75 
 
Santa Cruz (sc-30004) 
 
TLR9 
 
Mouse 
 
1:100 
 
Serotec CD289 
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Table 2.4.2.2: Secondary Antibodies used for Immunofluorescent staining 
Secondary antibody Dilution Supplier 
Alexa-Fluor 350 Goat Anti-Rabbit 
 
1:1000 
 
Molecular Probes 
Alexa-Fluor 350 Goat Anti-Mouse 
 
1:1000 Molecular Probes 
Alexa-Fluor 350 Goat Anti-Human
 
1:1000 Molecular Probes 
Alexa-Fluor 488 Goat Anti-Rabbit 
 
1:1000 Molecular Probes 
 
Alexa-Fluor 488 Goat Anti-Mouse 
 
1:1000 Molecular Probes 
Alexa-Fluor 488 Goat Anti-Human
 
1:1000 Molecular Probes 
Alexa-Fluor 546 Goat Anti-Rabbit 
 
1:1000 Molecular Probes 
Alexa-Fluor 546 Goat Anti-Mouse 
 
1:1000 Molecular Probes 
Alexa-Fluor 546 Goat Anti-Human
 
1:1000 Molecular Probes 
Alexa-Fluor 594 Goat Anti-Rabbit 
 
1:1000 Molecular Probes 
Alexa-Fluor 594 Goat Anti-Mouse 
 
1:1000 Molecular Probes 
Alexa-Fluor 594 Goat Anti-Human
 
1:1000 Molecular Probes 
 
2.4.3  Live cell imaging 
Cells of interest were seeded at a density of 2.5x104 cells, onto a well of a 24-well uncoated, 
0.13mm, 13mm diameter glass bottomed plate available from MatTek™ and grown overnight 
in serum free Gibco® Opti-Mem®. Cells were then incubated with 150nM LysoTracker™ Dye 
(Invitrogen) for 2hours. Post incubation, lysosomes were visualised with a Zeiss Axiovision 
LSM 510Meta confocal microscope with the stage and chamber set at temperature of 37°C. 
Acidification of lysosomes was performed in a similar manner as above with the media 
replaced with Gibco® Opti-Mem® containing 1µM Yellow/Blue DND-160 (PDMPO) 
LysoSensor™ (Invitrogen) and placed into the microscope chamber immediately. Time-lapse 
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imaging was used to scan the cells capturing a number of images of the same cells over varying 
incubation timepoints. 
 
2.4.4  Translocation Assays 
Visualising the nuclear translocation of proteins was performed by seeding the cells of interest 
onto microdot slides. Cells were grown overnight in normal growth media, the media was then 
replaced with either serum free Gibco® Opti-Mem® containing the appropriate concentration 
of chemical treatment or media alone. Slides were incubated for a variety of timepoints, and 
following incubation were fixed and incubated with primary and secondary antibodies as 
above. Slides were analysed using confocal laser microscopy and translocation assessed by the 
comparing the subcellular localisation of proteins with and without chemical treatment.  
Table 2.4.4.1: Antibodies and treatment used in Translocation Assay 
Antibody Species Dilution Supplier/ Reference Treatment 
IRF3 
 
Rabbit 1:500 Santa Cruz (sc-9082) Poly(I:C) 6 hours 
P65 Rabbit 
 
1:50 
 
Santa Cruz (sc-372) 
 
Poly(I:C) 6 hours 
 
2.5  Immunoblotting 
2.5.1  Solutions and buffers 
Tris buffered saline-Tween (TBS-T) 
24.2g Tris and 80g NaCl, dissolved in 10L SDW and pH adjusted to 7.6. 10ml of 
Polyoxyethylene sorbitan monolaurate (Tween-20) added and the solution mixed thoroughly. 
Resolving gel buffer 
1.5M Tris (pH 8.8) and 0.4% (w/v) SDS dissolved in SDW and stored at room temperature. 
Stacking gel buffer 
0.25M Tris (pH 6.8) and 0.2% (w/v) SDS dissolved in SDW and stored at room temperature. 
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Running buffer 
0.25M Tris, 1.92M glycine and 1% (w/v) SDS dissolved in SDW, and pH adjusted to 8.8.   
Transfer buffer 
0.25M Tris and 1.92M glycine dissolved in SDW and 20% (v/v) methanol added. 
5% Milk blocking buffer 
5% (w/v) powdered milk dissolved in TBS-T, stored at 4°C. 
5% Bovine serum albumen (BSA) 
5% (w/v) powdered BSA dissolved in TBS-T, stored at 4°C. 
RIPA Lysis buffer 
50mM Tris (pH 7.4), 150mM NaCl, 1mM EDTA, 1% (v/v) NP-40, 0.25% (w/v) sodium 
deoxycholate, dissolved in SDW. Protease inhibitors: 20µg/ml leupeptin (Sigma L8511), 
20µg/ml aprotinin (Sigma L1153) and 20µg/ml pepstatin (Sigma P5318) and 0.5mM sodium 
orthovanadate (Sigma, S6508), 0.5mM sodium fluoride (Sigma S7920) and 1mM PMSF 
(Sigma P7626) added prior to use and this complete lysis buffer stored short term at -20°C. 
3X Lamelli SDS Sample Buffer 
187.5 mM Tris-HCL pH 6.8, 6% w/v SDS, 30% Glycerol and 0.03% w/v bromophenol blue 
mixed and stored at -20 oC. 
Stripping Buffer 
100mM Tris-HCl pH 6.8, 2% (w/v) SDS, 50mM 2-β-mercaptoethanol. 
 
2.5.2  Protein extraction 
Whole cell lysates of adherent cells were prepared from the cells of interest by removing all 
growth media and washing dishes with ice-cold PBS, on ice. All PBS was removed and 200-
500µl of complete RIPA lysis buffer (ice-cold) was added. Cells were mechanically lysed 
using a cell scraper (Starstedt) and the lysate transferred to a prechilled labelled 1.5 ml 
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eppendorf Suspension cell cultures were pelleted by centrifugation, resuspended in ice-cold 
PBS, spun again, all PBS removed and complete lysis buffer added. All lysates were then 
sonicated for 10 seconds. Protein concentrations were determined using the Biorad protein 
assay kit (Biorad). Briefly, 5µl of diluted (50% in SDW) lysate was aliquoted in triplicate to 
wells of a 96-well plate, 25µl of Reagent A and 200µl of Reagent B were added. The plate was 
shaken gently for 5 minutes and the absorbance read at a wavelength of 620nm. A standard 
curve was constructed using known BSA standards and the concentrations of samples 
extrapolated from this. A minimum of 30µg of whole cell lysate was diluted with 3X Lamelli 
SDS sample buffer and boiled at 95°C for 5 minutes and returned to ice prior to loading. 
 
2.5.3  SDS-polyacrylamide gel electrophoresis, (SDS-PAGE) 
 SDS-polyacrylamide gels were cast using the mini-protean 3 electrophoresis system (Biorad). 
Varying percentages of acrylamide gels were prepared according to the molecular weight of 
the protein under analysis, typically containing 30% (w/v) acrylamide, 0.8% (v/v) N, N-bis 
acrylamide solution (National Diagnostics, UK) to a final concentration of 7.5-20%, 25% (v/v) 
resolving buffer, and 0.06% (v/v) TEMED. Addition of 20% APS (ammonium persulphate) to 
a final concentration of 0.1% enabled gel polymerisation. 100% ethanol was gently added to 
remove any air bubbles and removed using SDW upon gel setting. Stacking gels were prepared 
in a similar manner irrespective of the concentration of resolving gel, containing, acrylamide/ 
bis-acrylamide solution to a final percentage of 5% (v/v), 50% (v/v) stacking buffer, 0.1% (v/v) 
TEMED, and 0.1% APS. Combs were inserted into the stacking gel and once set wells were 
washed with SDW. The tank was filled with running buffer, appropriate volumes of samples 
added, alongside a molecular weight protein marker (Spectra Broad Range Pre-stained Protein 
Ladder, 10-260kDa Fermentas) and run at 135V and for 1.5-2 hours.  
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2.5.4  Immunoblotting 
Upon electrophoresis resolved protein samples were transferred to a nitrocellulose membrane, 
(Pall-Life Sciences 66-485) by removing gels from the plates and placing into the Mini-
transblot kit (Biorad). The gels along with the membrane were sandwiched between two layers 
of 3MM filter paper (Whatman), soaked in transfer buffer and run at 90V for 90 minutes on 
ice. Once transferred, membranes were added to blocking buffer (milk or BSA depending on 
primary antibody) and incubated with agitation for approximately 1 hour. The membrane was 
then transferred to 10mls of blocking buffer containing the primary antibody (Table 2.5.3.1.) 
and incubated with agitation overnight at 4°C or 3 hours at room temperature. Following 
primary incubation membranes were washed (3 x 5 minutes) with wash buffer and added to 
blocking buffer containing the appropriate secondary (HRP-conjugated, see Table 2.5.3.2.) and 
incubated for approximately 1 hour with agitation. Membranes were then washed (3 x 
5minutes) with wash buffer and immunoreactive bands detected using ECL (Enhanced 
chemiluminescence) (Amersham International, EZ-ECL Biological Industries) and visualised 
using autoradiography on hyperfilm (Amersham International) and developed on a Kodak X-
OMAT-1000 processor. Re-probing of membranes with additional primary antibodies was 
performed by incubating the membrane in heated stripping buffer, 50-55°C, for 1 hour in a 
sealed container at room temperature. The membrane was then washed (4 x 5 minutes) in wash 
buffer, re-blocked and probed as above. 
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Table 2.5.4.1: Primary Antibodies used for Immunoblotting 
Antibody Species Dilution Company 
A1- VTPase 
 
Rabbit 
 
1:500 
 
Sanata Cruz (sc-28801) 
β-actin (AC-15) 
 
Mouse  
 
1: 20000 
 
Sigma (A5441) 
CD63 
 
Mouse  1:50 Gift from R.Sadej 
Ductin 
 
Rabbit 1:300 Chemicon (AB5469) 
 
HA  
 
Rat 1:1000 Roche (3f10) 
 
HA(Y112) 
 
Rabbit 1:1000 Santa Cruz (sc-805) 
IFNαR1 
 
Rabbit 1:500 Santa Cruz (sc-845) 
 
IFNαR1 
 
Mouse 1:500 Santa Cruz (sc-7391) 
 
IFNγR 
 
Mouse 1:500 Santa Cruz (sc-12755) 
 
IκBα 
 
Rabbit 1:500 CST (9242) 
 
IRF1 
 
Rabbit 1:500 Santa Cruz (sc-497) 
IRF1 
 
Rabbit 1:1000 CST (4699) 
 
IRF2 
 
Rabbit 1:500 Santa Cruz (sc-498) 
 
IRF3 
 
Rabbit 1:500 Santa Cruz (sc-9082) 
 
IRF7 
 
Rabbit 1:500 Santa Cruz (sc-9083) 
 
Jak1 
 
Rabbit 1:500 Santa Cruz (sc-7288) 
 
Jak1 
 
Mouse 1:500 Santa Cruz (sc-1677) 
 
P65 Rabbit 
 
1:50 
 
Santa Cruz (sc-372) 
 
P-p65 
 
Rabbit 
 
1:1000 
 
CST (3031) 
 
p-IκBα 
 
Rabbit 
 
1:1000 
 
CST (2859) 
 
p-IRF3 
 
Mouse 
 
1:750 
 
CST (4961) 
 
Rab5 Rabbit 
 
1:500 
 
Santa cruz (sc-28570) 
 
Rab5 Mouse 
 
1:500 
 
Santa cruz (sc-46692) 
 
Rab7 Rabbit 
 
1:500 
 
Santa cruz (sc-10767) 
 
SOCS2 Rabbit 
 
1:500 
 
Santa Cruz (sc-9022) 
 
SOCS3 
 
Rabbit 
 
1:500 
 
Santa Cruz (sc-9023) 
 
SP-1 
 
Rabbit  
 
1:100 
 
Santa Cruz (sc-59) 
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Table 2.5.3.2: Secondary Antibodies used for Immunoblotting 
Secondary antibody Dilution Supplier 
Anti-Rabbit-HRP 
 
1:1000 
 
DAKO 
Anti-Mouse-HRP 
 
1:1000 DAKO 
Anti-Rat-HRP 
 
1:1000 DAKO 
Anti-Human protein A 
 
1:8000 Zymed 
 
 
2.6  Flow cytometry analysis (Fluorescence-activated cell sorting FACS) 
2.6.1 Solutions and buffers 
1% PFA (Paraformaldehye) 1g PFA powder was dissolved by stirring overnight at 42oC in 
100ml SDW.  Once in solution, 1 Dulbecco A tablet was added, the pH adjusted to 7.4 and the 
solution covered in foil, to protect from light. 
0.1% Saponin 0.1g of Saponin detergent dissolved in 100ml SDW and adjusted to a pH of 7.4. 
 
2.6.2  FACs analysis 
Cell to be labelled were seeded in triplicate on 10cm2 dishes at a density of 1 x 106 and grown 
until approximately 80% confluent. All media was then removed and the cells rinsed in PBS 
and then twice in EDTA. In order to prevent loss of cell surface receptors, cells were detached 
from the plastic in the absence of trypsin using fresh EDTA and incubated at 37°C until cells 
loosened.  Cell suspensions were pelleted at 1500rpm for 5 minutes, all EDTA removed and 
resuspended in 10ml of normal media for 30mins at 37°C. Cells were then counted and plated 
into the wells of a pre-chilled 96-well V plate at a density of 5 x 105 cells per well. Plates were 
centrifuged at 2000rpm for 2 minutes at 4°C and supernatants discarded. Samples were then 
washed three times in 1%FCS/PBS, pelleting the cells and discarding the supernatants as 
above. Cell pellets were resuspended in 1% FCS/PBS containing the appropriate concentration 
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of primary antibody (Table 2.6.2.1.) to a total volume of 50µl and incubated for 1.5hours on 
ice, in the dark. After incubation samples were washed in 1% FCS/PBS three times, as above, 
and incubated on ice for 1.5 hours with 1% FSC/PBS containing the relevant Alexa 488 
conjugated secondary antibody (Table 2.6.2.2.) to a total volume of 50µl. Plates were wrapped 
in foil to protect from the light. Post incubation the cells were washed three times in 1% 
FCS/PBS and supernatants discarded, following the final wash the cells were resuspended in 
50µl 1%FCS/PBS and added to FACS analysis tubes (Starstedt) containing 1ml 1% PFA. 
Samples were wrapped in foil and stored at 4°C until read on a flow cytometer. 
Table 2.6.2.1: Primary Antibodies used for FACS analysis  
Antibody Species Dilution Company 
 
TLR3 
 
Mouse 1:1000 Serotec CD283 
 
TLR4 
 
Mouse 1:1000 Serotec CD284 
 
TLR7 
 
Rabbit 
 
1:1000 Santa Cruz (sc-30004)
 
TLR9 
 
Mouse 
 
1:1000 Serotec CD289 
 
 
 
Table 2.6.2.2: Secondary Antibodies used for FACS analysis 
Secondary Antibody 
 
Dilution Company 
 
Alexa-Fluor 488 Goat Anti-Rabbit 
 
1:2000 Molecular Probes 
 
Alexa-Fluor 488 Goat Anti-Mouse 
 
1:2000 Molecular Probes 
Alexa-Fluor 488 Goat Anti-Human 
 
1:2000 Molecular Probes 
  
FACS analysis was also performed on permeabilised cells to compare the levels of receptors 
on the surface of cells compared with those bound to internal membranes. This was performed 
in a similar manner as above with the addition of 0.1% Saponin detergent at the primary and 
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secondary incubation steps. Washing and fixing were performed as normal. Data analysis of 
the output of a FACS analysis was performed using the WinMidi™ program, measuring only 
viable cells and standardising against negative internal controls.  
 
2.7  Immunohistochemistry 
2.7.1  Solutions and buffers. 
EDTA buffer: 100ml EDTA-Tween buffer diluted in 900ml SDW. 
Hydrogen Peroxide: Sigma, provided as a 30% Hydrogen peroxide solution in water and 
diluted to 0.3% in SDW.  
 
2.7.2  Agitated Low Temperature Epitope Retrieval Immunostaining Technique 
Paraffin embedded sections to be stained were cut using a micro-tome, transferred onto slides 
and heated to 60°C. Slides were then transferred to Xylene in a fume hood for 5 minutes, 
followed by IMS for 5 minutes. Slides were then washed in water to remove all traces of IMS, 
before placing into a 0.3% hydrogen peroxide solution for 15 minutes. Following this, slides 
were transferred into EDTA buffer pre-heated to 65°C for 16hours / overnight, with constant 
heat and stirring. The following day the buffer was cooled by placing under a running tap, the 
slides removed, covered with a cover plate and mounted onto a Sequenzer™ rack. Slides were 
then washed for five minutes with TBS, no Tween (pH 7.6). TBS containing the primary 
antibody at the required concentration (Table 2.7.2.1) at a total volume of 100µl was added and 
incubated for 1 hour at room temperature.  Sections were washed in TBS-Tween for five 
minutes, following which; 2 drops of Chemate Envision Secondary (Molecular probes) were 
added and incubated for 30 minutes.  Following another 5 minute wash with TBS-Tween 
sections were places onto a staining rack and kept moist by addition of TBS. Epitopes were 
then visualised by adding chromagen (DAB) using a Pasteur pipette and incubating for 5 
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minutes. Slides were then washed in SDW and counterstained in haematoxylin for 10-30 
seconds. Excess haematoxylin was removed by rinsing with warm water and the sections 
incubated in IMS for 5mins. Slides were then immersed in Xylene for 2 minutes dried and 
coverslips mounted using DPX (TBS Biosciences). Stained sections were visualised and 
photograph using a phase microscope.  
Table 2.7.2.1: Antibodies used for IHC staining. 
Antibody 
 
Species Dilution Company 
TLR3 
 
Mouse 
 
1:25 
 
Imgenex 417-A 
TLR4 
 
Mouse 
 
1:25 
 
Imgenex 579-A 
 
2.8  Electrophoretic mobility shift assay (EMSA) 
2.8.1  Solutions and buffers 
1% TBE Buffer: 10.8g Tris, 4.5g orthoboric acid and 0.74g EDTA in 1 litre SDW, 10mls in 
990mls of SDW and sterilised by autoclave. 
0.5% TBE Buffer: As above but diluted to 0.5% in SDW and autoclaved. 
10X binding buffer: 100 mM Tris, 500 mM KCl, 10 mM DTT, pH 7.5. 
2.8.2  Nuclear and cytosolic protein extractions 
Cells of interest were grown on 10cm2 dishes until 80-90% confluent. Normal growth media 
was replaced with serum free media alone or supplemented with a chemical treatment (see 
section 2.3.1), removal of serum ensured that in control samples only a basal level of 
transcription factor binding would be observed. Lysis of cells was performed using the NE-
PER nuclear and cytosolic extraction reagents (Pierce Biotechnology). Once cells had reached 
the required harvesting timepoint, all media was removed and the dishes washed gently with 
ice-cold PBS, on ice. All PBS was removed from the dish and cells lysed by addition of 100µl 
CERI reagent, on ice. Lysates were scraped, collected and transferred into pre-chilled, labelled 
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1.5ml eppendorf tubes. Samples were vortexed for 15 seconds and incubated for 10mins on ice. 
11µl of CERII was then added to each sample, vortexed and incubated for on ice for an 
additional minute. Lysates were then centrifuged for 5 minutes at 13000rpm and 4°C, the pellet 
contained the nuclei and the supernatant, which was removed and transferred to a clean 
eppendorf, the cytosolic fraction. The nuclear pellet was resuspended in 50µl of NERI on ice 
and vortexed for 15 seconds every 10 minutes for 40 minutes. Samples were then centrifuged 
as before and the supernatant containing the nuclear fraction removed and transferred to clean 
pre-chilled 1.5ml eppendorf. Protein concentration was measured as described previously 
(section 2.5.2.) and samples stored at –80°C. To ensure efficient separation of cell fractions, 
immunoblotting was performed on both extracts using antibodies specific to the cytoplasmic 
and nuclear markers, β-tubulin and Sp-1 respectively (data not shown), expression of each only 
detectable in the relevant extract.   
 
2.8.3  Preparation and annealing of probes  
EMSAs were performed using commercially available (MWG) end-labelled IR-Dye-700 
probes designed for specific DNA binding sites (See Table 2.8.3.1. for probes used). The 
oligonucleotides were diluted with DEPC treated water to 100pmole and for annealing 5µl of 
each of the sense and anti-sense complimentary probes were mixed with 90µl of Restriction 
buffer B (Roche). This was incubated at 95°C for 10 minutes, the heat block switched off and 
the sample allowed to cool overnight. The annealed probe was then aliquoted (20µl), covered 
in foil (to protect from light) and stored at –20°C until further use.  
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Table 2.8.3.1: IRD-700 end labelled probes used for EMSA assays. 
Probe 
 
Sequence 
PRDI FWD 
 
5’-GGGAGAAAGTGAAAGTG-3’ 
 
PRDI REV 
 
3’-CACTTTCACTTTCTCCC-5’ 
 
PRD11 FWD 
 
5’-GGGAAATTCCGGGAAATTCC-3’ 
PRD11 REV 
 
3’- GGAATTTCCCGGAATTTCCC-5’ 
 
NFKB FWD 
 
5’ - AGTTGAGGGGACTTTCCCAGGC -3’ 
 
NFKB REV 
 
3’ - TCAACTCCCCTGAAAGGGTCCG -5’ 
 
 
2.8.4  Preparation of native-PAGE gels 
6% Native-PAGE gels were prepared as outlined in Table 2.8.4.1, these were poured into 
Novex cassettes (Invitrogen) and stored at 4°C. Prior to sample loading the gels were placed 
into Novex cassette tanks (Invitrogen) and filled with 0.5% TBE buffer, combs removed and 
gels pre-run at 70V for 30 minutes.  
Table 2.8.4.1:Native-PAGE gel preparation for approx 8 10-well gels. 
Volume Reagent 
13.3ml 30% Acrylamide (0.8%N,N bis acrylamide) 
22.7ml SDW 
44ml TBE Buffer 
450µl 20% APS 
45µl TEMED  
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2.8.5  DNA: Protein binding reactions 
EMSA binding reactions were set up as outlined in Table 2.8.5.1, the value ‘x’ denoting the 
amount of sample to be loaded for a 5µg total. Once mixed reactions were incubated in the 
dark at room temperature for 30 minutes, following this 4µl of 5X Loading Buffer (Odyssey®) 
was added to each sample and mixed by gentle tapping. Total sample volumes were loaded 
onto the pre-cast gels and run at 100V for 1-1.5 hours or until the dye front reached the bottom 
of the gel. Visualisation and densitiometric analysis was performed on the Odyssey® infrared 
imaging system (Li-cor). 
Table 2.8.5.1: EMSA binding reaction 
Volume Reagent 
Xµl Nuclear Extract (5µg) 
(14-x)µl SDW 
1µl Annealed IRD-700 labelled Probe 
1µl Poly (dI:dC) 1µg/µl 
1µl  25 mm DTT/ 2.5% Tween-20   
2µl  10X Binding Buffer 
  
2.9  Molecular biology 
2.9.1  RNA extraction from cells in culture 
RNA extraction was performed using the Trizol reagent (Invitrogen) and a modified form of 
the manufacturers protocol. Prior to addition of Trizol cells of interest were grown to 80-85% 
confluency, all media removed and dishes washed with PBS. Upon removal of all PBS, cells 
were lysed by addition of 500µl per well of a 6-well plate of Trizol. Lysis was aided by 
repetitive pipetting and the lysate collected and transferred to a sterile 15ml screw cap 
polypropelene tube (Starstedt) and shaken vigorously for 2 minutes. 100µl of chloroform was 
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added to each sample, the tubes shaken for 2 minutes and centrifuged for 30 minutes at 
3000rpm and 4°C. The upper phase was carefully removed and transferred to a fresh, labelled 
1.5ml eppendorf tube. An equal volume of 100% isopropanol was then added, solution mixed 
by inversion and incubated at room temperature for 10 minutes. Samples were then centrifuged 
for a further 30 minutes at 3000rpm and 4°C and supernatant removed. 75% ethanol was then 
added and the pellets washed overnight at –20°C. The following day, samples were centrifuged 
for 10 minutes at 3000rpm and 4°C, ethanol removed and pellets allowed to air-dry for 5-10 
minutes. Pellets were resuspended in 200µl DEPC (diethylpyrocarbonate) treated water (Sigma   
Aldrich). Samples were then incubated for 10 minutes at 55°C and stored at –80°C. 
Concentration of the RNA was measured at absorbances of 260nm and 280nm using a 
Nanodrop ND-1000 spectrophotometer (Labtech International).   
 
2.9.2  cDNA synthesis 
Production of cDNA was performed using Random primers (Promega) and SuperScript III® 
reverse transcriptase, the reaction master mix was prepared on ice and is outlined in Table 
2.9.2.1. 
Table 2.9.2.1: cDNA synthesis reaction mix. 
Volume Reagent 
4µl 5X Buffer (Invitrogen) 
1µl 0.1M DTT (Invitrogen) 
1µl Random Primers 
1µl dNTPs (10mM) (Invitrogen) 
1µl RNaseOUT ribonuclease Inhibitor (40U/µl) (Invitrogen)  
1µl Superscript III Reverse Transcriptase (200U/µl) (Invitrogen) 
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1µg of RNA was diluted up to a total volume of 11µl in DEPC water and denatured at 65°C for 
5 minutes in a thermocycler. Following this 9µl of the reaction master mix detailed above was 
added and the samples returned to the thermocycler and the following program run: 25oC for 5 
minutes, 50oC for 1hour, 70oC for 15 minutes, with a final hold at 4oC. Samples were then 
further diluted with 80µl of DEPC, aliquoted and stored at -20°C until further use. 
 
2.9.3  Reverse transcriptase - polymerase chain reaction (RT-PCR) 
RT-PCR was performed using cDNA synthesised as described in section 2.9.2 and using 
GoTaq green polymerase mastermix (Promega). Reaction mixtures were made according to 
Table 2.9.3.1, and these were run on a thermocycler following the program in Table 2.9.3.2, 
where ‘x’ denotes the primer set specific annealing temperature.  
Table 2.9.3.1: RT-PCR reaction master mix  
Test Volumes Control Volumes Components 
25µl 25µl GoTaq Green  
1µl (100pmol) 1µl (100pmol) 5’ Primer 
1µl (100pmol) 1µl (100pmol) 3’ Primer 
18µl 23µl DEPC treated H2O 
5µl (50ng) 0µl cDNA 
 
Table 2.9.3.2: Typical RT-PCR thermocycler program 
Number of Cycles Temperature Duration 
1 95oC 1min 
25-35 94oC 45 sec 
 xoC 45 sec 
 72oC 1 min 
1 72oC 10 min 
 4oC Hold 
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Primer sets were specifically designed to avoid self-annealing, formation of hairpins and 
according to the following rules; GC content of 40-60%, high 5’ GC content, high 3’ AT 
content and a 3’ GC content less than 40%. The primers were also designed to span intron/exon 
boundaries to ensure mRNA amplification. Table 2.9.3.3. shows a list of primer sets used, their 
annealing temperatures and cycle numbers. GAPDH primers were used as an internal control 
to ensure equal levels of cDNA in each sample.  
 
Table 2.9.3.3: List of RT-PCR primer sets. 
Gene 
 
Sequence 
LMP2A Forward: ATGGGGTCCCTAGAAATGGT 
Reverse: TTATACAGTGTTGCGATATGGG 
LMP2B Forward: ATGAATCCAGTATGCCTGCCT     
Reverse: TTATACAGTGTTGCGATATGGG 
IFNβ Forward: CTGGCTGGAATGAGACTA 
Reverse:GCAGAATCCTCCCATAATA 
IRAK1 Forward: CGGGCAATTCAGTTTCTACAT 
Reverse:CCTCCTCAGCCTCCTCTT 
IRAK4 Forward: CCAGCTGACTCCACTACTAA 
Reverse: GGCCCTTTCAACAGTCTCAA 
MAP3K7 
 (TAK1) 
Forward: CGACCACCATGATAAAA 
Reverse: CCAGTGTAAGATAAGCCAT 
MYD88 Forward: GCGGGCATCACCACACTT 
Reverse: GCGAGTCCAGAACCAAGATT 
TIRAP (Mal) Forward: AGTAGTCGCTGGAGCAAA 
Reverse: CTTACAACGCATGACAGCTT 
TRAF3 Forward: CCGTGGAGGACAAGTACAA 
Reverse: CATGTGGCTTCCCGGTATT 
TRAF6 Forward: GCCCAGGCTGTTCATAGTT 
Reverse: GATTGTGGGTCGCTGGAAA 
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2.9.4 Agarose gel electrophoresis 
2.9.4.1 Solutions and Buffers 
TBE buffer: 10.8g Tris, 4.5g orthoboric acid and 0.74g EDTA dissolved in 1L SDW. 
2.9.4.2 Gel electrophoresis 
PCR and RT-PCR products were analysed and separated via horizontal gel electrophoresis. 
Depending on the expected size of the PCR product varying percentages of agarose gels were 
prepared (0.5-2% w/v) by dissolving the appropriate weight of agarose powder (Eurogentec) in 
TBE buffer. The solution was then heated and upon sufficient cooling 0.5µg/ml of Ethidium 
Bromide (Thermo Scientific, 0.625 mg/ml) was added to allow visualisation of DNA. The gel 
was then poured into a gel tray of appropriate size, to a thickness of approximately 7mm and 
allowed to cool until fully set. The combs were then removed and the gel submerged in TBE 
buffer in an electophoresis tank, samples loaded (usually 25µl of RT-PCR products) alongside 
500ng of a 100bp molecular weight marker (GeneRuler™ 100bp Plus, Fermentas). 
Electrophoresis was performed at 1-5V/cm, depending on the expected size of the fragment 
and the percentage of the gel. Following electrophoresis the DNA was visualised and 
photographed by ultraviolet illumination with a Syngene Bioimagine GeneFlash. 
 
2.9.5  Real time quantitative PCR (RT-QPCR) 
RT-QPCR for target genes was carried out on cDNA generated as described in section 2.9.2, 
using commercially available TaqMan® primer and probe sets (Applied Biosciences) (Table 
2.9.5.1). Cellular target primer and probes sets were FAM labelled and the internal baseline 
control used for data normalisation was a VIC labelled huGAPDH primer/probe set. Primers 
were designed to span intron-exon boundaries to ensure mRNA amplification. Reactions were 
set-up according to Table 2.9.5.2, loaded in triplicate onto an optical 96-well plates (Applied 
Biosystems) and run on an ABI 7500 Fast real-time PCR machine.  
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Table 2.9.5.1: Q-PCR primer probe sets from ABI Biosystems. 
Gene Catalogue Number
TLR3 Hs01551078_m1 
TLR4 Hs00152939_m1 
IFNβ Hs00277188_s1 
STAT1 Hs01014002_m1 
ISGF3/IRF9 Hs00959316_g1 
IRF1 Hs00971960_m1 
MXA1 Hs00895598_m1 
MXA2 Hs01550808_m1 
OAS1 Hs00973637_m1 
OAS2 Hs00942643_m1 
 
Table 2.9.5.2: Q-PCR reaction mix. 
Volume Components 
10µl 2 x ABI Q-PCR Master Mix  
0.5µl VIC huGAPDH primer/probe 
1µl  FAM Target primer/probe 
7.5µl DEPC treated H2O 
5µl (50ng) cDNA sample 
 
Cycle threshold or Ct values are defined as the cycle number where the fluorescent signal 
exceeds that of the background, an inverse relationship existing between the level of target 
DNA in a sample and the cycle number. Values for the dCt (for experiments performed in 
triplicate) were obtained by normalising the test Ct values against the GAPDH Ct values in the 
multiplexed reactions. The mean dCt was used to calculate the ddCt by normalisation using 
sample controls, the inverse relationship between cycle number and level of DNA in the cell 
was resolved by applying the formula 2^-ddCt.  
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2.10  Cytokine Array 
In order to assess the cytokines secreted from a variety of cell lines upon various treatments a 
cytokine array was performed (R & D Systems). The Human Cytokine Array Panel A Array 
Kit was used according to manufacturers protocols. The principle of the assay is to incubate 
supernatant from growing cells with a nitrocellulose membrane spotted in duplicate with 
selected capture antibodies. Cytokines within the supernatant will be bound onto the membrane 
by their cognate antibodies and following this can be visualised using Strepdavidin-HRP 
(Horseradish peroxidase) and chemiluminescent detection. The observed signal is directly 
proportional to the level of cytokine bound to the membrane and internal controls allow for 
normalisation within and between samples so that comparisons can be made between cytokine 
production in a number of cell lines for a number of cell treatments. Briefly, following 
stimulation with a variety of chemical treatments (see section 2.3.1, Table 2.3.1.1) the growth 
medium, 1.5ml per well of a 6-well plate, was removed and transferred to a labelled eppendorf. 
RNA was extracted from the cells for validation and optimisation purposes as described in 
section 2.9.1. Prior to sample incubation the membrane was blocked for 1 hour in Array Buffer 
4 on a rocking platform. While blocking, 15µl of Cytokine Array Panel A Detection Antibody 
Cocktail to each sample and incubated at room temperature for 1 hour. As the samples were 
growth medium from cell culture it was not necessary to dilute them further. Once blocked 
Array Buffer 4 was removed and the sample/antibody mixtures added to each membrane, this 
was incubated overnight at 4°C on a rocking platform. Following this the membranes were 
removed from the supernatant mix and washed (3 x 10 minutes) with the supplied Wash 
Buffer. The Strep-HRP antibody was diluted in Array Buffer 5, added to each of the 
membranes and incubated for 30 minutes at room temperature. Membranes were washed as 
above. Once washed ECL and autoradiography was used to visualise the membranes. 
Densitiometric analysis was performed using a Biorad© densitometry scanner.  
 108
Chapter 3  Results 
 
    CHAPTER 3 
Generation of a panel of LMP2 loop mutants in a lentiviral expression 
system. 
 
3.1 Introduction 
 
To further investigate the effects of stable LMP2A and LMP2B expression in epithelial cells 
and to ascribe a specific function to particular protein domains, a panel of LMP2 loop mutants 
were generated. As described previously the LMP2 proteins comprise 12 transmembrane 
spanning domains and, in the case of LMP2A, an amino-terminal cytosolic signalling domain. 
Although most of the effects attributed to LMP2A expression in epithelial cells are thought to 
result from the disruption of normal cellular signalling by this N-terminal domain, the effect of 
LMP2B expression alone on cell signalling pathways and on growth and differentiation cannot 
be explained by such a hypothesis (Allen, Young et al. 2005; Shah, Stewart et al. 2009). To 
examine the role, if any, of the transmembrane domains on the intracellular localisation and 
biological properties of LMP2A/2B, the loops of the LMP2A/2B protein were serially deleted.  
It is known that the transmembrane domains anchor the protein to internal phospholipid 
membranes (Longnecker, Merchant et al. 2000) and it is likely that this localisation can alter 
intracellular trafficking which in turn can attenuate and, in some cases, prime signalling 
responses. The use of a lentiviral vector expression system for this cloning strategy provided a 
means by which stable cell lines could be readily generated by viral transduction. These viruses 
could also be used to transduce primary keratinocytes, allowing an investigation into the 
contribution of the LMP2 proteins in early stages of cell transformation. As the transmembrane 
spanning domains of LMP2A and LMP2B are identical, recombinant lentiviral vectors 
expressing defined LMP2 membrane loops were engineered from a plasmid containing an 
LMP2B cDNA.  
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3.2 Generation of recombinant pCR8/GW/TOPO transfer plasmids containing LMP2 
membrane deletion mutants.  
3.2.1 PCR of LMP2 mutants. 
LMP2 loop mutant constructs were derived from the pMSCV/LMP2B-HA plasmid using 
oligonucleotide primers targeting sequences within the LMP2B cDNA such that the 
transmembrane domains would be sequentially deleted. Figure 3.1, shows a schematic of the 
binding sites for these primers and the expected gene and protein products. They include 
primers to delete loop 1 (LMP2-L1-Del), loops 1, 2 and 3 (LMP2-L3-Del), loops 1-4 (LMP2-
L4-Del), loops 1-5 (LMP2-L5-Del) and loops 1-6 (LMP2-L6-Del). The 3’ primer was designed 
to target sequences within the plasmid downstream of the STOP codon so that PCR 
amplification would include the coding sequence of the HA tag. Table 3.2.1.1 lists the 
sequences of each of the primers used and their respective annealing temperatures. The PCR 
reactions were set-up using High Fidelity DNA Polymerase according to Table 3.2.2.2, and run 
on a thermocycler according to the program in Table 3.2.2.3. The optimum annealing 
temperatures for each primer set were used.  
Table 3.2.3.1: PCR amplification of LMP2 loop mutant reactions  
Primer  Sequence, 5’-3’ Annealing temp 
LMP2-L1 Del Fwd GGCTCGAGATGTCATCTTGCCGCTGC 62.4˚C 
LMP2-L3 Del Fwd GCCTCGAGATGACTCTTGGTGCAG 62.4˚C 
LMP2-L4 Del Fwd GGCCTGAGATGCTGGCACGACTGTTCC 62.4˚C 
LMP2-L5 Del Fwd GGCTTCGAGATGCTTGCTATCCTGACCG 60.2˚C 
LMP2-L6 Del Fwd GGCCTCGAGATGTGCCGCTACTGCT 62.4˚C 
Rev Primer GGGGATCCCCAGACTGCCTTGGGAAAA N/a 
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Figure 3.1.Schematic representation of the cloning procedure for generation of 
LMP2 loop deleted mutants. 
 
The full-length sequence of LMP2B is shown with each transmembrane loop denoted 
by a differently coloured sequence. LMP2-L1 Del mutant is comprised of deletion of 
the first section of the gene (green), LMP2-L3 Del the first three loop domains (green, 
light blue, navy blue), LMP2-L4 Del the first four loop domains (green, light blue, 
navy blue and magenta), LMP2-L5 Del the first five loop domains (green, light blue, 
navy blue, magenta and green) and finally the LMP2-L6 Del, the majority of the gene 
with only the C terminal domain remaining (black). 5’ PCR primers for each of these 
sequences bind immediately upstream of the deletion with 3’ primer binding 
downstream of the HA tag (not denoted in schematic). Upon amplification by PCR 
the gene fragments were ligated into the pCR8/GW/TOPO™ vector at the site shown. 
Validation of correct insertion was performed using diagnostic digestion and 
sequencing. Following this the recombinant pCR8 vectors were recombined with the 
promoter of choice, pENTR™5’-UbCp, and the final pLenti6/R2R4/V5-DEST 
destination vector. The generated lentiviral vectors were then validated, expression of 
the mutant proteins assessed, virus produced and transduction of cell lines performed.  
Plasmid maps were obtained from the Invitrogen website.   
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Table 3.2.3.2: PCR amplification of LMP2 loop mutant reactions  
Volume Reagent 
1µl Plasmid Template DNA (10ng) 
1µl Forward Primer 
1µl  Reverse Primer 
5µl 10 X Reaction Buffer 
1µl DNTPs 
0.35µl High Fidelity DNA Polymerase 
40.65 DEPC Water 
Table 3.2.3.3: PCR thermocycler program   
Number of Cycles Temperature Duration 
1 96oC 1min 
96oC 10 sec 
50oC 5 sec 
25 
60oC 4 min 
Hold 4oC Hold 
 
Gel-loading buffer was added to the PCR reactions and they were run on an agarose gel, and 
photographed, Figure 3.2 shows each of the discrete bands and the difference in size 
depending on the extent of the deletion.   
 
3.2.2 Gel extraction of PCR products 
Once resolved by agarose gel electrophoresis, PCR products were compared with the DNA 
ladder to ensure their correct molecular weight. Each fragment was then isolated and purified 
for further cloning using a gel extraction kit from Qiagen (Qiagen). The products of interest 
were excised from the gel using a clean sterile scalpel and transferred into clean, labelled 1.5ml  
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Figure 3.2. PCR amplification of LMP2 gene fragments. 
 
Amplification of the required gene fragments was performed by PCR using the 
template pMSCV/LMP2B/HA plasmid, 5’ primers designed to delete required loop 
domains, a 3’ primer encompassing the C-terminal HA tag and High fidelity DNA 
polymerase. Following this gel electrophoresis was carried out and the resulting gel 
visualised using EtBr and photographed. Lane 1 (L1) shows the control full length 
LMP2B band and lanes 2-6 (L2-L6) the expected smaller loop deleted fragments.  
Fragment sizes were identified through comparison with DNA ladders (Norgen) and 
are denoted to the left and right of the photograph.  
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expenders. Gel slices were weighed and appropriate volumes of buffer QG were added (100µl 
per 100mg), this was heated to 55˚C for 15 minutes to dissolve polymerised agarose. The 
mixture was added onto a DNA binding column and centrifuged to remove dissolved agarose, 
while retaining required DNA in the column, at 13000rpm for 1 minute. Flow-through was 
discarded, 750µl of wash buffer WE added and the column centrifuged as above. Wash buffer 
was discarded and the now empty column centrifuged as above to ensure complete removal of 
buffer traces. The inner sleeve of the binding column was removed and placed into a clean pre-
labelled eppendorf, 40µl of DEPC treated water added to the centre of the filter and the 
samples centrifuged again. Flow through containing purified DNA was stored at –20˚C and its 
concentration subsequently measured using a Nano-drop spectrophotometer. 
 
3.2.3. Ligation of PCR-amplified products into pCR8/GW/TOPO® vector 
The gel-isolated PCR products were ligated into the destination vector, pCR8/GW/TOPO®, 
supplied by Invitrogen in the TA cloning kit. Reactions were set-up according to manufacturers 
protocol for chemically competent E. coli cells. As the PCR products varied in length the 
reaction mix was incubated for 15minutes at room temperature to ensure correct ligation of the 
larger fragments, e.g. LMP2-L1 Del mutant. The reaction mixture is outlined below, Table 
3.2.3.1. Reactions were cooled to 4˚C and if necessary stored at –20˚C.  
 
Table 3.2.3.1: pCR8/GW/TOPO® vector ligation mix.
Volume Reagent 
2µl Freshly Prepared PCR product 
1µl Salt Solution 
2µl  DEPC Water 
1µl TOPO® Vector 
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3.2.4 Transformation of One Shot ® TOP10 E. coli. 
pCR8/GW/TOPO® vectors containing various LMP2B loop deletion mutants were used to 
transform the TOPO-10 E. coli cells supplied with the cloning reaction kit, by heat-shocking 
the plasmid DNA into the bacterial cells. 2µl of each ligation reaction was mixed with one vial 
of bacterial cells (30µl) and incubated on ice for 30 minutes. Following this, samples were 
placed into a 42˚C water bath for 30 seconds and immediately returned to the ice. 250µl of pre-
warmed SOC medium was added to each culture and the samples incubated with horizontal 
shaking (200rpm) at 37˚C for 1 hour. 75µl of each culture was then plated onto LB-Agar plates 
containing 100mg/ml spectinomycin and grown overnight in a 37˚C incubator. As a positive 
control 10pg of PUC-19 plasmid was transformed in a similar manner, but under ampicillin 
selection, a non-transformed bacterial culture was used as a negative control.  
  
3.2.5. Analysis of Transformants. 
After overnight incubation, agar plates were screened for bacterial colony growth. For each of 
the five loop deleted mutants, 4 colonies were picked using a sterile loop and grown overnight 
in 3ml of LB nutrient broth containing 100mg/ml spectinomycin at 37˚C with shaking at 
220rpm.   
 
3.2.5.1 Miniprep 
Bacterial cultures were removed from the incubator and 1.5ml removed and transferred to a 
clean eppendorf, cells were pelleted by centrifugation at 13000rpm for 10 minutes and the 
supernatant discarded. Plasmid DNA was then extracted using the Qiagen DNA Miniprep Kit. 
(Qiagen). The cell pellet was first resuspended in 100µl PB buffer and then lysed by addition 
of 250µl of buffer PL, mixed by inversion and incubated on ice for 15 minutes. Cellular lysis 
was neutralised by the addition of 350µl Buffer NB and the solutions mixed by inversion. 
 117
Chapter 3  Results 
 
Samples were then transferred into the supplied DNA binding columns and centrifuged at 
13000rpm at 4˚C for 2 minutes. Flow-through was discarded, 750µl wash buffer carefully 
added and each sample centrifuged as above. Complete removal of wash buffer from the DNA 
binding column was ensured by a second centrifugation upon emptying the waste. The inner 
sleeve of each column was then transferred into a clean labelled 1.5ml eppendorf and 20µl 
DEPC water added to the centre of the binding column. This was incubated for 2 minutes at 
room temperature, centrifuged as before, a further 20µl of DEPC water added and re-
centrifuged. The staggered addition of DEPC water ensured the highest yield of plasmid DNA 
possible was obtained. Concentrations were measured using a Nano-drop spectrophotometer 
and samples stored at –20˚C.  
 
3.2.5.2 Diagnostic digests 
To ensure that the pCR8/GW/TOPO® vectors contained the desired PCR-amplified fragments 
in the correct orientation, a series of diagnostic restriction digests was performed. These 
involved incubating the plasmid of interest with a restriction endonuclease and its required salt 
buffer and resolving the samples on an agarose. Figure 3.3, shows representative results of 
these digests and depicts the samples that were deemed to have digested correctly. As shown in 
Figure 3.3 B, although some colonies grew and plasmid DNA was successfully extracted, for 
all of the LMP2 Loop deletion mutants, not all contained fragments that were inserted in the 
correct orientation. Digest reaction mixtures were set-up according to Table 3.2.5.2.1, and 
incubated at room temperature for 16 hours or overnight. Following incubation, 4 X Gel 
loading buffer was added and samples separated by gel electrophoresis. EcoRI (New England 
Biosciences) was used to analyse which samples contained an inserted fragment of the correct 
size and subsequent digestion with Nco1 and Xba1 (New England Biosciences) revealed 
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fragment orientation. Table 3.2.5.2.2, contains a list of the band sizes expected for correctly 
orientated inserts. 
Table 3.2.5.2.1: Restriction Endonuclease reaction mix
Reagents Single Digest Double Digest 
Plasmid DNA (0.5µg) Xµl Xµl 
Enzyme 1 1µl 1µl 
Enzyme 2  -------- 1µl 
10x Buffer  2µl 2µl 
DEPC Water 17-Xµl 16-Xµl 
Table 3.2.5.2.2: Expected fragment sizes upon gel electrophoresis 
   
Sample EcoR1 Sizes Orientation Fragment Sizes 
LMP2-L1 Del 1337bp 433bp, 350bp, linearisied vector 
LMP2-L3 Del 959bp 433bp, 350bp, linearisied vector 
LMP2-L4 Del 781bp 433bp, 350bp, linearisied vector 
LMP2-L5 Del 646bp 433bp, 350bp, linearisied vector 
LMP2-L6 Del 428bp 250bp 
 
 
3.2.5.3 Sequencing 
In addition to diagnostic restriction digestion, samples selected from this initial screening were 
subjected to sequencing to ensure specificity prior to homologous recombination with the 
lentiviral vector.  Chosen samples were sequenced using the ABI Prism 310 (Applied 
Biosystems) sequencing protocol. Briefly, this involved sequencing the gene sequence of 
interest with primers specific to sequences on the pCR8 plasmid surrounding the inserted gene. 
These GW1 and GW2 primers are situated no less than 55 nucleotides from the insertion site  
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Figure 3.3. Diagnostic digests of pCR8/GW/TOPO™ containing amplified LMP2 
gene fragments. 
 
A series of diagnostic digestions were performed to validate insertion of the LMP2 
gene fragments into the pCR8/GW/TOPO™ plasmid.  
 
(A)  Restriction endonuclease digestion of ligated pCR8/GW/TOPO™ plasmids by 
EcoR1 was performed to validate insertion of gene fragments of interest. Upon 
incubation reactions were resolved by gel electrophoresis, visualised and 
photographed. LMP2-L1 Del panel shows digestion of four prepped LMP2-L1 
Del samples, LMP2-L3 Del panel three digested samples and the LMP2-L4/L5L6 
panel two LMP2-L4 Del samples, and four of each of the LMP2-L5 Del and 
LMP2-L6 Del vectors. Correctly digested samples are denoted by the green boxes 
and the band size measured by comparison against the DNA CloneSizer ladder.  
(B)  Double Restriction endonuclease digestion of ligated pCR8/GW/TOPO™ 
plasmids by Xba1 and Nco1 (LMP2-(L1-L5) Del) and a single digest with the 
Bser1 enzyme (LMP2-L6 Del) were performed to validate the correct orientation 
of inserted gene fragments of interest. Samples were visualised by gel 
electrophoresis and photographed. LMP2-L1/L3/L4 Del panel shows digestion of 
two LMP2-L1-Del, three LMP2-L3 Del and one LMP2-L4 Del samples. LMP2-
L5 Del Xba1+Nco1 shows four samples, an empty lane and two LMP2-L6 Del 
samples digested by BseR1. Green boxes denote correctly digested samples, the 
expected fragment sizes are shown, for LMP2-(L1-L5) samples these are of equal 
size whereas the linearised plasmid sizes differ. 
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and fall between the attL1 and attL2 sites on the restriction map in Figure 3.1. The PCR 
reaction mix was set-up for each respective correctly digested plasmid according to Table 
3.2.5.3.1 and run on a thermocycler using the program outlined in Table 3.2.5.3.2. Following 
amplification the resulting extension product was purified by addition of 2µl of 125mM 
EDTA, followed by addition of 2µl 3M sodium acetate and 50µl of 100% ethanol. Samples 
were then mixed by inversion, incubated at R.T. for 15 minutes and centrifuged at 2000g for 
45mins at 4˚C. The supernatant was then carefully removed and 70µl of 70% ethanol added, 
this was then centrifuged for 15mins at 1650g, supernatant removed and samples air-dried. 
10µl of Hi-Di™ (Applied Biosystems) was added to each reaction and the samples run on the 
sequencer or stored at 4˚C.  
Table 3.2.5.3.1: Sequencing PCR reaction mix 
Volume Reagents 
Xµl DNA sample (100ng) 
2µl Ready Reaction Premix  (Applied Biosystems) 
2µl Big Dye Sequencing Buffer (Applied Biosystems)
1µl (3.2pmol) Primer GW1 –or- GW2 
15-Xµl DEPC Water 
 
Table 3.2.5.3.2: Sequencing PCR cycle.
Number of Cycles Temperature Duration 
1 96oC 1min 
96oC 10 sec 
50oC 5 sec 
25 
60oC 4 min 
Hold 4oC Hold 
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The sequences were then analysed using the Chromas software, and the sequences checked 
against the consensus LMP2 sequence using the online alignment tool BLAST (bl2seq), 
(NCBI). This ensured that the DNA sequences generated during the cloning process had not 
acquired mutations. Figure 3.4.shows sequencing results from one of the samples as viewed in 
Chromas and the respective BLAST alignment.   
 
3.3 Recombination 
3.3.1. Homologous Recombination 
pCR8 plasmids containing correctly sequenced inserts were recombined with the lentiviral 
destination vector, pLenti6/R4R2/V5-DEST (Invitrogen) and a plasmid containing the 
Ubiquitin promoter, pENTR™-UbCp. These reactions involved incubating all the component 
parts of the new recombinant vector, pLenti6 backbone, promoter of choice and the 
recombinant pCR8/GW/TOPO® plasmids according to Table 3.3.1.1. 
Table 3.3.1.1: Homologous recombination reaction
Volume Reagents 
2µl Recombinant pCR8 
2µl pENTR™-UbCp 
1µl pLenti6/R4R2/V5-DEST 
2µl  Gateway® LR Clonase™ II Enzyme Mix 
3µl DEPC Water 
 
The reactions were incubated at room temperature for 16 hours, following which, 1µl of 2µg/µl 
Proteinase K Solution (Invitrogen) was added, samples incubated at 37˚C for 10 minutes and 
stored at 4˚C until transformation. 
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Figure 3.4. Representative example of the output of the sequencing reaction. 
 
Sequencing, using the ABI Prism 310 protocol, of the pCR8/GW/TOPO™ vectors 
was used to validate the gene fragment inserted.  
 
(A) Schematic representation of the output of a sequencing reaction following 
visualisation using the Chromas program. Each peak represents a discrete signal 
from each base of the analysed sequence, Red: Thymine, Green: Adenine, Blue: 
Cytosine and Black: Guanine.  Depicted here is the sequence of the LMP2-L1 Del 
fragment, using the GW1 forward primer. 
 
(B) Gene sequences were exported from Chromas in FASTA format and aligned 
against the full-length LMP2B sequence using BLAST. A sample of the BLAST 
output is shown where the LMP2-L1 Del sequence above is shown to have 98% 
identity with the consensus LMP2B sequence. Small errors in sequence were 
analysed and resolved by matching mismatches in the alignment with overlapping 
peaks visualised in Chromas.  
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3.3.2. Transformation of ONE SHOT® Stbl3™ E. coli. 
Transforming the ONE SHOT® Stbl3™ strain of E. coli was carried out in a manner similar to 
that described in section 3.2.4, using one vial of competent cells (30µl) and 2µl of 
recombination reaction. Post-heat shock, 75µl of culture was plated onto pre-warmed LB-Agar 
plates containing 100mg/ml ampicillin and grown overnight at 37˚C.  
 
3.3.3. Analysis of Transformants 
As above in section 3.2.5, colonies were picked and grown overnight in 3ml of LB broth 
containing 100mg/ml ampicillin. 1.5ml of these cultures were miniprepped as outlined in 
section 3.2.5.1, the remaining cultures were stored at 4˚C for Maxi-Prep of cultures deemed to 
contain successfully recombined plasmids.  
 
3.3.3.1 PCR amplification of genes of interest 
To further validate the insertion of the correct LMP2B loop deletion mutant, the generated 
plasmids were subjected to PCR using the primers from the initial amplification step of the 
cloning process. Figure 3.5, shows a photograph of PCR products following gel 
electrophoresis. From this it can be observed that the inserted genes could be amplified from 
the recombinant pLenti6/R4R2/V5-DEST vectors. Further validation was carried out to show 
that expression of these genes occurs in the correct manner upon transfection into human 
epithelial cells. 
  
3.3.4. Maxi prep 
The refrigerated cultures corresponding to samples that yielded correctly sized fragments after 
digestion were used to inoculate 500ml of LB-broth containing 100mg/ml ampicillin, these 
were then grown overnight at 37˚C with shaking at 220rpm.  Using the PureLinkTM Hi Pure  
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Figure 3.5. Validation of recombinant pLenti6/R2R4/V5-DEST by PCR of 
inserted gene fragments. 
 
PCR was performed on the pLenti6/R2R4/V5-DEST vectors using the 5’ forward 
primers used in the initial amplification step and a reverse 3’ primer designed to 
amplify LMP2B without the HA tag., to ensure correct insertion of LMP2 deleted 
gene fragments. Following amplification samples were resolved by gel 
electrophoresis, visualised and photographed. Lane 1 shows the expected band for 
PCR of full-length LMP2B, lanes 2-6, (L2-L6) show the expected smaller loop 
deleted gene fragments. Band sizes were compared against a DNA CloneSizer ladder 
and are indicated to the left and right of the photograph.  
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plasmid DNA purification Kit (Invitrogen, UK) the DNA was extracted and purified according 
to manufacturers instructions. The bacterial cells were first pelleted using a Sorvall bucket 
centrifuge at 5000rpm for 10 minutes. Supernatants were carefully decanted off and discarded, 
20ml of  buffer R3 was added and the pellet resuspended by repetitive pipetting and vortexing. 
Cells were lysed by addition of 20ml ice-cold L7 lysis buffer, gently mixed by inversion and 
incubated at R.T. for no longer then 5 minutes. 20ml of buffer N3 was added to each sample to 
both neutralise the lysis buffer and to precipitate cellular debris and solutions were then 
centrifuged for 10 minutes at 12000rpm. The DNA binding columns were equilibrating by 
adding 30ml of buffer EQ1 to each column, this was allowed to drain through by gravity.  
 Once centrifuged the supernatants were carefully transferred into the now empty 
columns and allowed to drain by gravity. Columns were then washed with 60ml W8 wash 
buffer, and once drained the inner sleeve of the column was removed and the DNA eluted by 
addition of 15ml of E4 elution buffer. 10.5ml of ice-cold 100% isopropanol was added to each 
collection tube and then centrifuged at 15000rpm for 30mins at 4˚C. Supernatants were 
discarded, the pellet washed in 5ml 70% ethanol and samples centrifuged at 15000rpm for 10 
minutes at 4˚C.  All residual ethanol was carefully removed and the pellet allowed to air-dry 
prior to resuspension with 500µl DEPC treated water. The DNA was transferred to clean 1.5ml 
eppendorfs and the concentration of each plasmid was then measured using a Nano-drop 
spectrophotometer. Samples were aliquoted and stored at –20˚C and 1µg/µl for further use. 
 
3.5 Generation of virus 
The human kidney epithelial packaging cell line 293FT was used to produce whole virus from 
the recombinant plasmids generated in the sections above. Cells were seeded into 10cm2 at a 
density of 6 x 106 and grown until dishes were 85-90% confluent. 4µg of each of the packaging 
plasmids, psPAX2, pMD2G and 4µl of each of the recombinant lentiviral plasmids containing 
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the LMP2 loop deletion mutants were transfected into each 10cm2 dish. Following transfection 
the cells were grown in 5ml of normal growth medium for approximately 72 hours. The media 
was then collected and centrifuged at 3000rpm for 15 minutes to remove and cellular debris. 
Supernatants, containing virus were then transferred to a fresh universal tube and stored at –
80˚C. A GFP lentivirus was created in tandem with the LMP2 mutants for use as a transduction 
control. CNE-2 cells to be transduced by whole virus were seeded onto the wells of a 6-well 
plate at a density of 2.5 x 105 and grown at 37˚C until 65-70% confluent. 2µl of polybrene 
(5mg/ml) (Millipore) was mixed with 1ml of the virus containing supernatant and added to 
each well of a six-well plate and cells returned to a 37˚C incubator overnight. Polybrene was 
used to increase the efficiency of viral transduction. 2ml of normal growth media was then 
added to each well and the cells grown for a further 2-3 days. Viral infection was assessed by 
visualisation of GFP in those cells transduced with the control virus. Drug selection was 
effected through the use of the blastocidin resistance cassette within the pLenti6/V5-DEST 
backbone, this allowed cells stably expressing mutant forms of LMP2B to be generated. 
Although drug selection was undertaken time constraints prevented generation of stable cell 
lines and as such validation of expression of the recombinant lentiviruses was performed 
transiently. 
 
3.5 Validation of recombinant Lentiviral vectors. 
3.5.1. Transient expression  
CNE-2 cells were seeded into 10cm2 dishes and grown until 80 % confluent. These were then 
transfected 2µg of one of the recombinant lentiviral plasmids containing LMP2B loop mutants, 
full length LMP2A or LMP2B in a lentiviral backbone (provided by Dr K. Shah) or pSG5-
LMP2A-HA, pSG5-LMP2B-HA, or a pSG5 control. Cells were grown for 48 hours to allow 
expression of proteins of interest prior to harvesting for RNA and protein extraction. A panel 
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of transiently transfected dishes was also trypsinised and cells seeded at a density of 1 x 104 
onto each well of a 12-well microdot Teflon-coated slide for immunofluorescence staining.  
 
3.5.2  RT-PCR of RNA extracts 
Post-transfection, cells were harvested for RNA extraction and isolation (section 3.5.1). The 
RNA was used to synthesise cDNA, which was subjected to RT-PCR for the LMP2 gene 
inserts, using primers specific to full length LMP2A, LMP2B and the primers used to amplify 
the LMP2B loop deletion mutants. Figure 3.6 shows a photograph of a representative RT-PCR 
reaction following gel electrophoresis. Products of the correct size were observed for each of 
the cDNA samples analysed.  
 
3.5.3  Immunofluorescence staining for the LMP2B loop deletion mutants 
To determine the intracellular localisation of the LMP2B loop deletion mutants, transfected 
cells were seeded onto microdot Teflon-coated slides (see section 3.5.1) and subjected to 
immunofluorescent staining with a mAb specific for the HA epitope. Slides were viewed and 
photographed on a confocal microscope, Chapter 2, section 2.4. One representative analysis, 
shown in Figure 3.7, illustrates the pattern of LMP2 staining as green punctate staining. When 
comparing the localisation of full-length LMP2A and LMP2B proteins (transient transfecton of 
pSG5-LMP2A-HA/pSG5-LMP2B-HA) with the LMP2B loop deletion mutants, there is a 
distinct loss of perinuclear intracellular membrane localisation as the loops are sequentially 
deleted. Thus, whereas LMP2A, LMP2B and the LMP2-L1-del and LMP2-L2-del mutants 
localise to perinuclear vesicles, the LMP2-L4-Del mutant begins to show loss of signal, with 
all signal lost in the cases of LMP2-L5-Del and LMP2-L6-Del. It is hypothesised that the loss 
of membrane anchoring due to the deletion of transmembrane domains results in an unbound 
and unstable protein that is degraded.   
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Figure 3.6. RT-PCR of LMP2 mutant gene fragments upon transient expression 
in CNE-2 parental cells.   
 
CNE-2 parental cells were seeded at a density of 2.5 X 105 per well of a 6-well plate and 
incubated overnight at 37˚C and 5% CO2 to allow cell adherence. The following day the cells 
were transiently transfected with the recombinant lenti-viral plasmids, grown for 48 hours to 
allow expression and RNA extracted and purified. cDNA was synthesised and all samples 
subjected to RT-PCR for expression of the loop deleted genes. The original 5’ forward primers 
were used in tandem with a 3’ reverse primer specific to a site upstream of the STOP codon of 
LMP2B. Samples were resolved by gel electrophoresis, visualised and photographed.  Lanes 1-
3 are samples from LMP2-L1 transfected samples, lanes 4-6 LMP2-L3 Del, lanes 7-9 LMP2-
L4 Del, lanes 10-12 LMP2-L5 Del and lanes 13-15 LMP2-L6 Del. Band sizes were 
compared against a DNA CloneSizer ladder.  RT-PCR was also performed for GAPDH acting 
as a control to ensure equal cDNA concentrations across samples.  
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Figure 3.7. Validation of recombinant protein expression by Immunofluorescent 
staining for HA-tag. 
 
CNE-2 parental cells were seeded at a density of 2.5 X 105 per well of a 6-well plate 
and incubated overnight at 37˚C and 5% CO2 to allow cell adherence. The following 
day the cells were transiently transfected with the recombinant lenti-viral plasmids, 
grown for 48 hours to allow expression and removed from the dishes by addition of 
trypsin. Cells were then seeded at a density of 2 x 104on to 12-well microdot Teflon 
coated slides and placed into a 37˚C incubator with 5% CO2 overnight to allow cell 
adherence. The following day slides were subjected to immunofluorescent staining for 
the HA-tag. Cells transiently transfected with pSG5/LMP2A/HA and 
pSG5/LMP2B/HA were used as positive controls while a null transfectant and those 
transfected with the control pSG5 vector were negative controls.   
Bar = 10µm. 
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3.6  Discussion and Future Work 
While some small experiments were performed to validate the efficacy of the lentiviral vectors 
as plasmids, their use in investigative research was limited by time constraints. It was possible 
however to transiently express the loop deleted forms of the LMP2 protein in three epithelial 
cell backgrounds and to examine their effect on lysosome numbers, Chapter 5, Figure 5.9. 
This small investigation highlights the benefit of the truncated tagged versions of LMP2 in 
further investigating and understanding the effect of LMP2 expression on epithelial cells and 
its contribution to carcinogenesis and tumour progression. In the context of this thesis it would 
be of particular interest to further investigate the effect of stable expression of the truncated 
LMP2 proteins on the modulation of endosomal and lysosomal trafficking. In order to do so, 
panels of cells stably expressing the modified LMP2 proteins would be generated, facilitating a 
more robust experimental system and one which is readily comparable with those used in the 
remaining chapters of this thesis. 
 Using a lentiviral system to create the vectors enables easy and effective infection of 
additional epithelial cell-lines and even primary keratinocytes with full length and truncated 
forms of LMP2, upon creation of whole virus. This would allow further examination of the role 
of the LMP2 protein in early stages of tumourigenesis, as the current cell models use systems 
that are initially tumourigenic and have subsequently been retro-virally transduced to express 
the EBV protein, e.g. CNE-2, H103. The use of a Ubiquitin driven promoter ensures 
expression of the proteins at a high level, while vectors could be readily made with an 
inducible metallothionein promoter, thus allowing lower levels of expression. Generation of 
the variant forms of LMP2 was successful and the small investigations carried out utilising 
them demonstrate how applicable they are in terms of understanding the function of LMP2.  
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        CHAPTER 4 
Modulation of innate immune signalling by the LMP2A and LMP2B proteins 
4.1 Introduction 
LMP2A expression in epithelial cells has been shown to affect a variety of signalling 
pathways, which include PI3K/Akt, ERK-MAPK and Wnt/β-catenin (Scholle et al., 2000; 
Morisson et al., 2003; Lu, Lin et al. 2006; Ikeda and Longnecker, 2007; Anderson and 
Longnecker, 2008a/b). Although LMP2B lacks intrinsic signalling ability, previous work from 
this laboratory has shown that LMP2B can influence cell adhesion and motility through as yet 
unidentified mechanisms (Allen et al., 2005). Like LMP2A, LMP2B can modulate signalling 
from certain classes of immune receptors, particularly those involved in the Type I interferon 
response (Shah, Stewart et al. 2009). Here, these analyses are expanded to investigate the effect 
of LMP2A and LMP2B expression on the TLR signalling network. These receptors are 
responsible for the first wave of the innate immune response and are also shown to modulate 
adaptive immunity (Goodsell 2001). This is important in terms of both initial viral infection 
and more specifically in terms of maintenance of viral latency in cells of epithelial origin, 
where stable latent infection with EBV can predispose cells to growth transformation.  In the 
context of viral latency, evasion of the innate immune response is fundamental to viral 
persistence (Levy and Garcia-Sastre 2001). Recognition of products of viral replication (RNA 
and protein) within the infected cell is performed by the pattern recognition receptors (PRRs), 
of which two classes have been identified. The membrane bound, Toll-like receptors (TLRs) 
and the cytsolic retinoic acid inducible gene I/ Mda 5 complexes (Chen, Huang et al. 2007).  
 
TLR signalling is initiated through recognition of a PAMP, pathogen associated molecular 
pattern, these molecules varying from components of the bacterial cell wall to viral DNA or 
RNA products of replication (Sandor and Buc 2005). Five receptors are responsible for this 
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process including, TLR3, TLR4, TLR7, TLR8 and TLR9. Activation of the receptor results in 
phosphorylation of signalling intermediates and adaptor molecules, including, among others, 
the IRAK proteins, IRAK1 and IRAK4, the TRAF proteins TRAF3 and TRAF6 and adaptor 
molecules such as TRIF and MyD88. The signalling pathways result in the activation by 
phosphorylation, nuclear translocation and dimerisation of a variety of transcription factors, 
including IRF1, IRF3, IRF7 and IRF9; NFκB subunits, specifically p65/RelA; p50 
heterodimers; and subunits of the AP1 transcription factor family (Albiger, Dahlberg et al. 
2007). Transcriptional activation results in series of positive feedback loops to amplify 
production of pro-inflammatory cytokines such as IFNβ, which can signal in an autocrine or 
paracrine manner to mount a type I interferon response (Bowie and Haga 2005). The TLRs 
focused on here include those known to be involved in regulating IFNβ, whose expression is 
controlled by an enhancesome complex (Yie, Senger et al. 1999; Panne 2008). Activation of 
this transcription factor complex is the first step in the innate immune response and is thought 
to be the gateway for cellular immunological responses to viral infection.  
 
Whilst studies in B-cells show that LMP2A enhances signalling through these receptors 
(Wang, Nicholas et al. 2006), data presented here suggest that LMP2A, and to a lesser extent, 
LMP2B, attenuate TLR signalling through mechanisms involving transcriptional repression of 
the receptors and signalling intermediates. Together with previously published data, these 
findings indicate the wide scope of LMP2A effects on innate immune responses in epithelial 
cells.  
 
Modulation of TLR expression by LMP2A results in dampening of signalling responses, due 
most likely to the disruption of IRF3 activity. Investigations into each of the individual 
components of the enhancesome revealed that whilst efficient IRF3 activation is attenuated, the 
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activity of NFκB activity is enhanced, findings which reflect a complexity in LMP2A 
signalling. Assessing the levels of cytokine production of control cells compared to LMP2A 
expressing counterparts revealed distinct differences, showing both increases and decreases of 
levels of secreted cytokines, indicative perhaps of the functional consequences of dampening 
one signal whilst initiating another. The scope of these findings was expanded to include an 
analysis of the effect of LMP2A on EBER induced IFNβ activity and the consequences of this 
in EBV infected cells.  
 
Findings below indicate that the LMP2A and, to a lesser extent LMP2B, dramatically alters the 
innate immune signalling landscape of epithelial cells. The significance of this in terms of the 
maintenance of viral latency and tumour progression are discussed as well as an attempt to 
elucidate the mechanisms underlying these effects.  
 
4.2 LMP2A and LMP2B modulate type I interferon responses 
4.2.1 Expression level of type I interferon receptors and tyrosine kinases. 
To assess the integrity of the interferon-signalling pathway in CNE2 cells, the expression of 
various components of the IFNR signalling network were characterised at the mRNA and 
protein level by RT-PCR and immunoblotting. It has previously been shown that type I 
interferon responses are modulated by LMP2A and LMP2B in epithelial cells (Shah et al., 
2009). To confirm this, immunoblotting was performed for the IFNα/β-receptor-I (IFNAR), the 
IFNγ-receptor-I (IFNGR) and Tyk2 and Jak1, two tyrosine kinases that associate with these 
receptors (Garcia-Sastre and Biron 2006). A representative immunoblot, shown in Figure 4.1, 
shows that compared to control cells, expression of both the IFNAR and IFNGR and the JAK 
and Tyk2 tyrosine kinases are reduced in cells expressing LMP2A and LMP2B, the effect 
 139
Chapter 4  Results 
 
being more pronounced for LMP2A. Reprobing of the blot with a monoclonal antibody (mAb) 
to β-actin confirmed equal protein loading. 
 
4.2.2 LMP2 expression modulates expression of IFN signalling intermediates 
4.2.2.1 Effect of LMP2 on IRF protein expression 
Extending the above findings to regulatory elements of the IFN signalling cascade, 
immunofluorescence staining and immunoblotting was performed for positive and negative 
regulators of the IFN signalling pathways. The interferon regulatory factors (IRFs) are a family 
of proteins whose function is to control signalling from type I interferon receptors and to 
control immune responses of a variety of additional pathways including Toll-like receptors 
(TLRs) (Honda and Taniguchi 2006). As transcription factors, the IRF proteins control 
expression of a variety of genes involved in cytokine production and mounting further type I 
interferon cascades. IRF1, is involved in control of antibacterial and antiviral innate immunity 
and regulates expression of a variety of genes including, NOS2 and GBP1 (Ko, Gendron-
Fitzpatrick et al. 2002). IRF2 is a negative regulator of innate immunity and has been shown to 
attenuate the type I interferon response (Honda and Taniguchi 2006). IRF3 is also involved in 
positive regulation of anti-viral responses and controls expression of a variety of genes 
including IFNB, IFNA4 and CCL5 (Hiscott 2007). The final IRF examined, IRF7, is involved 
in antiviral immunity and is inducible by the type I interferon response; its function is closely 
tied to that of IRF3 and is known to control expression of IFNβ and IFNα and is of most 
significance in mediating responses from the cytosolic pattern-recognition receptors, e.g. 
retenoic-acid-inducible gene I (RIG-I) (Gingras, Parganas et al. 2004; Honda, Yanai et al. 
2005). Immunofluorescence staining was performed on the CNE-2 cell panel (see section 2.4,) 
using antiserum or mAbs specific for IRF1, IRF2 and IRF3. Representative confocal images 
are shown in Figure 4.2. Under basal conditions, cells expressing LMP2A showed reduced 
 140
Chapter 4  Results 
 
levels of cytoplasmic IRF1 protein expression compared to control cells, with intermediate 
levels of expression being observed in LMP2B expressing cells. Unlike IRF1, expression of 
IRF2 and IRF3 appeared extremely low in control and LMP2B expressing cells whereas they 
were barely detectable in LMP2A expressing cells.  
 
Immunoblotting using antisera or mAbs specific for IRF1, IRF2, IRF3 and IRF7, (Figure 4.2 
B), shows a general reduction in IRF protein expression in LMP2A and LMP2B expressing 
cells compared to control cells, although the reduction was always more pronounced in cells 
expressing LMP2A. Whilst expression of IRF2, IRF3 and IRF7 was most noticeably reduced 
in LMP2A expressing cells, lower levels of IRF1 were also observed. In the case of IRF2, 
IRF3 and IRF7, immunoblotting revealed the expression of the higher molecular weight 
species, which may represent different phosphorylated forms of IRF2, IRF3 and IRF7. 
However, in all cases, the abundance of these species was also reduced in LMP2A expressing 
cells. There are apparent discrepancies between the levels of expression comparing between 
the immunofluorescent and immunoblotting data, this is attributable to the differences in 
sensitivity of the antibodies in different applications/protocols. The extent of the modulation in 
LMP2A expressing cells was surprising given the varying functions of the IRFs throughout the 
IFN signalling network, especially in the case of IRF2, which has been shown to attenuate type 
I interferon responses, for reasons which are highlighted later.  
 
4.2.2.2 Effect of LMP2A and LMP2B on SOCS protein expression 
While positive regulators and initiator factors of type I IFN responses appeared to be reduced 
by LMP2A, it was deemed appropriate to examine the effect, if any, on negative regulators of 
this pathway. The suppressors of cytokine signalling, (SOCS) (Yoshimura, Naka et al. 2007), 
are a family of proteins that are induced by cytokines, such as IFNγ, and by certain TLRs as 
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part of a negative feedback loop to attenuate IFN signalling responses (Andrea, Frey et al. 
2004). They have been shown to function to control innate immunity through a variety of 
mechanisms including disruption of JAK-STAT signalling. Immunofluorescence staining was 
performed on the CNE-2 cell panel (see section 2.4) using antiserum or mAbs specific for three 
of the eight family members. SOCS-2 is a 22kDa protein that is shown to inhibit JAK 
signalling and interacts with insulin-like growth factor I receptor (IGF-1R) (Dey, Spence et al. 
1998; Lee, Moon et al. 2008; Quentmeier, Geffers et al. 2008). SOCS-3 is a 24kDa protein that 
is also involved in negative regulation of JAK signalling, interacting with JAK2 (Dey, 
Furlanetto et al. 2000; Yamamoto, Yamaguchi et al. 2003). Finally, SOCS-6 is a 59kDa protein 
that has been shown to interact with and degrade STAT3 (Hwang, Min et al. 2007). 
Representative confocal images of immunofluoresence staining for SOCS proteins in the 
CNE2 panel is shown in Figure 4.3A. In contrast to the IRF proteins (Figure 4.2.A), expression 
of SOCS 2, SOCS3 and SOCS6 were elevated in LMP2A expressing cells relative to control 
and LMP2B expressing cells. Although predominantly cytosolic, a diffuse punctate pattern of 
staining was also observed in the nuclei of LMP2A expressing cells. 
 
Immunoblotting using antiserum specific for SOCS-3 and SOCS-6 (see section 2.5.4) are 
shown in Figure 4.3 B. Mirroring findings from immunofluorescence staining, expression of 
SOCS-3 was elevated in LMP2A expressing cells compared to either control or LMP2B 
expressing cells, whilst expression of SOCS 6 was increased in both LMP2A and LMP2B 
expressing cells. Reprobing of the blot with an antibody to β-actin confirmed equal protein 
loading. Taken as a whole, these findings demonstrate that LMP2A down-regulates the 
expression of proteins involved in innate immune responses, by decreasing IFN receptor and 
associated tyrosine kinase expression, decreasing positive regulators of signalling and 
augmenting the expression of proteins involved in negatively regulating these pathways.  
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Figure 4.1: Immunoblotting for type I interferon receptors and related tyrosine kinases 
across the CNE-2 cell panel. 
 
Protein extracts were isolated from CNE-2 cells expressing either a neomycin resistance 
cassette, full length LMP2A or full length LMP2B. Samples were then subjected to 
immunoblotting analysis using antibodies specific for the receptors (A) IFNα/βR1 and (B) 
IFNγR1 and the tyrosine kinases (C) Tyk2 and (D) Jak1. The panels show representative 
immunoblots of each of the proteins examined, using β-Actin as a loading control. Expression 
of IFNα/βR1 is down regulated in LMP2A expressing cells and to a lesser extent in LMP2B 
expressing cells compared to controls. IFNγR1 expression follows a similar pattern of 
expression, with the tyrosine kinases showing marked downregulation in both LMP2A and 
LMP2B expressing cells compared to controls. 
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Figure 4.2: Protein expression of the IRF proteins across the CNE-2 cell panel by 
immunoblotting and immunofluorescent staining.  
 
(A) CNE-2 cells expressing either a control neomycin resistance cassette, full length 
LMP2A or LMP2B were seeded at a density of 2 x 104 on to 12-well microdot Teflon 
coated slides and placed into a 37˚C incubator with 5% CO2 overnight to allow cell 
adherence. The following day immunofluorescent staining was performed for members 
of the IRF family of proteins, known to be regulators of the type I interferon response, 
including (i) IRF-1, (ii) IRF-2 and (iii) IRF-3. Slides were viewed and photographed 
using a Zeiss LSM510-meta confocal microscope. Comparing signal levels between 
control and LMP2A expressing cells, levels of expression appear to be attenuated for 
all proteins examined, this is most pronounced in the case of IRF-1. LMP2B expressing 
cells do not show such differences and signals here are comparable with control levels. 
 
(B) Protein extracts were isolated from the CNE-2 cell panel and immunoblotting 
performed with anti-bodies specific to the following members of the IRF family of 
proteins, (i) IRF-1, (ii) IRF-2, (iii) IRF-3, and (iv) IRF-7. Representative immunoblots 
of each analysis are shown with β-Actin used as a loading control. Comparing levels of 
expression between LMP2 expressing cells and their control counterparts it is clear that 
the level of all IRFs examined is decreased in the presence of LMP2A and to a lesser 
extent LMP2B when compared to control levels.  
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Figure 4.3: Protein expression of the SOCS proteins across the CNE-2 cell panel by 
immunoblotting and immunofluorescent staining.  
 
(A) CNE-2 cells expressing either a control neomycin resistance cassette, full length 
LMP2A or LMP2B were seeded at a density of 2 x 104 on to 12-well microdot Teflon 
coated slides and placed into a 37˚C incubator with 5% CO2 overnight to allow cell 
adherence. The following day immunofluorescent staining was performed for members 
of the SOCS family of proteins, known to negatively regulate the type I interferon 
response, including (i) SOCS-2, (ii) SOCS-3 and (iii) SOCS-6. Slides were viewed and 
photographed using a Zeiss LSM510-meta confocal microscope. Comparing the levels 
of detected signal between controls and LMP2A and LMP2B cells, it is clear that in the 
presence of LMP2A expression of each SOCS protein examined is augmented. Small 
increases can be detected in LMP2B expressing cells compared to their control 
counterparts for SOCS-3 and SOCS-6 but this is much less significant than the LMP2A 
induced differences.  
(B) Protein samples were isolated from the CNE-2 cell panel and subjected to 
immunoblotting with antibodies specific for the (i) SOCS-3 and (ii) SOCS-6 proteins. 
Representative immunoblots of each analysis are shown with β-Actin used as a loading 
control. Comparing levels of expression between LMP2A expressing cells and their 
control counterparts, a clear augmentation of expression of both proteins is observable 
in the presence of LMP2A. LMP2B expression also appears to slightly augment SOCS-
3 and SOCS-6 expression compared to control cells but not to the same extent as in 
LMP2A expressing cells. 
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4.2.2.3 LMP2 modulates the induction of IFN signalling in response to TLR stimulation 
To extend these data beyond assessing levels of protein expression, quantitative reverse 
transcriptase polymerase chain reaction analysis was performed (see section 2.9.5), for 
signalling intermediates (STAT1, IRF9) and downstream effectors (IRF1) involved in type I 
IFN signalling. The function of IRF-1 is outlined above and it is known to be an integral 
effector of type I interferon signalling. STAT1 (signal transducer and activator of transcription) 
is a transcription factor responsible for regulation of interferon-stimulated genes (ISGs), 
binding to either ISRE or GAS elements in the promoter of these genes. It functions as a 
phosphorylated trimer when bound to ISRE elements, with either a dimer of itself and IRF-9 or 
another STAT e.g. STAT2 and IRF-9 (Levy and Garcia-Sastre 2001; Hu, Chen et al. 2007). It 
binds to GAS elements upon phosphorylation and dimerisation with another of the STAT 
family, e.g STAT2, STAT3 or itself. IRF-9 is a component of the ISGF3 complex, along with 
members of the STAT family, it is also known as ISGF3γ or p48 and is integral for signalling 
from IFNαβ receptors (Levy and Garcia-Sastre 2001).  
 
To examine the impact of LMP2A expression on the transcription of STAT1, IRF1 and IRF9, 
their expression in response to TLR stimulation was examined. This was achieved by 
stimulation of cells with polyinosinic-polycytidylic acid (poly(I:C)), a synthetic double-
stranded RNA molecule known to activate type I interferon responses by signalling through 
TLR3 and/or RIG-I/mda-5. Once stimulated, RNA was extracted from the cells (see section 
2.9.1) and RT-QPCR performed using primer and probe sets specific for the genes of interest.  
 
Graphical representations of the expression fold-changes between control, LMP2A and 
LMP2B expressing cells under basal and stimulated conditions are shown in Figure 4.4. 
Although basal levels are comparable between control, LMP2A and LMP2B expressing cells, 
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the levels of STAT1 mRNA were induced six fold in control cells in response to poly(I:C) 
stimulation. In marked contrast, cells expressing LMP2A were almost completely refractory to 
poly(I:C) stimulation with less than a one fold induction observed upon poly(I:C) stimulation. 
Similar results were observed for LMP2B, where poly(I:C) stimulation resulted in a one fold 
induction in STAT1 mRNA expression. This result mirrors those previously published data 
(Shah, Stewart et al. 2009) demonstrating a dampened type I interferon response in LMP2A 
and LMP2B expressing cells.  
 
Compared to control and LMP2B expressing cells, the basal levels of IRF9 mRNA expression 
were lower in LMP2A expressing cells, findings that are in broad agreement with 
immunofluorescence staining for other IRF family members (Figures 4.2 A, B). Poly(I:C) 
treatment stimulated IRF-9 mRNA expression almost four fold in control cells whilst this 
induction was reduced to two fold in LMP2A and LMP2B expressing cells. Although the basal 
levels of IRF1 mRNA expression were lower in LMP2A expressing cells relative to control 
cells, they were similar between control and LMP2B expressing cells. However, in response to 
poly(I:C) stimulation, the levels of IRF-1 mRNA were induced five fold in control cells yet 
barely induced in both LMP2A and LMP2B expressing cells. From these RT-QPCR data it is 
shown that LMP2A expression modulates basal RNA expression of IRF-9 compared to 
controls. Upon poly(I:C) stimulation LMP2A appears to attenuate control expression responses 
for all three genes examined, while LMP2B attenuates expression of STAT-1 IRF-9 and IRF-1 
to a lesser extent.  
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Figure 4.4  RT-QPCR for components of the type I interferon signalling pathway. 
 
CNE-2 cells expressing either a control neomycin resistance cassette, full-length LMP2A or 
full length LMP2B were stimulated with the artificial agonists for TLR3, 5µg/ml poly(I:C) and 
TLR4, 200ng/ml LPS. After 6 hours, RNA was extracted from each cell type, pre- and post- 
treatment. cDNA was subsequentially synthesised and RT-QPCR performed using primer-
probe sets specific for each of the following genes, (A) STAT-1, (B) IRF-9 and (C) IRF-1, 
using probes for the housekeeping gene GAPDH as internal baseline controls. Data was 
analysed using Microsoft Excel and the fold change differences calculated between cell types 
and between each cell type before and after stimulation. Histograms are displayed, depicting 
fold change differences (mean = +/- SD, n=3). STAT-1 expression increases after stimulation 
with either poly(I:C) or LPS, in control cells compared to basal levels. This increase is 
attenuated in LMP2A expressing cells and to a lesser extent, LMP2B expressing cells. IRF-9 
and IRF-1 expression follow similar patterns but show augmented expression in LMP2A 
expressing cells upon stimulation with LPS.  
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4.2.3 LMP2A and, to a lesser extent LMP2B, attenuates IFNβ expression in response to 
TLR3 and TLR4 stimulation 
While the previous data has focused on the effect of LMP2A and LMP2B on signalling from 
IFNα/βR1 and IFNγR1 receptors, their effects on the TLR signalling pathway was examined 
given that TLR activation stimulates the induction of IFNs. To investigate this, the expression 
of IFNβ was assessed across the CNE-2 cell panel by RT-QPCR (see section 2.9.5). Basal 
levels of expression were compared to those after agonist stimulation of cells with poly(I:C) 
and LPS to activate TLR3 and TLR4, respectively (see section 2.3.1.). A graphical 
representation of the levels of IFNβ mRNA expression across the CNE2 cell panel, with and 
without stimulation, is shown in Figure 4.5. Basally, both LMP2A and LMP2B expressing 
cells synthesised lower levels of IFNβ mRNA. However, upon stimulation with either 
poly(I:C) or LPS, IFNβ mRNA expression was markedly increased twelve fold, for poly(I:C), 
and five fold, for LPS, in control cells. Comparing this activation across the cell panel it was 
evident that LMP2A, and to a lesser extent LMP2B, attenuate the ability of TLR3 and TLR4 to 
stimulate IFNβ expression. Although levels of expression increase upon stimulation the 
response is dramatically attenuated when compared to the effect of stimulation of control cells, 
for both agonist treatments. IFNβ expression is a good output to use when assessing TLR3 and 
TLR4 activity as these receptors are two of the five TLRs shown to be involved in IFNβ 
production (Colonna 2007).  
 
4.2.4 LMP2A and LMP2B attenuate IFNβ induction of “classical” IFN targets in 
response to TLR3 and TLR4 stimulation  
The above data reveal that IFNβ expression is decreased in LMP2A and LMP2B expressing 
cells both the basally, and in response to TLR activation. To investigate the effect of this 
abrogation on IFN signalling, RT-QPCR analysis was performed for four classical interferon 
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stimulated genes: MXA1, MXA2, OAS1 and OAS2. As in previous analyses, basal levels were 
compared to those after TLR3 and TLR4 stimulation. Graphical representations of the Q-PCR 
data obtained are shown in Figures 4.6A and 4.6B. From Figure 4.6.A, it is evident that TLR3 
and TLR4 activation stimulates a 6-fold increase in the expression of MXA-1 and a 40-fold 
(TLR3) to 6-fold (TLR4) increase in MXA-2, in control cells. Comparing the effect of these 
stimuli in LMP2A and LMP2B expressing cells with control cells, clear differences are 
apparent and, although some activation occurs, it is severely attenuated. Similar results were 
observed using primer and probe sets for OAS1 and OAS2 (Figure 4.6.B). Again, the 
expression of OAS1 and OAS2 are increased in control cells upon TLR3 and TLR4 
stimulation, OAS1 15-fold and 6-fold respectively and OAS2, 17-fold (TLR3) with no 
apparent activation with TLR4. These increases are attenuated in cells expressing LMP2A and, 
to a lesser extent, LMP2B. Taken as a whole, the above results suggest that LMP2A and, to a 
lesser extent, LMP2B modulate early events in the type I interferon response by modulating 
TLR signalling. 
 
4.3  Expression profiling of TLRs in control, LMP2A and LMP2B expressing cells 
4.3.1 LMP2A modulates the expression of TLR3 and TLR4 mRNAs 
To ascertain whether attenuation of the TLR-mediated type I IFN response by LMP2A and 
LMP2B occurred as a result of modulation of the TLR receptors themselves, TLR profiling 
was performed on the CNE2 panel by RT-QPCR. The TLR signalling network is described in 
detail in section 1.7.1. This study focussed on TLRs that localise on internal membranes of 
epithelial cells; namely, TLR3, TLR4, TLR7, TLR8, and TLR9 (Nishiya, Kajita et al. 2005) as 
it was reasoned that LMP2A and LMP2B, which also localise to internal membranes, may 
somehow modulate their activity.  
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Figure 4.5  Modulation of IFNβ transcription by LMP2A in CNE-2 cells pre- and post-
stimulation with TLR artificial agonists.  
 
CNE-2 cells expressing either a control neomycin resistance cassette, full-length LMP2A or 
full length LMP2B were stimulated with the artificial agonists for TLR3, 5µg/ml poly(I:C) and 
TLR4, 200ng/ml LPS. After 6 hours, RNA was extracted from each cell type, pre- and post- 
treatment and cDNA synthesised. RT-QPCR was performed using a primer-probe set specific 
for IFNβ and using the housekeeping gene GAPDH as an internal baseline control. Data was 
analysed using Microsoft Excel and the fold change differences calculated between cell types 
and between each cell type before and after stimulation. Histograms are shown displaying 
mean fold change differences (mean = +/- SD, n=3). Basally, small fold changes differences 
are observable between LMP2A expressing cells and their control and LMP2B expressing 
counterparts. Upon stimulation with either agonist IFNβ transcription increases in control cells, 
such augmentation is markedly attenuated in LMP2A expressing cells and to a lesser extent 
LMP2B expressing cells, for both cell treatments.  
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Figure 4.6 Modulation of transcription of targets of IFNβ by LMP2A and LMP2B in 
CNE-2 cells pre- and post-stimulation with TLR artificial agonists.  
 
CNE-2 cells expressing either a control neomycin resistance cassette, full-length LMP2A or 
full length LMP2B were stimulated with the artificial agonists for TLR3, 5µg/ml poly(I:C) and 
TLR4, 200ng/ml LPS. After 6 hours, RNA was extracted from each cell type, pre- and post- 
treatment, and cDNA synthesised. RT-QPCR was performed using primer-probe sets for 
classical targets of IFNβ signalling, (A) MXA1, (B) MXA2, (C) OAS1 and (D) OAS2, and the 
housekeeping gene GAPDH was used as an internal baseline control. Data was analysed using 
Microsoft Excel and the fold change differences calculated between cell types and between 
each cell type before and after stimulation. Histograms are shown displaying mean fold change 
differences (mean = +/- SD, n=3).  In the case of MXA1, stimulation with either agonist 
increases expression levels in control cells. This increase is attenuated in LMP2A expressing 
cells and to a lesser extent in those expressing LMP2B. MXA2 expression is augmented upon 
stimulation in control cells for both treatments such increases are however, attenuated in the 
presence of both LMP2A and LMP2B. OAS1 expression is similarly augmented upon 
stimulation in control cells, an increase that is attenuated upon LPS stimulation in both LMP2A 
and LMP2B expressing cells. Upon poly(I:C) stimulation the attenuation is most pronounced in 
LMP2A expressing cells compared  to its LMP2B counterparts. OAS2 expression level is not 
increased upon LPS treatment of any cell type and while poly(I:C) augments expression in 
controls, this increase is attenuated in both LMP2A and LMP2B expressing cells 
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Primers and probes specific for TLR3 and TLR4 were used in the manner described in section 
2.9.5 to assay the levels of TLR expression in the CNE2 cell panel. A graphical representation 
of the Q-PCR data is shown in Figure 4.7. In addition to assaying the levels of TLR3 and 
TLR4 basally, the effects of agonist stimulation on their expression was examined to determine 
whether LMP2A or LMP2B interfere with the positive feedback loops that control TLR 
expression levels. No significant differences were observed between control and LMP2A or 
LMP2B expressing cells for either TLR3 or TLR4 expression. Upon stimulation with 
poly(I:C), TLR3 expression increased dramatically in control cells, whereas LMP2A 
expressing cells show no increase in expression denoting a signalling network that is markedly 
attenuated. Similar findings were observed in LMP2B expressing cells but to a lesser extent. In 
a similar manner, LPS stimulated TLR4 expression in control cells, yet this response was 
attenuated in LMP2A expressing cells and to a lesser extent in cells expressing LMP2B.  
 
4.3.2 LMP2A and LMP2B modulate the levels of TLR3 and TLR4 protein.  
4.3.2.1 Immunofluorescence staining for TLR expression. 
Although LMP2A and LMP2B modulated TLR expression at the RNA level, it was important 
to ascertain whether they also affected the levels of protein expression. Immunofluorescence 
staining was performed on both the CNE-2 cell panel and another squamous cell carcinoma 
derived cell line H103, transduced to stably express LMP2A and LMP2B (see section 2.4). As 
described in section 2.1.2, the H103 cells were retrovirally transduced to express a full 
neomycin resistance cassette and either full length HA-tagged LMP2A or LMP2B. These serve 
to act as a direct counterpart to the CNE-2 cell panel and allow extending hypotheses of 
signalling modulation across another epithelial cell line.  
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Immunofluorescence staining was performed on cells grown in situ, using monoclonal 
antibodies specific for TLR3, TLR4, TLR7 and TLR9. Representative confocal images are 
shown in Figure 4.8 and Figure 4.9. In both cell panels it can be seen that the receptors are 
expressed throughout the cytoplasm of cells, with some plasma membrane staining observed in 
the H103 cells. In the case of TLR4, staining was observed at both the plasma membrane and 
internal endosomal membranes reflecting the dual localisation of this receptor (Sandor and Buc 
2005). Comparing expression levels across the cell panels, compared to control cells, 
expression of all TLRs examined was reduced in cells expressing LMP2A, whilst levels of 
TLR expression were broadly similar to control cells in cells expressing LMP2B. Overall it is 
evident that at the protein level, expression of internal TLRs is decreased upon stable 
expression of LMP2A.  
 
4.3.2.2 Quantitation of TLR expression by FACS 
To extend these findings, flow cytometric analysis was performed quantitate the levels of cell 
surface and cytosolic TLR expression between control, LMP2A and LMP2B expressing cells. 
This was achieved by performing immunofluorescence staining in the presence or absence of 
0.1% Saponin, a detergent that allows access of antibodies to the cell cytoplasm. FACS 
analysis was performed (see section 2.6) and data analysed using the WinMidi program. 
Graphical representations of the analysis with mean fluorescent intensities are shown in Figure 
4.10. In the case of TLR3, increased levels of staining were observed in control cells treated 
with 0.1% saponin, indicating higher levels of internal TLR3. Comparisons within each cell 
panel revealed reduced expression in LMP2A expressing cells and, to a lesser extent, in cells 
expressing LMP2B. A similar pattern can be observed across the remaining TLRs examined. 
TLR4 staining does not have as dramatic a comparison between permeabilised and non-
permeabilised cells, indicating its dual localisation at both the plasma membrane and cytosolic 
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membranes.  Mean fluorescent intensity values are also shown which have been normalised 
against control samples for each analysis.  
 
4.3.3 LMP2A expression reduces the basal levels of TLR signalling components. 
Although altered expression of TLRs would have a detrimental effect on cellular responses to 
TLR agonists, an examination of TLR signalling intermediates was undertaken to determine 
whether LMP2A and LMP2B altered the expression of TLR signalling components. RT-PCR 
analysis was performed using oligonucleotide primers specific for IRAK1, IRAK4, MyD88, 
TIRAP, MAP3K7, TRAF3 and TRAF6. Primers to GAPDH were used as a control to 
normalise the amounts of input RNA. A representative analysis, shown in Figure 4.11, shows 
that compared to control and LMP2B expressing cells, there is a general reduction in 
expression of all TLR signalling components in LMP2A expressing cells. These results 
indicate that not only are levels of receptor expression altered but also that LMP2A affects the 
expression of components of the signalling pathways themselves. It must be noted however, 
that endpoint RT-PCR reactions such as these and no quantitative inference can be made from 
the results of such analyses. It is possible that signalling intermediate expression is modulated 
through indirect distortion by LMP2A of the feedback loops controlling their expression. 
 
4.3.4 Immunohistochemical analysis of TLR3 and TLR4 expression in normal 
nasopharyngeal epithelium and NPC biopsies.  
Thus far it has been identified that expression at both the RNA level and the protein level of 
certain classes of TLRs is modulated in epithelial cell lines expressing LMP2A and to a much 
lesser extent LMP2B. Examining these expression levels in an in vivo context allows increased 
significance to be attributed to these findings in the context of tumourigenesis and disease 
progression. To this end, immunohistochemical staining was performed in the manner 
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described in section 2.7, using antisera specific for TLR3 and TLR4. Comparisons were made 
between normal nasopharyngeal epithelium, tonsil epithelium and clinically diagnosed NPC 
tumour biopsies provided in the form of a tissue array (kindly provided by Dr C.F.Hu, Institute 
for Cancer Studies). Representative immunohistochemical staining, Figure 4.12, shows that 
TLR3 and TLR4 localise predominantly to the basolateral surface of normal nasopharyngeal 
epithelium. Although speculative given the number of sections available it is interesting to note 
that stronger staining was observed in nasopharyngeal epithelium compared to tonsil 
epithelium. In contrast, the NPC sections showed weaker staining for both TLR3 and TLR4. 
Unfortunately, due to the lack of a suitable reagent, expression of LMP2A could not be 
performed. Due to the lack of available biopsy material these data were the result of a single 
staining experiment, further examination and increased numbers of NPC sections are needed to 
attach significance to these findings.  
 
4.4 TLR signalling capacity is modulated in LMP2A expressing cells 
As mentioned previously, the signalling pathways of the TLRs examined in the course of this 
study are responsible for the initiation of innate immunity. Activation of transcription factors 
that produce IFNβ, NFκB and AP1 subunits is a vital result of the pathway and assessing 
LMP2’s effect on this functionality was the next focus. Nuclear translocation of transcription 
factors is an integral process in full signalling of the receptors, the transcription factors 
themselves include, IRF3, IRF7 homo and heterodimers, NFκB heterodimers, specifically 
containing p65/RelA and the AP1 subunits, Atf-2 and c-Jun.  (Panne 2008). Once in the 
nucleus these factors and others, CBP/p300, form a complex known as the enhancesome, 
binding of which is fundamental for transcription of IFNβ. In order to assess whether or not 
LMP2 expression affected formation and functionality of the complex each component part 
was analysed.  
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Figure 4.7  Modulation of TLR3 and TLR4 expression by LMP2A in CNE-2 cells. 
 
CNE-2 cells expressing either a control neomycin resistance cassette, full-length LMP2A or 
full length LMP2B were stimulated with the artificial agonists for TLR3, 5µg/ml poly(I:C) and 
TLR4, 200ng/ml LPS. After 6 hours, RNA was extracted from each cell type, pre- and post- 
treatment and cDNA synthesised. RT-QPCR was performed using primer-probe sets specific 
for  (A) TLR3 and  (B) TLR4 and using the housekeeping gene GAPDH as an internal baseline 
control. Data was analysed using Microsoft Excel and the fold change differences calculated 
between cell types and between each cell type before and after stimulation. Histograms are 
shown displaying mean fold change differences (mean = +/- SD, n=3). Upon stimulation with 
either agonist expression of its respective receptor is increased in control cells, this 
augmentation is abrogated in LMP2A expressing cells and markedly attenuated in LMP2B 
expressing cells.  
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Figure 4.8:  Immunofluorescent staining of Toll-like receptors in the CNE-2 cell panel. 
 
CNE-2 cells expressing either a control neomycin resistance cassette, full length LMP2A or 
LMP2B were seeded at a density of 2 x 104 on to 12-well microdot Teflon coated slides and 
placed into a 37˚C incubator with 5% CO2 overnight to allow cell adherence. The following 
day immunofluorescent staining was performed for (A) TLR3, (B) TLR4, (C) TLR7, and (D) 
TLR9. Comparisons between the cell lines reveal that for all TLRs examined expression at the 
protein level is decreased in cells expressing LMP2A compared to controls and decreased to a 
lesser extent in LMP2B expressing cells.  
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Figure 4.9:  Immunofluorescent staining of Toll-like receptors in the H103 cell panel. 
 
H103 cells expressing either a control neomycin resistance cassette, full length LMP2A or 
LMP2B were seeded at a density of 2 x 104 on to 12-well microdot Teflon coated slides and 
placed into a 37˚C incubator with 5% CO2 overnight to allow cell adherence. The following 
day immunofluorescent staining was performed for (A) TLR3, (B) TLR4, (C) TLR7, and (D) 
TLR9. Comparisons between the cell lines reveal that for all TLRs examined expression at the 
protein level in decreased in cells expressing LMP2A compared to controls and decreased to a 
lesser extent in LMP2B expressing cells.  
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Figure 4.10: FACS analysis of TLR expression in CNE-2 cells pre- and post-
permeabilisation. 
 
CNE-2 cells expressing either a neomycin resistance cassette, full length LMP2A or full length 
LMP2B were seeded at a density of 1 x 106 onto 10cm2 dishes and grown to 80% confluence. 
Following this cells were removed from the surface of the plastic through successive washing 
and incubation with EDTA. Samples were then probed with antibodies specific to, TLR3, 
TLR4, TLR7 and TLR9 with and without addition of 0.1% saponin. Cells were fixed in 1% 
PFA and fluorescence measured using a flow cytometer. Mean fluorescent intensities and 
graphical representations of the analyses are displayed. Movement of the graph peaks to the 
right along the X-axis are indicative of an increase of receptor detection on a log-scale. In non-
permeabilised samples, across all TLRs examined levels of receptor are decreased in LMP2A 
expressing cells compared to control and LMP2B counterparts. Upon permeabilisation of cells 
increased levels of receptor are detectable for all TLRs examined and similarly LMP2A 
expressing cells show decreased levels of receptor expression compared to their control and 
LMP2B counterparts. Mean fluorescent intensity (MFI) values are also depicted which have 
been normalised against the isotype controls and are relative to Neomycin control values.  
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Figure 4.11: LMP2A modulates expression of intermediates of TLR signalling pathways.   
  
CNE-2 cells expressing either a control neomycin resistance cassette, full length LMP2A or 
full length LMP2B were seeded at a density of 1 x 106 onto 10cm2 dishes and allowed to grow 
to 80% confluence. Following this RNA was extracted and cDNA synthesised. RT-PCR was 
performed using primers specific to components of TLR signalling pathways including (A) 
IRAK1, (B) IRAK4, (C) MyD88, (D) TIRAP, (E) MAP3K7, (F) TRAF3, (G) TRAF6 and the 
housekeeping gene GAPDH was included as an internal control to confirm equal RNA input 
into the PCR reactions. Reactions were examined using gel electrophoresis and representative 
photographs are displayed. Comparing levels of expression of each gene examined between 
control and LMP2A and LMP2B expressing cells, it is observable that in the presence of 
LMP2A levels all components examined are decreased compared to levels in both controls and 
LMP2B expressing cells. It must be noted however, that endpoint RT-PCR reactions such as 
these and no quantitative inference can be made from the results of such analyses.  
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Figure 4.12: Immunohistochemical staining for TLR3 and TLR4. 
 
Paraffin embedded tissue sections, including normal epithelium, tonsillar epithelium and NPC 
biopsies were ALTER treated to retrieve the respective antigens and probed using IHC 
compatible antibodies specific to TLR3 and TLR4. Slides were viewed and photographed 
using a light phase microscope. Representative images from the analyses are shown. 
Comparing between the epithelial sections and the tumour itself it is clear that receptor 
expression is downregulated and that cell morphology is also altered. 
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Prior to this, as it has been shown previously, Figure 4.5, that IFNβ expression is attenuated in 
the presence of LMP2A, analysis of the activity of the IFNβ promoter activity as whole was 
carried out. This determined whether LMP2 expression effected enhancesome formation and 
thus IFNβ production. To assess this luciferase reporter assays were performed using stimuli 
for each of the relevant TLRs. This allowed comparison of the basal level of promoter activity 
compared to that of an activated signalling network while also allowing for comparisons 
between the cell panels examined.  
 
4.4.1 IFNβ promoter activity is attenuated in presence of LMP2A 
4.4.1.1 Effect of LMP2A on TLR3 induced IFNβ activity 
Briefly, cells of interest, the CNE-2 and H103 controls and their LMP2A or LMP2B 
expressing counterparts were transfected with a luciferase reporter plasmid or the relevant 
control plasmid (see section 2.3.2) prior to stimulation with the appropriate agonist. Luciferase 
assays were then carried out to examine the extent of IFNβ promoter activity at two time 
points, 6 and 9 hours, using the Dual Luciferase Assay technique (Promega). 
 
A graphical representation of the IFNβ reporter assay of the CNE-2 cell panel after poly(I:C) 
stimulation is shown in Figure 4.13.A. Each assay was performed in biological and technical 
triplicates and the standard errors calculated. The control samples show, at the basal level, 
activity of the IFNβ promoter, upon stimulation this activity is, as expected, augmented four-
fold, indicating a functioning signalling pathway. This augmentation occurs at both 6 and 9 
hours post-incubation with poly(I:C). Comparing this to the LMP2A expressing cells, it can be 
seen that even basal levels of transcriptional activity are attenuated, mirroring the RT-QPCR 
data, Figure 4.5. Stimulating these cells with poly(I:C) has little effect on the IFNβ promoter, 
with little or no augmentation observed. LMP2B expressing cells display results matching 
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those of their control counterparts, with a similar four-fold augmentation upon stimulation and 
as such this attenuation of TLR3 induced IFNβ transcription is an LMP2A specific effect. 
Figure 4.13.B, shows a graphical representation of the analyses performed on the H103 cell 
panel, in agreement with the CNE-2 cells, LMP2A expression here is concomitant with 
attenuated TLR3 signalling. Although the fold differences are of the order of a two-fold 
difference. The effect of LMP2A is also more pronounced at a basal level in these cells and 
samples appear almost refractory to poly(I:C) stimulus.  
 
4.4.1.2 Effect of LMP2A on TLR4 induced IFNβ activity 
Extending these findings to other TLR members, cells were stimulated with LPS to activate 
TLR4. A graphical representation of the resulting data in the CNE-2 cell panel is shown in 
Figure 4.14.A. Control and LMP2B expressing cells again show robust activation of IFNβ 
promoter activity upon LPS stimulation at both the 6-hour and 9-hour time points with 
approximately two to three fold induction in activity. LMP2A expressing cells show a slight 
increase in IFNβ promoter activity but compared to controls and LMP2B expressing cells the 
effect is markedly decreased. Figure 4.14.B. shows graphical representation of the same 
analyses but performed in the H103 cell panel. Comparing null controls to the IFNβ promoter 
expressing counterparts, basal activity of the promoter is increased and an augmentation occurs 
upon stimulation with LPS on both LMP2B expressing cells and the neomycin controls. 
LMP2A expressing cells in line with the CNE-2 result show no such augmentation and similar 
to that observed upon poly(I:C) stimulation, appear refractory to TLR4 activation by LPS.  
 
4.4.1.3 Effect of LMP2A on TLR7, TLR8 and TLR9 signalling 
Figure 4.15.A, depicts the effect of TLR7 stimulation on IFNβ promoter activity analysed in 
the CNE-2 cell panel. The agonist for TLR7, Imiquimod is a synthetic drug that has been used 
 176
Chapter 4  Results 
 
previously to treat basal and squamous cell carcinoma. Here it does not appear to activate IFNβ 
promoter activity in control LMP2A or LMP2B expressing cells. Although the cells express 
TLR7, Figures 4.8, 4.9 and 4.10, agonist treatment does not appear to stimulate IFNβ 
transcription. The concentrations used were sufficient to mount a TLR7 response, as observed 
in later sections, but not to induce IFNβ. Although it may appear that LMP2A disrupts the 
limited activation observed in control and LMP2B samples, comparing the basal attenuation of 
IFNβ promoter activity between controls and LMP2A expressing cells demonstrates that this is 
not the case. Figure 4.15.B. is a graphical representation of IFNβ promoter activity upon TLR8 
stimulation with ssRNA. Mirroring the result observed with poly(I:C) and LPS stimulation, 
there is an attenuation of signal observed in LMP2A expressing cells when compared with 
their LMP2B expressing and control counterparts. Promoter activity in LMP2B expressing 
cells appears to be primed, whereby there is an augmentation of activity upon treatment greater 
than that seen in the control samples. This could be due to the effect of LMP2B on TLR8 
retention in the endosome, which could facilitate super-activation of the receptor complex, or 
an increased uptake of the ssRNA agonist due to increased endosomal traffic, an effect that 
many be counteracted in LMP2A expressing cells due to the signalling capacity of its amino-
terminal domains, see chapter 5. Figure 4.15.C, shows the effect of TLR9, CpG DNA 
stimulation on IFNβ promoter activity across the CNE-2 cell panel. Here similar to the effects 
observed after TLR8 stimulation with ssRNA, the augmentation of activity is not as great as in 
the case of TLR3 and TLR4. However, LMP2A expression attenuates the limited capability of 
TLR9 agonists to induce IFNβ promoter activity.  
 
The effects of TLR8 and TLR9 stimulation on IFNβ activity here are not as dramatic as with 
TLR3 and TLR4 stimulation. This can be explained by, the different pathways that the 
receptors utilise to mount a signalling response. While TLR3 signals MyD88 independently, 
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and TLR4 can signal through both MyD88 independent and dependent mechanisms, TLRs, 7, 
8 and 9, use exclusively MyD88 mediated signalling pathways. Although there is an 
observable attenuation upon TLR8 and TLR9 stimulation it is likely that LMP2A preferentially 
exerts its effect on TLR3 signalling given its activation by poly(I:C) and the potential for the 
EBV encoded EBERs to activate this response.  
 
4.4.1.4 Modulation of TLR1, TLR2, TLR5 and TLR6 signalling by LMP2A 
Findings presented thus far have focused on TLR members that localise to internal membranes 
and the effect that LMP2A has on their expression and signalling. To examine whether these 
effects were broad i.e. affecting other TLR family members, IFNβ promoter luciferase reporter 
assays were performed using commercially available agonists specific for TLR1, TLR2, TLR5 
and TLR6. A graphical representation of IFNβ promoter activity as assessed by luciferase 
assay across the CNE-2 cell panel in response to TLR1, TLR2, TLR5 and TLR6 agonist 
stimulation is shown in Figures 4.16 A, B, C and D. In all cases, IFNβ promoter activity is not 
markedly augmented in CNE2 control cells upon stimulation, indicative of the lack of direct 
activation of IFNβ responses from these receptors. However, in keeping with observation on 
TLR3 and TLR4, the basal levels of activity in LMP2A expressing cells is reduced compared 
to control and LMP2B expressing cells. Augmentation of activity in cells expressing LMP2A 
and LMP2B upon treatment with any of these four agonists is comparable to levels observed in 
control cells. Thus these assays clearly demonstrate that, IFNβ production is not associated 
with activation of signalling from these receptors and that LMP2A or LMP2B do not modulate 
the little activity that is observable. Analysis of the activity of TLR signalling in terms of IFNβ 
production revealed an LMP2A specific effect on IFNβ promoter activity.. To examine this in 
more detail, the effect of LMP2A on components of the IFNβ enhancesome was analysed. 
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Figure 4.13 Modulation of IFNβ promoter activity by LMP2A expression in epithelial 
cells upon stimulation of TLR3. 
 
(A) CNE-2 cells and (B) H103 cells expressing either a control neomycin resistance cassette, 
full length LMP2A or LMP2B were seeded at a density of 2.5 x 105  cells per well of a six-well 
dish and allowed to adhere overnight at 5% C02 and 37°C. The following day cells were 
transfected with an IFNβ promoter luciferase reporter construct and a plasmid expressing 
Renilla firefly luciferase or relevant controls. Cells were allowed to recover for 24 hours and 
subsequentially stimulated with 5µg/ml poly(I:C) for six and nine hours, harvested and read 
using a luminometer. Histograms are shown which, display the relative luminescence of each 
sample set standardised against Renilla firefly signals and comparisons made between control 
cells transfected with a control vector with those transfected with the IFNβ promoter and also 
stimulated cells with the unstimulated basal level of promoter activity. LMP2A and LMP2B 
expressing cells are normalised against the activity measured in the control cells with and 
without stimulation (mean ± SD; n=3).  
 
 
(A)  CNE-2 cells: Comparing basal levels of activity between controls, LMP2A and 
LMP2B expressing cells, there are discrete differences observable, LMP2A expressing 
cells showing slightly decreased activity. Upon stimulation of TLR3 by exogenous 
poly(I:C) control cells show significant increases in IFNβ promoter activity when 
compared with baseline levels at both time points examined. This augmentation is also 
seen in LMP2B expressing cells but is abrogated in LMP2A expressing cells, where 
activity does not markedly increase beyond basal levels. 
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(B) H103 cells: Comparing basal levels of activity between controls, LMP2A and LMP2B 
expressing cells, differences are readily observable, LMP2A expressing cells showing 
slightly decreased activity compared to both LMP2B and control samples. Upon 
stimulation of TLR3 by exogenous poly(I:C) control cells show significant increases in 
IFNβ promoter activity when compared with baseline levels at both time points 
examined. This augmentation is also seen LMP2B expressing cells but is completely 
abrogated in LMP2A expressing cells, where activity does not markedly increase 
beyond basal levels and appears almost refractory to stimulation.  
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Figure 4.14 Modulation of IFNβ promoter activity by LMP2A expression in epithelial 
cells upon stimulation of TLR4. 
 
(A) CNE-2 cells and (B) H103 cells, expressing either a control neomycin resistance cassette, 
full length LMP2A or LMP2B were seeded at a density of 2.5 x 105 cells per well of a six-well 
dish and allowed to adhere overnight at 5% C02 and 37°C. The following day cells were 
transfected with an IFNβ promoter luciferase reporter construct and a plasmid expressing 
Renilla firefly luciferase or relevant controls. Cells were allowed to recover for 24 hours and 
subsequentially stimulated with 200ng/ml LPS for six and nine hours, harvested and read using 
a luminometer. Histograms are shown which, display the relative luminescence of each sample 
standardised against Renilla firefly signals and comparisons made between control cells 
transfected with a control vector with those transfected with the IFNβ promoter and also 
stimulated cells with the unstimulated basal level of promoter activity. LMP2A and LMP2B 
expressing cells are normalised against the activity measured in the control cells with and 
without stimulation (mean ± SD; n=3).  
 
(A) CNE-2 cells: Comparing basal levels of activity between controls, LMP2A and 
LMP2B expressing cells, there are discrete differences observable, LMP2A expressing 
cells showing slightly decreased activity. Upon stimulation of TLR4 by exogenous 
LPS control cells show significant increases in IFNβ promoter activity when compared 
with baseline levels at both time points examined. This augmentation is also seen 
LMP2B expressing cells but is attenuated in LMP2A expressing cells, where activity 
does not markedly increase beyond basal levels. 
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(B) H103 cells: Comparing basal levels of activity between controls, LMP2A and LMP2B 
expressing cells, differences are readily observable, LMP2A expressing cells showing 
decreased activity compared to both LMP2B and control samples. Upon stimulation of 
TLR4 by exogenous LPS control cells show significant increases in IFNβ promoter 
activity when compared with baseline levels at both time points examined. This 
augmentation is also seen LMP2B expressing cells but is completely abrogated in 
LMP2A expressing cells, where activity does not markedly increase beyond basal 
levels and appears almost refractory to stimulation.   
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Figure 4.15 Modulation of IFNβ promoter activity by LMP2A expression in CNE-2 cells 
upon stimulation of TLR7, TLR8 and TLR9.  
 
CNE-2 cells expressing either a control neomycin resistance cassette, full length LMP2A or 
LMP2B were seeded at a density of 2.5 x 105 cells per well of a six-well dish and allowed to 
adhere overnight at 5% C02 and 37°C. The following day cells were transfected with an IFNβ 
promoter luciferase reporter construct and a plasmid expressing Renilla firefly luciferase or 
relevant controls. Cells were allowed to recover for 24 hours and subsequentially stimulated 
with (A) 2.5µg/ml Imiquimod for twenty-four and forty-eight hours (TLR7), (B) 1µg/ml 
ssRNA for six and nine hours (TLR8) or (C) 1µM ODN2006 CpG DNA for six and nine hours 
(TLR9), harvested and read using a luminometer. Histograms are shown which, display the 
relative luminescence of each sample set standardised against Renilla firefly signals and 
comparisons made between control cells transfected with a control vector with those 
transfected with the IFNβ promoter and also stimulated cells with the unstimulated basal level 
of promoter activity. LMP2A and LMP2B expressing cells are normalised against the activity 
measured in the control cells with and without stimulation (mean ± SD; n=3).  
 
(A) TLR7: Basal levels of IFNβ promoter activity are attenuated in LMP2A expressing 
cells compared to control and LMP2b expressing cells. Stimulation with the TLR7 
agonist however does not appear to augment this activity in any cell type examined.  
 
(B) TLR8: Discrete differences in promoter activity between control and LMP2A 
expressing cells are observable. Upon stimulation with ssRNA levels of activity are 
increased in basal and LMP2B expressing cells, this increase is attenuated in LMP2A 
expressing cells. 
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(C) TLR9: In a similar manner to the above result, discrete differences are observable 
between basal levels of promoter activity between control and LMP2A expressing 
cells. The augmentation of this activity by CpG DNA in control cells is attenuated in 
LMP2A expressing cells.  
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Figure 4.16 Effect of LMP2A expression on IFNβ promoter activity in CNE-2 cells upon 
stimulation of TLR1, TLR2, TLR5 and TLR6.  
 
CNE-2 cells expressing either a control neomycin resistance cassette, full length LMP2A or 
LMP2B were seeded at a density of 2.5 x 105 cells per well of a six-well dish and allowed to 
adhere overnight at 5% C02 and 37°C. The following day cells were transfected with an IFNβ 
promoter luciferase reporter construct and a plasmid expressing Renilla firefly luciferase or 
relevant controls. Cells were allowed to recover for 24 hours and subsequentially stimulated 
with (A) 0.5Μµg/ml Pam3CSK4 (B) 108 cells/ml HKLM (C) 50ng/ml ST-Flagellin or (D) 
400ng/ml FSL-1 for six and nine hours, harvested and read using a luminometer. Histograms 
are shown which, display the relative luminescence of each sample set standardised against 
Renilla firefly signals and comparisons made between control cells transfected with a control 
vector with those transfected with the IFNβ promoter and also stimulated cells with the 
unstimulated basal level of promoter activity. LMP2A and LMP2B expressing cells are 
normalised against the activity measured in the control cells with and without stimulation 
(mean ± SD; n=3).  For all stimulations on all cell types no significant differences were 
detected.  
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4.4.2 LMP2A expression does not alter AP1 activity in CNE-2 cells 
The AP1 transcription factor is composed of homo or hetero dimers of the Jun, Fos and ATF 
protein families (Malliri, Symons et al. 1998; Ozanne, Spence et al. 2006). It can function to 
either trans-activate or repress transcriptional activity of a variety of genes involved in cellular 
pathways including, transformation, cell migration, cell cycle and immune regulation (Vesely, 
Staber et al.). As outlined in the introduction, AP1 is a key component of the IFNβ 
enchancesome complex and, in conjunction with NFκB and IRF3, regulates IFNβ 
transcription. To ascertain whether LMP2A affects AP1 activity, a generic AP1 luciferase 
reporter plasmid was used to examine whether LMP2A affected TLR-mediated AP1 activation. 
In a similar manner to the experiments described above, AP1 activity was assessed using the 
Dual-luciferase reporter kit (Promega). Graphical representations of the data are shown in 
Figures 4.17.A, B, C and D. In response to TLR4, TLR7 and TLR8 agonist stimulation, AP1 
reporter activity was increased in control, LMP2A and LMP2B expressing cells equally, with 
comparable levels of activation being observed between the different TLR agonists. However, 
a slight attenuation in AP1 activity was observed in LMP2A expressing cells treated with the 
TLR3 agonist, poly(I:C), Figure 4.16.A, where a much weaker response was observed 
compared to control and LMP2B expressing cells. Overall however, it is determined that AP1 
activity is not modulated enough to account for the observable disruption of IFNβ promoter 
activity, e.g. Figure 4.13.  
4.4.3 LMP2A attenuates IRF3 activation in response to TLR stimulation 
The second component of the complex to be examined in more detail was the transcription 
factor IRF3. As shown previously, basal protein expression of this transcription factor was 
downregulated in cells expressing LMP2A compared to their control counterparts, Figure 
4.2A, B. It is known that IRF3 is more important than IRF7 in the initial early phase of an 
interferon responses as it is expressed constitutively in all cells, whereas IRF7 is expressed 
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only at low levels (Peters, Smith et al. 2002), which are augmented by IFNβ, contributing to 
paracrine and autocrine signalling loops necessary for full type I responses (Hiscott 2007). 
IRF3:IRF7 heterodimers are involved in the secondary stage of IFNβ production and as the 
data here are focused on the first wave of the innate response analysis of IRF3 binding to the 
IFNβ promoter were of primary importance (Dragan, Hargreaves et al. 2007).  
4.4.3.1 Nuclear translocation of IRF3 in epithelial cells 
To further analyse the effect of LMP2A on IRF3 activity, a translocation assay was performed 
using immunofluorescence staining, as outlined in section 2.4. Briefly, the CNE-2 and H103 
cell panels were grown in situ prior to TLR3 activation with poly(I:C). After 6 hours, cells 
were fixed, permeabilised and subjected to immunofluorescence staining with an antiserum 
specific for IRF3. Representative confocal images of the CNE-2 cell panel and the magnified 
insets, Figure 4.18, show the translocation more clearly, with arrows indicating the nuclei of 
cells. Comparing basal levels of expression of IRF3 between control, LMP2A expressing cells 
and those expressing LMP2B, this result mirrors the immunoblotting results, where levels of 
IRF3 are slightly lower in LMP2A expressing cells. Whereas most, if not all IRF3 is 
cytoplasmic in unstimulated control cells, upon stimulation with poly(I:C), a robust nuclear 
translocation is observed in many cells. A similar effect is observed in the LMP2B expressing 
cells, although the magnitude of the response appeared somewhat reduced. The LMP2A cell 
panel however shows much less translocation when compared to control and LMP2B 
expressing counterparts. This indicates a disruption in IRF3 activation by LMP2A, a finding 
which may account for the attenuation in IFNβ promoter activity described in section 4.4.1. To 
ensure that these findings were not cell type specific, identical experiments were performed in 
the H103 cell panel. Representative confocal images of immunofluoresence staining for IRF3 
are shown in Figure 4.19. As with CNE2 cells, control and LMP2B expressing cells expressed 
similar basal levels of IRF3 with LMP2A having a slightly lower levels of expression. Upon 
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poly(I:C) stimulation, nuclear translocation occurs in control and LMP2B cells but is 
attenuated in cells expressing LMP2A.  
4.4.3.2 IRF3:DNA binding is disrupted by LMP2A 
Having demonstrated that LMP2A and., to a lesser extent LMP2B, attenuated IRF3 activation 
and nuclear translocation, the binding of IRF3 to its target sequences within the IFNβ promoter 
was explored. IRF3 homodimers are known to bind to two sequences within this region: the 
PRDI and the PRDIII domains. The NFκB p50/p65 heterodimers bind to the PRDII domain 
and the AP1 subunits bind to the PRDIV domain (Panne 2008). Full binding of all of the 
subunits of the enhancesome complex is necessary for its function and interference at one or 
more of these sites could disrupt transcriptional activity of the promoter, Chapter 1, section 
1.7.6. To assess this binding, electrophoresis mobility shift assays (EMSA) were performed, as 
described in section 2.8.3. Briefly, nuclear extracts were isolated from the CNE-2 cell panel 
that had been stimulated with poly(I:C) to activate TLR3. To ensure efficient separation of cell 
fractions, immunoblotting was performed on both extracts using antibodies specific to the 
cytoplasmic and nuclear markers, β-tubulin and Sp-1 respectively (data not shown), expression 
of each only detectable in the relevant extract.  Nuclear extracts were then incubated with IRD-
700 labelled probes specific to the PRDI binding domain of the IRF3 transcription factor. 
Binding was measured after scanning of the EMSA gel on a LiCor© infrared laser device. 
DNA:Protein complexes were resolved and the binding of proteins to the synthetic 
oligonucleotide PRD domain probe quantitated by measuring relative fluorescence intensities.   
Densiometric analyses, shown graphically, along with the scanned EMSA gels are shown in 
Figure 4.20. The level of protein binding to the PRDI probe is increased in response to 
poly(I:C) treatment in control cells. In marked contrast, the level of binding to the PRDI probe 
observed with nuclear extracts from LMP2A expressing cells is markedly reduced, whereas 
intermediate levels of binding are observed with extracts from LMP2B expressing cells.  
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Figure 4.17 Effect of LMP2A expression on AP-1 activity in CNE-2 cells upon stimulation 
of TLR3, TLR4, TLR7 and TLR8. 
 
CNE-2 cells expressing either a control neomycin resistance cassette, full length LMP2A or 
LMP2B were seeded at a density of 2.5 x 105 cells per well of a six-well dish and allowed to 
adhere overnight at 5% C02 and 37°C. The following day cells were transfected with an AP-1 
luciferase reporter construct and a plasmid expressing Renilla firefly luciferase or relevant 
controls. Cells were allowed to recover for 24 hours and subsequentially stimulated with (A) 
5µg/ml poly(I:C) (TLR3), (B) 200ng/ml LPS (TLR4) for six and nine hours, (C) 2.5µg/ml 
Imiquimod for twenty-four and forty-eight hours (TLR7) and (D) 1µg/ml ssRNA for six and 
nine hours (TLR8), harvested and read using a luminometer. Histograms are shown which, 
display the relative luminescence of each sample set standardised against Renilla firefly signals 
and comparisons made between control cells transfected with a control vector with those 
transfected with the IFNβ promoter and also stimulated cells with the unstimulated basal level 
of promoter activity. LMP2A and LMP2B expressing cells are normalised against the activity 
measured in the control cells with and without stimulation (mean ± SD; n=3).  For all 
stimulations on all cell types no significant differences were detected., although stimulation 
with agonists did augment AP-1 activity to an equal level across cell types, with ssRNA 
(TLR8) being the most effective. 
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Figure 4.18  Effect of LMP2A expression on IRF-3 translocation in CNE-2 cells upon 
stimulation of TLR3.  
 
CNE-2 cells expressing either a control neomycin resistance cassette, full length LMP2A or 
LMP2B were seeded at a density of 1 x 104 on to 12-well microdot Teflon coated slides and 
placed into a 37˚C incubator with 5% CO2 overnight to allow cell adherence. The following 
day samples were stimulated in situ, with 5µg/ml poly(I:C) for six hours. Slides were fixed and 
permeabilised with 4% PFA and 0.5% Triton-X and immunofluorescent staining performed on 
both stimulated and unstimulated samples using an antibody specific to IRF-3. Samples were 
viewed and photographed using a Zeiss LSM510-meta confocal microscope and representative 
images are shown. Levels of IRF-3 protein detected were slightly lower in LMP2A expressing 
cells when compared to their LMP2B and control counterparts, in line with data from Figure 
4.2(A)(iii). Upon stimulation with poly(I:C), translocation of IRF-3 from the cytosol to the 
nucleus is observed in control and LMP2B expressing cells. Levels of translocation in LMP2A 
expressing cells however, are attenuated when compared with other cell types. Inset images are 
displayed to show effects at increased magnification with arrows indicating the signal detected 
with the nuclei of cells.  
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Figure 4.19  Effect of LMP2A expression on IRF-3 translocation in H103 cells upon 
stimulation of TLR3.  
 
H103 cells expressing either a control neomycin resistance cassette, full length HA tagged 
LMP2A or LMP2B were seeded at a density of 1 x 104 on to 12-well microdot Teflon coated 
slides and placed into a 37˚C incubator with 5% CO2 overnight to allow cell adherence. The 
following day samples were stimulated in situ, with 5µg/ml poly(I:C) for six hours. Slides were 
fixed and permeabilised with 4% PFA and 0.5% Triton-X and immunofluorescent staining 
performed on both stimulated and unstimulated samples using an antibody specific to IRF-3. 
Samples were viewed and photographed using a Zeiss LSM510-meta confocal microscope and 
representative images are shown. Levels of IRF-3 protein detected were slightly lower in 
LMP2A expressing cells when compared to their LMP2B and control counterparts. Upon 
stimulation with poly(I:C), translocation of IRF-3 from the cytosol to the nucleus is observed 
in control and LMP2B expressing cells. Levels of translocation in LMP2A expressing cells 
however, are attenuated when compared with other cell types. Inset images are displayed to 
show effects at increased magnification with arrows indicating the signal detected with the 
nuclei of cells.  
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Figure 4.20 Effect of LMP2A on binding at PRDI domains in CNE-2 cells upon 
stimulation of TLR3.  
 
CNE-2 cells expressing either a control neomycin resistance cassette, LMP2A or LMP2B were 
seeded at a density of 1 x 106 cells per 10cm2 dish and allowed to adhere overnight at 37˚C and 
5% CO2. The following day samples were stimulated with 5µg/ml poly(I:C) for six hours and 
nuclear and cytosolic extracts were isolated from control and stimulated samples. The nuclear 
extracts were then incubated with IRD-700 probes specific to the PRDI domain of the IFNβ 
promoter. Samples were then separated by gel electrophoresis and analysed using infrared 
scanning and imaging. Densitometry was also performed and histograms created depicting 
mean differences in binding affinities between cell types with and without stimulation. 
Histograms and representative images of the infrared scanning are shown (mean ± SD; n=3).  
Basally no significant differences are observable between cell types, upon stimulation with 
poly(I:C) binding is augmented in control and LMP2B expressing cells. This increase is 
attenuated in LMP2A expressing cells. 
 
 
 
 
 
 
 
 
 
 
 199
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
2
R
el
at
iv
e 
B
in
di
ng
CTRL       LMP2A       LMP2B
Densitometry
CTRL    LMP2A  LMP2B  CTRL  LMP2A LMP2B 
PRDI P(I:C)
Basal Poly(I:C) Stimulated
Chapter 4  Results 
 
Enhancesome activity at the IFNβ promoter depends also on binding of p50/p65 dimers to the 
PRDII domain. Identical experiments were performed using a labelled-probe specific to this 
domain. Graphical representations of the results and the scanned EMSA gels are shown in 
Figure 4.21. Here, comparing the binding intensities of nuclear extracts prepared from 
unstimulated and poly(I:C) stimulated cells, there is a robust increase in probe binding in 
control cells. Comparing this to LMP2B expressing cells a small augmentation occurs in 
stimulated cells, but the level here is more comparable to the attenuated activation state 
observable in LMP2A expressing cells. These results demonstrate an attenuation of PRDII 
domain binding in both LMP2A and LMP2B expressing cells upon TLR-3 stimulation, 
whereas binding at PRDI domains is attenuated only upon LMP2A expression.  
 
These experimental results clearly outline a proposed mechanism for the disruption of TLR3 
induced IFNβ promoter activity by attenuating binding of IRF3 transcription factor at the PRDI 
domain of the promoter. To further investigate this effect it would be necessary to examine the 
PRDIII domain as this has been reported to be important in both IFNβ and IFNα4 transcription. 
Although probes were designed and analysed, investigations into the binding affinities in the 
CNE-2 cell panel were unsuccessful. Data for the PRDII domain revealed that binding here 
was decreased in both LMP2A and LMP2B expressing cells when compared with controls. 
Taken together with the effect of LMP2A on binding at the PRDI domain, these results could 
account for the observed decreases in IFNβ promoter activity described earlier.  
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Figure 4.21 Effect of LMP2A on binding at PRDII domains in CNE-2 cells upon 
stimulation of TLR3.  
 
CNE-2 cells expressing either a control neomycin resistance cassette, LMP2A or LMP2B were 
seeded at a density of 1 x 106 cells per 10cm2 dish and allowed to adhere overnight at 37˚C and 
5% CO2. The following day samples were stimulated with 5µg/ml poly(I:C) for six hours and 
nuclear and cytosolic extracts were isolated from control and stimulated samples. The nuclear 
extracts were then incubated with IRD-700 probes specific to the PRDII domain of the IFNβ 
promoter. Samples were then separated by gel electrophoresis and analysed using infrared 
scanning and imaging. Densitometry was also performed and histograms created depicting 
mean differences in binding affinities between cell types with and without stimulation. 
Histograms and representative images of the infrared scanning are shown (mean ± SD; n=3).  
Basally no significant differences are observable between cell types, upon stimulation with 
poly(I:C) binding is augmented in control. This increase is attenuated in LMP2A expressing 
cells and to a lesser extent in cells expressing LMP2B. 
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4.4.4 Modulation of NFκB activity by LMP2A 
4.4.4.1 Effect of LMP2A on TLR3-induced NFκB activity 
The final component of the enhancesome complex to be examined was the NFκB transcription 
factor. To investigate the impact of LMP2A and LMP2B on NFκB activity, luciferase reporter 
assays were performed using pConALuc, a plasmid containing tandem consensus NFκB 
binding motifs from the HIV LTR (Huen et al., 1995). CNE-2 and H103 cell panels were 
transfected with the NFκB reporter plasmid or the relevant control vector and subsequently 
stimulated with TLR agonists for 6 and 9 hours. Figures 4.22A and B, show graphical 
representations of the relative levels of basal activity, and the extent of NFκB activation 
following poly(I:C) stimulation. These results were expected to show little variation in 
augmentation activity upon stimulation between LMP2A or LMP2B expressing cells and 
controls, in line with the results for the AP1 promoter analyses. Or if differences in activation 
levels were observed it was reasoned that LMP2A expressing cells would show decreased 
NFκB activity, in agreement with lower levels of IFNβ production. Surprisingly however, it is 
clear from both the CNE-2, Figure 4.22.A and the H103, Figure 4.22.B cell panels that this 
was not the case. Although the basal level of NFκB activity were similar between control and 
LMP2B expressing cells, LMP2A expressing cells displayed elevated levels of NFκB activity, 
up to a six fold increase in basal NfκB activity, a result that is at odds with the IFNβ data 
described earlier. Upon stimulation with poly(I:C) little increases in activity are observable 
across all cell types compared to their basal levels. These results are recapitulated in the H103 
cell panel indicating that it is not a cell type specific phenomenon, with LMP2A expressing 
cells displaying a two to three-fold increase in NFκB activity compared with controls and 
LMP2B expressing cells.  
 
 
 204
Chapter 4  Results 
 
Figure 4.22 Modulation of NFκB activity by LMP2A in epithelial cells upon stimulation 
of TLR3. 
 
(A) CNE-2 cells and (B) H103 cells, expressing either a control neomycin resistance cassette, 
full length LMP2A or LMP2B were seeded at a density of 2.5 x 105 cells per well of a six-well 
dish and allowed to adhere overnight at 5% C02 and 37°C. The following day cells were 
transfected with an NFκB (3Enh-κB-ConAluc ) luciferase reporter construct and a plasmid 
expressing Renilla firefly luciferase or relevant controls. Cells were allowed to recover for 24 
hours and subsequentially stimulated with 5µg/ml poly(I:C) for six and nine hours, harvested 
and read using a luminometer. Histograms are shown which, display the relative luminescence 
of each sample standardised against Renilla firefly signals and comparisons made between 
control cells transfected with a control vector with those transfected with the NFκB promoter 
and also stimulated cells with the unstimulated basal level of promoter activity. LMP2A and 
LMP2B expressing cells are normalised against the activity measured in the control cells with 
and without stimulation (mean ± SD; n=4).  
(A) CNE-2 cells: Basal levels of activity of the NFκB reporter are increased in LMP2A 
compared to both control and LMP2B expressing samples. Upon stimulation with 
poly(I:C), activity is augmented in control and LMP2B expressing cells at the nine-
hour time point compared to basal levels. LMP2A expressing cells do not show 
increased activity beyond the basal response.  
(B) H103 cells: A similar situation to that for CNE-2 cells is observed, whereby activity is 
augmented in control and LMP2B expressing cells upon stimulation with poly(I:C) 
and activity in LMP2A expressing cells is not augmented beyond basal responses.  
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4.4.4.2 Effect of LMP2A on TLR4-induced NFκB activity  
Extending this to examine the effect of other TLR agonists on NFκB signalling was necessary 
in light of the results from poly(I:C) stimulation. The CNE-2 and H103 cell panels were treated 
with LPS to activate TLR4. Figures 4.23.A,B, show graphical representations of the results for 
both cell panels. In agreement with the previous investigation, NFκB activity in LMP2A 
expressing cells appeared higher compared to LMP2B expressing cells and the control 
counterparts. However, upon stimulation with LPS, NFκB activity in control cells increased 
considerably, with a similar result observed in LMP2B expressing cells. Surprisingly, LMP2A 
expressing cells did not show increased NFκB activation and appeared refractory to TLR4 
stimulation. A similar pattern of results can be observed in the H103 cell panel, Figure 4.23.B, 
indicating once again that the effects are not cell type specific. Comparing these results with 
those obtained from investigations of poly(I:C) stimulation demonstrates an intriguing 
phenomenon. LMP2A expression in epithelial cells appears to augment NFκB signalling at the 
basal level and upon stimulation with poly(I:C) no increases in activity are observed. But 
stimulation of TLR4 signalling results in augmentation of signalling in control and LMP2B 
expressing cells and abrogation of the primed response in LMP2A expressing cells. A rationale 
for these data may be explained through examining the signalling cascades involved in TLR3 
and TLR4 activity. As mentioned previously, Chapter 1, section 1.7, TLR3 signalling occurs 
signals in a MyD88 independent manner, whilst TLR4 signalling can occur in both MyD88 
dependent and independent manners. To further determine whether this effect could explain, at 
least in part, these data, analysis of NFκB signalling in response to TLR members that signal 
solely through MyD88 was undertaken.  
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Figure 4.23 Modulation of NFκB activity by LMP2A in epithelial cells upon stimulation 
of TLR4. 
 
(A) CNE-2 cells and (B) H103 cells, expressing either a control neomycin resistance cassette, 
full length LMP2A or LMP2B were seeded at a density of 2.5 x 105 cells per well of a six-well 
dish and allowed to adhere overnight at 5% C02 and 37°C. The following day cells were 
transfected with an NFκB (3Enh-κB-ConAluc) luciferase reporter construct and a plasmid 
expressing Renilla firefly luciferase or relevant controls. Cells were allowed to recover for 24 
hours and subsequentially stimulated with 200ng/ml LPS for six and nine hours, harvested and 
read using a luminometer. Histograms are shown which, display the relative luminescence of 
each sample standardised against Renilla firefly signals and comparisons made between control 
cells transfected with a control vector with those transfected with the NFκB promoter and also 
stimulated cells with the unstimulated basal level of promoter activity. LMP2A and LMP2B 
expressing cells are normalised against the activity measured in the control cells with and 
without stimulation (mean ± SD; n=3).  
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(A)  CNE-2 cells: Basal levels of activity of the NFκB reporter are increased in LMP2A 
compared to both control and LMP2B expressing samples. Upon stimulation with LPS 
activity is augmented in control and LMP2B expressing cells compared to basal levels. 
LMP2A expressing cells do not show increased activity and activity was measured as 
less than basal levels.  
 
(B) H103 cells: Basal levels of activity of the NFκB reporter are increased in LMP2A 
compared to both control and LMP2B expressing samples. Upon stimulation of TLR4, 
reporter activity was augmented in control cells at the six-hour time point and to a 
lesser extent in LMP2B expressing cells. LMP2A expressing cells show no increase in 
activity post-stimulation with LPS. 
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4.4.4.3 LMP2A attenuates TLR7, TLR8 and TLR9-induced NFκB activity. 
Analyses performed to measure NFκB activity upon stimulation with TLR7, TLR8 and TLR9 
agonists in the CNE-2 cell panel are shown in Figure 4.24.A, B and C. Here, basal levels of 
NFκB activity appear to be augmented in cells expressing LMP2A compared to control and 
LMP2B expressing cells. In agreement with experiments involving LPS stimulation, 
significant increases in NFκB activity were observed after stimulation with Imiquimod, ssRNA 
and CpG DNA in control and LMP2B expressing cells. Taken together, these data with those 
for the LPS stimulation of epithelial cells, indicate that MyD88 dependent TLR activation of 
NFκB signalling is attenuated in LMP2A expressing cells. MyD88 independent signalling, as 
in the case of TLR3 activity appears unaltered in LMP2A expressing cells. Basally however, 
an increase in NFκB activity is observed and although this is at odds with previously published 
data from our group (Stewart et al 2005), which demonstrated decreased in NFκB mediated IL-
6 activity, these data are deemed important into the analysis of the complex mechanism of 
LMP2A action. The previous publication dealt with the affect of LMP2A expression in an 
adeno-carcinoma cell line, Ad/Ah, whereas here the epithelial cell lines examined are the NPC 
derived, CNE-2 cell line and the squamous cell carcinoma, H103, which are postulated to bear 
more physiological resemblance and thus significance to NPC research. As mentioned above 
however, this measurement of NFκB activity was performed using a luciferase reporter 
construct for one of NFκB’s target genes. Many signalling pathways can activate NFκB 
activity and as such in order to demonstrate that LMP2A expression could modulate p65 
activity in a more direct manner, a translocation assay and an EMSA were performed. 
 
4.4.4.4 LMP2A augments poly(I:C) induced p65 translocation 
Representative confocal images of a p65 translocation assay are shown in Figure 4.25. Briefly, 
CNE-2 cells, seeded into wells of a teflon-coated microscope slide were serum-starved for 3 
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hours prior to stimulation with poly(I:C). After 6 hours, cells were fixed, permeabilised and 
subjected to immunofluorersence staining with a mAb/antiserum specific for p65. Although no 
significant differences in the basal levels of p65 expression were apparent between control 
cells and those expressing LMP2A and LMP2B, a robust p65 translocation from the cytosol to 
the nucleus was observed upon poly(I:C) stimulation. Although this effect was observed in all 
cell types it was more pronounced in cells expressing LMP2A, findings which suggest that 
LMP2A primes NFκB responses in response to poly(I:C)/TLR3 activation. Given the basal 
decrease in expression of TLR3 in LMP2A positive cells, it is difficult to reconcile how 
priming of NFκB signalling could be mediated through this receptor. However, although TLR3 
expression is decreased in LMP2A expressing cells basally it is not absent and there is a 
priming of NFκB responses without any stimulation. It is therefore hypothesised, that sufficient 
receptor is expressed to further initiate an already primed response resulting in an increased 
level of p65 translocation in LMP2A expressing cells compared to their control counterparts. 
The importance of TRAF proteins to this should also not be discounted and is discussed in 
detail below.  
  
4.4.4.5 DNA binding of p65 in presence of LMP2A.  
To determine whether the increased nuclear translocation of p65 in LMP2A expressing cells 
treated with poly(I:C) was associated with increased DNA binding, EMSAs were performed 
using an IRD-700 labelled oligonucleotide NFκB probe containing consensus p65 binding 
sites. Previously it has been shown protein binding to the PRDII domain in the IFNβ promoter 
was reduced in cells expressing LMP2A and LMP2B. It is thought that this could be a direct 
effect of disrupting enhancesome formation through IRF3 binding attenuation at neighbouring 
sites rather than decreases in NFκB activity, which as shown above appears to be augmented in 
the presence of LMP2A (see Figure 4.22). Briefly, nuclear extracts isolated from basal and 
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poly(I:C) stimulated cells, along with the relevant controls, were incubated with the IRD-700 
labelled NFκB probe, separated by gel electrophoresis and the extent of protein binding 
measured after scanning of the EMSA gel on a LiCor© infrared laser device. DNA:Protein 
complexes were resolved and the binding of proteins to the synthetic oligonucleotide NFκB 
probe quantitated by measuring relative fluorescence intensities. 
 
A scan of the gel and a graphical representation of fluorescence intensities are shown in Figure 
4.26. Mirroring data obtained from the immunofluorescence staining, the basal levels of 
binding between control and LMP2A or LMP2B expressing cells do not yield significant 
differences. Upon poly(I:C) stimulation however, increased p65 binding is observed in cells 
stably expressing LMP2A compared to both control and LMP2B expressing cells.  
 
It is hypothesised that the augmentation of NFκB activity in LMP2A expressing cells may be 
due to p65 independent mechanisms of activation. It is thought that this basal augmentation 
could prime p65 responses, allowing them to become activated beyond control levels upon 
stimulation of TLR3 signalling with poly(I:C), which could account at least in part for the 
increased binding and translocation of the p65 protein. Further analysis of the specific 
alterations in NFκB signalling by LMP2A are necessary to test and confirm this hypothesis, 
which is beyond the scope of this thesis. Preliminary analysis using the TLR4 agonist LPS, 
which investigated p65 binding, showed that LMP2A expressing cells show decreased p65 
binding post-stimulation compared with controls (data not shown), instigating MyD88 
dependent signalling as a mechanism of this attenuated affect and highlighting the differential 
effects of LMP2A on the various pathways of the TLR signalling network.  
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Figure 4.24 Modulation of NFκB activity by LMP2A in CNE-2 cells upon stimulation of 
TLR7, TLR 8 and TLR9.  
 
CNE-2 cells expressing either a control neomycin resistance cassette, full length LMP2A or 
LMP2B were seeded at a density of 2.5 x 105 cells per well of a six-well dish and allowed to 
adhere overnight at 5% C02 and 37°C. The following day cells were transfected with a NFκB 
luciferase reporter construct (3Enh-κB-ConAluc) and a plasmid expressing Renilla firefly 
luciferase or relevant controls. Cells were allowed to recover for 24 hours and subsequentially 
stimulated with (A) 2.5µg/ml Imiquimod for twenty-four and forty-eight hours (TLR7), (B) 
1µg/ml ssRNA for six and nine hours (TLR8) or (C) 1µM ODN2006 CpG DNA for six and 
nine hours (TLR9), harvested and read using a luminometer. Histograms are shown which, 
display the relative luminescence of each sample set standardised against Renilla firefly signals 
and comparisons made between control cells transfected with a control vector with those 
transfected with the NFκB construct and also stimulated cells with the unstimulated basal level 
of promoter activity. LMP2A and LMP2B expressing cells are normalised against the activity 
measured in the control cells with and without stimulation (mean ± SD; n=3).  
 
 
(A) TLR7: Basally NFκB activity is augmented in LMP2A expressing cells compared with 
their control and LMP2B expressing counterparts. Post-stimulation with Imiquimod, 
activity is increased in control and LMP2B expressing cells but these increases are 
attenuated in cells expressing LMP2A. 
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(B) TLR8: NFκB activity is increased in control and LMP2B expressing cells upon 
stimulation with ssRNA, however this augmentation is abrogated in LMP2A expressing 
cells. 
 
(C) TLR9: Basally NFκB activity is augmented in LMP2A expressing cells compared to 
control and LMP2B expressing samples. Upon stimulation with ssRNA increased 
activation occurs after nine hours in control and LMP2B expressing samples but this 
activation is attenuated in LMP2A expressing cells. 
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Figure 4.25 Effect of LMP2A expression on p65 translocation in CNE-2 cells upon 
stimulation of TLR3.  
 
CNE-2 cells expressing either a control neomycin resistance cassette, full length LMP2A or 
LMP2B were seeded at a density of 1 x 104 on to 12-well microdot Teflon coated slides and 
placed into a 37˚C incubator with 5% CO2 overnight to allow cell adherence. The following 
day samples were stimulated in situ, with 5µg/ml poly(I:C) for six hours. Slides were fixed and 
permeabilised with 4% PFA and 0.5% Triton-X and immunofluorescent staining performed on 
both stimulated and unstimulated samples using an antibody specific to p65. Samples were 
viewed and photographed using a Zeiss LSM510-meta confocal microscope and representative 
images are shown. Basal levels of p65 protein detected did not alter greatly across the cell 
panel. Upon stimulation with poly(I:C) however, translocation of p65 from the cytosol to the 
nucleus is observed in control and LMP2B expressing cells.  The level of this translocation in 
LMP2A expressing cells however, is markedly augmented when compared with that observed 
in the other cell samples.  
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Figure 4.26 Effect of LMP2A on p65 nuclear binding in CNE-2 cells upon stimulation of 
TLR3. 
 
CNE-2 cells expressing either a control neomycin resistance cassette, LMP2A or LMP2B were 
seeded at a density of 1 x 106 cells per 10cm2 dish and allowed to adhere overnight at 37˚C and 
5% CO2. The following day samples were stimulated with 5µg/ml poly(I:C) for six hours and 
nuclear and cytosolic extracts isolated from  both control and stimulated samples. The nuclear 
extracts were then incubated with IRD-700 labelled probes specific to the p65-binding domain 
of promoters. Samples were then separated by gel electrophoresis and analysed using infrared 
scanning and imaging. Densitometry was also performed and histograms created depicting 
mean differences in binding affinities between cell types with and without stimulation. 
Histograms and representative images of the infrared scanning are shown (mean ± SD; n=3).  
Basally no significant differences are observable between cell types, upon stimulation with 
poly(I:C) binding is increased across the cell panel. This increase is augmented in LMP2A 
expressing cells compared to the effect in control and LMP2B expressing counterparts. 
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4.5  LMP2A and, to a lesser extent, LMP2B, modulate EBER1/2 induction of IFNβ. 
As mentioned previously, in the context of EBV infection, poly(I:C) and ssRNA are the most 
physiologically relevant TLR agonists given that EBV encodes both dsRNA (i.e. EBER1/2) 
and ssRNA (BART transcripts) at very high levels in latently infected epithelial cells. Indeed, 
numerous studies have demonstrated that the EBER RNAs can stimulate IFNβ expression 
when introduced into epithelial cell lines (Takada, 2001) although it is presently unknown if 
the BARTs can stimulate TLR8. Although speculative, it is possible that modulation of TLR3 
signalling by LMP2A provides a mechanism by which EBV can subvert the “anti-viral” effects 
of EBER expression on the innate immune signalling network. To further investigate this and 
to ascertain whether EBER1/2 expression could mount a type I interferon response, IFNβ 
promoter luciferase reporter assays were performed using plasmids expressing EBERI and 
EBER2. The CNE-2 panel were transfected with the reporter plasmids, allowed to recover for 
16 hours and subsequentially transfected with a plasmid expressing the EBER1/2 RNAs, as 
described in section 2.2.1, and incubated for an additional 24 hours to allow EBER1/2 
expression. A graphical representation of the data is shown in Figure 4.27. In control cells it is 
clear that IFNβ promoter activity is activated upon EBER1/2 expression. Comparing this 
activation with the effect in cells expressing LMP2A or LMP2B, it can be seen that the 
LMP2B samples that there is significant activation but it is slightly attenuated. LMP2A 
expressing cells do not however show any activation of IFNβ promoter activity. This 
demonstrates the ability of LMP2A to limit EBER1/2-induced type I interferon responses and 
infers physiological and functional relevance to LMP2A’s modulation of TLR3 signalling in 
the context of whole virus infections.  
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Figure 4.27 Effect of LMP2A expression on EBER induced IFNβ activity in CNE-2 cells.  
 
CNE-2 cells expressing either a control neomycin resistance cassette, full length LMP2A or 
LMP2B were seeded at a density of 2.5 x 105 cells per well of a six-well dish and allowed to 
adhere overnight at 5% C02 and 37°C. The following day cells were transfected with an IFNβ 
promoter luciferase reporter construct and a plasmid expressing Renilla firefly luciferase or 
relevant controls. Cells were allowed to recover overnight and subsequentially transfected with 
a plasmid expressing both EBERI and EBERII or relevant controls and allowed to recover for 
24 hours at 5% C02 and 37°C. The following day samples were harvested and read using a 
luminometer. Histograms are shown which, display the relative luminescence of each sample 
set standardised against Renilla firefly signals and comparisons made between control cells 
transfected with a control vector with those transfected with the IFNβ promoter construct and 
also EBER expressing cells with those transfected with control plasmids. LMP2A and LMP2B 
expressing cells are normalised against the activity measured in the control cells with and 
without stimulation (mean ± SD; n=3).  Basally no differences in promoter activity are detected 
between control cells and those expressing LMP2A or LMP2B. Upon expression of the EBERs 
IFNβ promoter activity is augmented in control and to lesser extent in LMP2B expressing 
cells. This increase in activity is attenuated in cells expressing LMP2A.  
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4.6 LMP2A modulates cytokine release upon TLR stimulation 
4.6.1 LMP2 attenuates IFNβ production 
To further establish the physiological effects of LMP2A and LMP2B on innate immune 
signalling, cytokine profiling was performed on the CNE2 panel using a commercially 
available custom cytokine antibody array (Tebu-Bio). This analysis served to explore the 
modulatory role of LMP2A and LMP2B in TLR-mediated cytokine secretion. The cytokine 
array was performed as described in section 2.10. The CNE2 cell panel was either left 
untreated or stimulated with the TLR3 and TLR4 agonists, poly(I:C) and LPS for 3, 6, 9 and 12 
hours. Cell culture supernatants were removed and applied to small array units containing 
duplicate embedded antibodies specific for 26 cytokines. Total RNA was extracted from each 
of the samples and RT-QPCR performed for IFNβ in the manner described in section 2.9.2. 
This identified the ideal time point to perform the array analysis. Figure 4.28, shows a 
graphical representation of the data. Three of the time-points chosen are depicted: 6 hours, 24 
hours and finally 72 hours; intermediate time points between these show similar patterns of 
expression (data not shown). This analysis showed that compared to control and LMP2B, 
LMP2A attenuates IFNβ production in response to TLR3 and TLR4 agonist stimulation. It was 
decided, using these data as a guideline, that supernatants from samples stimulated with the 
agonists for 72 hours would best serve this experiment, given the differences in IFNβ 
production by RT-QPCR and also allowing for sufficient time for secretion of cytokines.  
 
4.6.2 Cytokine profiling of the CNE-2 cell panel 
A representative cytokine antibody array is shown in Figure 4.29.A. Comparing the arrays 
visually, it is apparent that LMP2A expressing cells show modulation of the cytokine profiles 
compared to control and LMP2B expressing cells, a tenet that is most pronounced upon 
stimulation with the TLR agonists. The effect of stimulation on cytokine release is also 
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observed when comparisons are made between control and TLR-stimulated samples within the 
same cell type. Densitometric analysis was performed by comparing signals from each pair of 
embedded antibodies with the internal positive controls. This allowed standardisation of each 
array and also direct comparisons between stimulated and unstimulated samples and between 
control and LMP2A and LMP2B expressing cells. 
 
Figure 4.29 B, shows the cytokines whose expression was most modulated in response to TLR 
stimulation in the CNE2 panel. Table B top, consists of the levels of two of the cytokines 
examined, levels of which were deemed to be markedly decreased in LMP2A expressing cells 
upon stimulation with the TLR agonists. Expression of RANTES or CCL5 as mentioned above 
is controlled by IRF3 and so decreased levels of its secretion add further weight to the 
argument that LMP2A expression abrogates IRF3 activity. Soluble ICAM-1 is a cytokine 
involved in pro-inflammatory response and as such decreases in its expression in LMP2A 
expressing cells compared to controls sits well with the IRF3 and IFNβ signalling data. Table 
B bottom, shows those cytokines whose expression is increased in LMP2A expressing cells 
relative to controls upon TLR agonist stimulation. An increase in IL-6 and IL-8 secretion in 
LMP2A expressing cells is in general agreement with the increases in NFκB activity outlined 
above. The increases however in the cytokines, IL-1α, IL-1Rα and IP-10 were surprising given 
the attenuation of the type I interferon responses described previously and confirmed here. 
Further analysis into these data is necessary to elucidate the exact nature of these alterations. 
Overall however, it is clearly demonstrated through this assay that the consequences of 
LMP2A’s effect on the TLR signalling is borne out functionally through alteration of the 
cytokine complement of the cells examined.  
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Figure 4.28 Modulation of IFNβ transcription by LMP2A in CNE-2 post-stimulation of 
TLR3 and TLR4. 
 
CNE-2 cells expressing either a control neomycin resistance cassette, full length LMP2A or 
full length LMP2B were stimulated with the artificial agonists for (A) TLR3, 5µg/ml poly(I:C) 
and  (B) TLR4, 200ng/ml LPS, for  six hours, nine hours, twelve hours, twenty four hours, 
thirty six hours, forty eight hours and seventy two hours. RNA was extracted from each cell 
type, pre- and post- treatment and cDNA synthesised. RT-QPCR was performed using a 
primer-probe set specific for IFNβ and using the housekeeping gene GAPDH as an internal 
baseline control. Data was analysed using Microsoft Excel and the fold change differences 
calculated between cell types and between each cell type before and after stimulation. 
Histograms are shown displaying mean fold change differences, for control samples and three 
of the above time points, (mean = +/- SD, n=3).  Upon stimulation with either (A) or (B) 
agonists IFNβ expression is augmented in control cells and to a lesser extent in those 
expressing LMP2B. Samples expressing LMP2A show attenuated responses for both 
stimulations, in terms of IFNβ expression.  
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Figure 4.29 Effect of LMP2A expression on cytokine production in CNE-2 cells upon 
stimulation of TLR3 and TLR4. 
 
Supernatants were removed from CNE-2 cells expressing either a control neomycin resistance 
cassette, LMP2A or LMP2B, pre and post-stimulation with 5µg/ml poly(I:C) for 72 hours or 
200ng/ml LPS. Samples were incubated with array membranes embedded with antibodies 
specific to a variety of cytokines, (R & D Systems) washed and signals detected using 
chemiluminesence.  
(A) Scans of the films of the array membranes upon signal detection are shown 
including an example of the method of densitometric analysis used, performed with 
a BioRad scanner. 
 
Data analysis was performed using Microsoft Excel, whereby the results of densitometric 
analysis, i.e. the binding affinities of each of the cytokines was normalised against an internal 
membrane control for each array. Each binding affinity value was then normalised against the 
unstimulated Neomycin CTRL value. Stimulated samples for each cell type, CTRL, LMP2A 
and LMP2B expressing cells were then compared to their respective basal counterparts. Tables 
were then formed displaying the cytokines with the greatest degree of difference, upon receptor 
stimulation. 
(B) The top section of the Table depicts the cytokines displaying attenuated expression 
in the presence of LMP2A and/or LMP2B compared to controls, upon stimulation 
with agonists for TLR3 or TLR4. The bottom section of the Table depicts the 
cytokines displaying increased production and secretion in the presence of LMP2A 
and/or LMP2B compared to controls, upon stimulation with TLR3 or TLR4. 
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4.7  Discussion and Future Work
Data presented in this chapter confirm and extend the original observations of Shah and 
colleagues (Shah et al., 2009) demonstrating an ability of LMP2A and LMP2B to modulate 
innate immune response in nasopharyngeal epithelial cells. This study has revealed modulation 
of IFN receptors, regulatory factors (IRFs/SOCS) and signalling intermediates (Jak/Tyk2) by 
LMP2A and LMP2B, an effect that renders cells less responsive to IFN. Although LMP2A and 
LMP2B both modulate IFN receptor signalling, this study has identified an effect on TLR 
signalling that appears to be specific for LMP2A.    
 
Although the mechanism(s) by which LMP2A modifies TLR signalling was not fully resolved, 
the lack of responsiveness to TLR agonists is likely linked to reduced expression of the TLRs 
themselves. RT-PCR, IF and FACS profiling of cells revealed a global reduction in TLR 
expression in LMP2A expressing cells, an effect that was only marginal for LMP2B. These 
observations imply that the amino-terminal signalling domain of LMP2A is required for TLR 
modulation and suggests that the effects of LMP2A on IFNR and TLR signalling may occur 
through distinct mechanisms. Although LMP2A mutants defective for the ITAM (Y74/85), 
Lyn kinase (Y112) and ubiquitin-ligase (WWW) domains were in the process of development, 
time did not permit a thorough investigation into their function. Thus, the domains and/or 
signalling pathways responsible for LMP2A’s effects on TLR expression could not be 
identified.  
 
Previous studies in B-cells have shown that the amino-terminal domain of LMP2A is required 
for cell signalling. By sequestering and targeting tyrosine kinases (Lyn and Syk) for ubiquitin-
mediated degradation, LMP2A inhibits B-cell receptor signalling whilst providing a tonic 
signal to promote cell survival (Caldwell, Wilson et al. 1998). Findings presented here 
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demonstrate that LMP2A also acts to inhibit signalling from certain classes of receptors in 
epithelial cells, in this case, IFNRs and TLRs. Whether this constitutes the true function of 
LMP2A in EBV infected epithelial tissue is unknown, although modulation of both IFNR and 
TLR function may limit epithelial cell responsiveness to the growth inhibitory effects of viral 
infection and may facilitate viral persistence.  
 
Findings show that LMP2A is clearly able to attenuate IFNβ promoter activity, both basally, 
and in response to TLR agonist stimulation. This does not appear to involve the disruption of 
AP1 or NFκB, as LMP2A does not influence their expression or activity of these transcription 
factors; in the case of the latter, LMP2A appears to prime NFκB responses. However, findings 
do show that the inhibitory effects on IFNβ promoter activity may be due, in part, to 
attenuation of IRF3 activation. Although not formally assayed, the lack of IRF3 may prevent 
the formation of a “complete” enhancesome complex and thus fail to initiate IFNβ 
transcription. Decreases in IFNβ production also has an effect in terms of cytokine output by 
decreasing levels of the pro-inflammatory cytokines sICAM-1 and RANTES (CCL5), which 
are regulated by IRF3. Putting these observations into context, it appears that whilst LMP2A 
and LMP2B can both limit the actions of IFN, by inhibiting signalling from both the IFNAR 
and IFNGR, LMP2A can also reduce the extent of TLR signalling, thereby providing a more 
robust blockade of anti-viral activity.  
 
The differences in extent of signalling attenuation between the TLRs by LMP2A may be 
partially explained through analysis of their signalling pathways. MyD88-independent 
pathways are utilised only by TLR3 and TLR4, (Kawai and Akira 2006) with signalling being 
solely dependent on TRIF, Chapter 1, section 1.7. In contrast, TLR7, TLR8 and TLR9 
signalling is mediated through MyD88. Preliminary results indicate that the expression of 
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Myd88 are equal across the CNE-2 cell panel, which is surprising given reduced expression of 
MyD88 at the mRNA level in LMP2A expressing cells (see Figure 4.11). Although the levels 
of Myd88 protein were not assayed, it is possible, given that the levels of mRNA are reduced, 
that LMP2A targets components of the TLR3 and TLR4 signalling complex for degradation. 
Further examination is necessary to fully characterise this apparent disparity and the roles of 
both MyD88 and TRIF in attenuation of signalling response. It is likely that LMP2A 
preferentially disrupts TRIF-IRF3-mediated signalling facilitating a robust dampening of 
responses from the pathways engaged by TLR3 and TLR4. TRIF engages the IRF3 and NFκB 
transcription factors through the engagement of TRAF3 and TRAF6, (Häcker, Redecke et al. 
2006). It is known that differential ubiquitination of TRAF3 can result in its degradation or 
activating potential for IRF3, (Nakhaei, Mesplede et al. 2009; Tseng, Matusuzawa et al. 2010) 
and there maybe a role of the E3 ubiquitin ligases OTUB1, OTUB2 which negatively 
regulative IFN induction in this process, (Li, Zheng et al. 2010). Two additional ubiquitin 
ligases, which have been shown to regulate the different ubiquitin status of TRAF3, cIAP1/2, 
could also play a role in LMP2A’s modulation of response, (Mao, Li et al. 2010). The disparity 
in terms of activation of NFκB and attenuation of IRF3 could be explained by these 
ubiquitination events. Future studies will determine whether LMP2A alters TRAF3/6 
expression or activity to impede IRF3 activation yet augment TRAF6-mediated NFkB 
activation including analysis of the ubiquitin status of TRAF3 in the presence of LMP2A.  
 
Signalling through TLR9 is mediated mainly by IRF7 (Honda and Taniguchi 2006) and, as 
shown above, some modulation of its signalling capacity is observed by LMP2A. Given this 
and the previous data on IRF3 activation, it would be interesting to determine the effect on the 
secondary wave of IFNβ production, mediated through IRF3 and IRF7 heterodimers, and to 
analyse whether disruption of IRF3 activity is limited to the initial wave of response or if the 
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secondary wave is also affected. Characterisation of IRF7 activity was beyond the scope of this 
thesis but a more robust understanding of LMP2A’s effect on this transcription factor would 
yield further understanding into the viral protein’s mode of action. It should be noted however 
that while it is hypothesised that attenuation of IRF3 binding is the main contributing factor to 
decreases in IFNβ production, IRF7 also binds to PRDI domains and this may also contribute 
to the observed modulation specifically during secondary waves of response. 
 
The issue of NFκB “priming” was surprising given the extent of the attenuation of TLR-3 and 
TLR-4 driven IFNβ production by LMP2A. Although overall p65 binding is increased in cells 
expressing LMP2A, borne out by concomitant increases in NFκB controlled cytokine secretion 
(e.g. IL-6 and IL-8), p65 binding at the IFNβ promoter PRDII domain is reduced in LMP2A 
expressing cells. It is hypothesised that the observed decreases in binding at this domain are the 
result of disruption of enhancesome formation and not decreases in p65/RelA activity. The 
priming of NFκB activity remains the most surprising and one of the more interesting aspects 
of the above results. It appears that LMP2A must be acting to both repress the activity of 
certain TLR signalling cascades whilst initiating or promoting others. Although speculative, 
this could be due to the recruitment of TLR signalling components by the amino-terminal 
domains of LMP2A resulting in a constitutive activation of the NFκΒ. Co-
immunoprecipitation experiments and co-localisation studies could elucidate whether this is 
the case.  It is also necessary to further expand these studies to consider the role of the TRAF 
proteins (TRAF3/6) in these effects. A more in depth analyses of intermediates involved in this 
pathway and how their function is altered in the presence of LMP2A is necessary to confirm 
this. Preliminary data suggests that IκBα degradation is increased in LMP2A expressing cells 
compared to control and LMP2B expressing counterparts stimulated for TLR3 and TLR4 and 
treated with cycloheximide, an inhibitor of de novo protein synthesis (data not shown). 
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Putting the findings of LMP2A in a physiological context, data presented here shows that 
EBER1/2 were able to activate IFNβ production and that LMP2A could attenuate this 
response. In the context of a viral infection this highlights an important mechanism by which 
EBER1/2 can exert its effects on tumour progression (Wu, Maro et al. 2007) with other viral 
gene products, such as LMP2A limiting anti-viral responses. It would be interesting to observe 
the effect of EBER1/2 expression in the presence of LMP2A on NFκB activity. A more robust 
cell line model is being developed where both the EBERs and LMP2A expression are 
expressed stably thus allowing more in depth analysis of this effect. It is thought that this 
would illuminate the exact nature of the interplay of expression of these viral gene products 
and aid understanding of epithelial cells with latent EBV infection. 
 
Experimentally there are many avenues worth exploring to advance the findings presented 
here. Key experiments have been performed in another epithelial cell line, H103, to ensure that 
the data is not cell type specific, and these results match those from the CNE-2 cell panel as 
shown above. Preliminary EMSAs for the PRDI and PRDII domains in this cell line match the 
CNE-2 results, indicating that LMP2A expression can also modulate IRF3 binding in this 
epithelial cell background. As mentioned above, to examine the possibility that LMP2A 
inhibits the formation of the IFNβ enhancesome, EMSAs should be performed on the PRDIII 
domain of the IFNβ promoter, as this is reported to be an important additional binding site for 
IRF3 homodimers and IRF3:IRF7 heterodimers. Analysis of the effect of LMP2A on the 
CBP/p300 (Yoneyama, Suhara et al. 1998) protein would also illuminate this result more 
clearly. Throughout these experiments stimulation of TLR3 with poly(I:C) was performed by 
transfecting the agonist into cells of interest in order to eliminate activation of response from 
the cytosolic PRRs, RIG-I and Mda5. Examination of IFNβ production upon stimulation of 
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these receptors would define whether attenuation of IRF3 activity is the sole reason for the 
LMP2A induced decreases in IFNβ, or if LMP2A is also acting further upstream in this 
signalling cascade to interfere with signalling, possibly at the level of the TRIF adaptor protein. 
Such an experiment would also define the role of the localisation of LMP2A on internal 
membranes in this process.   
 
Overall, data presented here clearly show that LMP2A modulates the expression and function 
of a broad range of TLRs in epithelial cells. These data account in part for the attenuation of 
type I responses previously reported (Shah, Stewart et al. 2009) whilst highlighting important 
differences between LMP2A and LMP2B. Further analysis is required to pinpoint exact 
mechanisms for the observed modulation and to further understand the total contribution of this 
to disease progression. One further avenue of exploration involves the effects of LMP2A and 
LMP2B on LMP1 signalling. LMP1 utilises components of the IL1R/TLR signalling pathway 
to activate NFκB. LMP2A may inhibit or modulate LMP1 signalling whereas LMP2B may 
not. Physiological relevance is also attributed to these results in the context of the interplay of 
viral gene products during EBV latency and also in terms of cytokine secretion into the extra-
cellular milieu.  
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  CHAPTER 5 
Modulation of the endosomal trafficking network by the LMP2A and LMP2B 
proteins. 
 
5.1 Introduction 
 
The endosomal/lysosomal network, as described in detail in Chapter 1, Section 1.9, is a series 
of interconnected intracellular vesicles that function to transduce signals from cell surface 
receptors or membrane-associated proteins. This system controls important aspects of the 
signalling response, regulating receptor internalisation, receptor signalling, receptor recycling 
and/or degradation. Many viruses express proteins that high-jack this pathway to modulate 
signalling, both positively and negatively, from membrane proteins involved in growth factor 
responses and immune modulation. As part of a strategy to limit host cell responses, many 
viruses target IFNRs, TLRs or MHC molecules to limit the actions of interferon and thereby 
facilitate immune evasion. Here, the role of the LMP2A and LMP2B proteins has been 
investigated in this context and their ability to disrupt endosomal trafficking and receptor 
turnover examined. Dysregulation of this interconnected vesicular transport system by LMP2A 
and LMP2B may play an important role in maintaining latent EBV infection of epithelial cells. 
This function may facilitate host immune recognition of EBV infected cells, thereby 
inadvertently promoting viral-mediated tumourigensis (Pegtel, Subramanian et al. 2005). 
 
Findings presented here show that LMP2A and LMP2B disrupt normal endosome trafficking 
in epithelial cells, an effect that may enhance the transport of IFN and TLR receptors from the 
cell surface to the lysosome for degradation. Previous studies in this laboratory have shown 
that LMP2A and LMP2B promote degradation of internalised IFN receptors thereby 
abrogating full IFNR signalling responses (Shah, Stewart et al. 2009). Previous reports have 
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mainly focused on the function of LMP2A in B-cells and its role in attenuating signalling from 
the BCR. In the case of epithelial cells, LMP2A attenuates signalling networks that engage 
NFκB, STAT3 (Stewart, Dawson et al. 2004), whilst stimulating the Wnt/β-Catenin (Morrison, 
Klingelhutz et al. 2003) and ERK/MAPK signalling pathways (Allen, Young et al. 2005). 
LMP2A has previously been shown to alter trafficking and antigen processing in B-cells 
through its ability to block phosphatidylcholine-specific phospholipase D (PLD) activity 
(Snyder and Pierce 2006), an enzyme that has been implicated in vesicular trafficking 
(McDermott, Wakelam et al. 2004). These data however focus not on LMP2A-specific effects, 
which require the amino-terminal signalling domain, but rather on effects that are common to 
both LMP2A and LMP2B. 
 
Vesicular trafficking encompasses many different pathways and processes, including secretion 
of newly synthesised protein from the golgi network, extracellular secretion of cytokines and 
chemokines, autophagy, antigen presentation and processing, protein degradation and receptor 
signalling. The overall network is vast, dynamic and intricately controlled by a variety of 
proteins, e.g. the Rab small GTPases and phospholipids. This study has focused on one section 
of this network, namely the internalisation of receptors into early endosomes and their 
trafficking from these compartments to the lysosome for degradation.  
 
Briefly, activated receptors are endocytosed, along with additional membrane bound factors in 
a clathrin/Rab5-mediated manner. These internalised vesicles then fuse with early endosomes 
and the receptor and endocytosed membrane form part of the internal membrane. Endosomal 
movement continues and the internalised molecules are transported to Rab7 positive late 
endosomes and finally to the lysosome, were proteins are degraded by acid hydrolysis. Prior to 
this, receptor recycling can occur through Rab4 and Rab11 associated endosomes (Zerial and 
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McBride 2001; Deneka, Neeft et al. 2003; McDermott, Wakelam et al. 2004; Hirota, Kuronita 
et al. 2007).  
   
To investigate whether LMP2A and LMP2B influence receptor internalisation and turnover 
through modulation of the endosomal/lysosomal network, the integrity and activity of these 
networks was examined in more detail. This involved characterising these pathways in the 
CNE-2, H103 and H157 cell lines by comparing the expression of proteins integral to the 
correct functioning of the pathway. Increases in the levels of both early and late effectors of the 
pathway and of markers of early and late endosome/lysosomal compartments indicated that the 
effects were “global”, with both viral proteins affecting all stages of the trafficking network. 
However, it is important to note that the LMP2 proteins are almost exclusively localised to the 
trans-golgi network (Lynch, Zimmerman et al. 2002) and, as assessed by immunofluorescence 
staining, co-localise with EEA1 and Rab5, to early endosomes, but not to acidified late 
endosomes or lysosomes. The effects of LMP2A and LMP2B on these compartments involve 
both an increase in the number of late endosomes/lysosomes and an increase in their 
degradative properties. Whether LMP2 acts to directly increase the levels of late compartments 
or whether by increasing levels of Rab5 and indeed Rab5 activity, increased Rab5 to Rab7 
conversion occurs, thus facilitating membrane changes sufficient for lysosome formation, 
remains to be determined. Results discussed below allude to a mechanism that involves both 
increases in these conversion events and also interference by LMP2 at later stages of the 
trafficking network.   
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5.2  Profiling components of the endosomal/lysosomal network in LMP2A and LMP2B 
expressing cells. 
5.2.1 Immunoblotting  
To investigate whether expression of LMP2A and LMP2B influence the levels of protein 
components of the endosomal/lysosomal network, immunoblotting was performed on control, 
LMP2A and LMP2B expressing CNE-2 and H103 cells (as described in section 2.5), using 
antibodies specific for Rab5, Rab7, CD63 and Ductin (a component of the V-ATPase 
complex). Results from a representative experiment are shown in Figure 5.1. Reprobing of the 
blots with a mAb to β-actin served as a loading control.  
 
Rab5 is a well-characterised small GTPase that has defined functions in the biogenesis of early 
endosomes, endocytic vesicles and a role in endosomal trafficking (Woodman 2000; Mousavi, 
Malerod et al. 2004). Rab7 is another GTPase that is most associated with late endosomes 
(Bucci, Thomsen et al. 2000), and has been shown to be responsible for deciding the fate of 
certain classes of receptors, including growth factor receptors (Saxena, Bucci et al. 2005), and 
those involved in immune surveillance (Wang, Chen et al. 2007). CD63 is a member of the 
tetraspanin superfamily and is associated with acidified lysosomes (Metzelaar, Wijngaard et al. 
1991) and, although this localisation is well defined, its role in endosomal traffic remains to be 
fully elucidated. It is thought however that it acts in tandem with the Vacuolar ATPase 
machinery in the process of lysosomal acidification (Forgac 2007), of which the 16kd protein, 
Ductin is a key component.  Results presented in Figure 5.1, show that the expression of all 
proteins analysed is increased in cells expressing LMP2A or LMP2B relative to control cells. 
The larger more diffuse bands for CD63 are likely to result from protein glycosylation. These 
increases are indicative of an increased level of intracellular compartments and vesicles, an 
increase, which is not restricted to a particular stage of the network but rather a global 
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upregulation of the endosomal – lysosomal pathway. Given their roles in lysosomal 
acidification, the increased levels of Ductin and CD63 provide further evidence for the 
hypothesis that expression of LMP2A and LMP2B results in increased intracellular traffic, 
which may act to turnover and inactivate immune receptors through lysosomal degradation in 
acidified compartments.  
 
5.2.2 Immunfluoresence staining for endosomal/lysosomal proteins. 
To further examine the extent of the increase in endosome/lysosme compartments in LMP2A 
and LMP2B expressing CNE2 cells, immunofluorescence staining was performed for the early 
endosome markers Rab5 and EEA1, and a protein associated with the lysosomal membrane, 
lysosome associated membrane protein 1 (LAMP1). Cells of interest were fixed and 
permeabilised as described in section 2.4 and probed with antibodies specific for Rab5 and 
EEA1. Figure 5.2 shows representative confocal images for Rab5, EEA1 and LAMP1 after 
staining with selected mAbs and human serum, SK, used to detect LMP2A and LMP2B. In 
agreement with the immunoblotting data, levels of Rab5 were increased in cells expressing 
LMP2A and LMP2B compared to control cells. Levels of the second early endosome marker 
EEA1, which is associated with Rab5 on the membrane of the early endosome compartment 
and has been characterised as the first effector of Rab5 GTPase activity (Christoforidis, 
McBride et al. 1999), were also markedly upregulated. Staining for LAMP1, a highly 
glycosylated membrane bound protein with one spanning domain and a luminal N-terminal 
shown to be involved in tumour metastasis (Eskelinen, Tanaka et al. 2003), revealed an 
upregulation in cells expressing LMP2A and LMP2B. Taken together with findings from 
immunoblotting, it is likely that LMP2A and LMP2B expression results in the increase in 
formation of at least two intracellular compartments in epithelial cells.  
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Figure 5.1 Immunoblotting for proteins associated with endosomal trafficking 
components. 
 
Protein lysates were extracted from CNE-2 and H103 cells expressing either a Neomycin 
resistance cassette, full length LMP2A or LMP2B. Immunoblotting was then performed for 
markers of endosomal traffic using antibodies specific to the early endosome/endocytic vesicle 
marker Rab5, the late endosome/lysosome marker Rab7, the lysosome-associated protein 
CD63 and the 16kD V-ATPase component, Ductin. β-actin was used as a loading control. 
Representative scans of the immunoblots are shown, in which it can clearly be seen that in cells 
expressing LMP2A or LMP2B, in both cell types, expression of all proteins examined is 
increased when compared with neomycin controls. The bands for the CD63 are more diffuse 
compared with the others due to protein glycosylation.  
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Figure 5.2 Immunofluorescent staining for markers of endosomal compartments. 
 
CNE-2 cells expressing either a control neomycin resistance cassette, full length LMP2A of 
LMP2B were seeded at a density of 2 x 104 on to 12-well microdot Teflon coated slides and 
placed into a 37˚C incubator with 5% CO2 overnight to allow cell adherence. The following 
day immunofluorescent staining was performed for, the early endosome protein, Early 
Endosome Antigen 1 (EEA1), the early endosome/endocytic vesicle associate Rab protein, 
Rab5, the lysosome associated protein, Lysosome associated membrane protein 1 (LAMP1), 
and finally the human serum SK was used to detect LMP2 expression. Representative confocal 
images are shown of each cell type with each antibody. Comparing the signals observed 
between control and LMP2 expressing cells, it can be seen that levels of each of the markers 
examined are increased with LMP2 expression. Differential subcellular location is also 
observable between each antibody demarcating the varying localisations of each of the 
markers.      
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5.3 Co-localisation of Rab5 and EEA1 in CNE-2 cells 
To ascertain whether the increase in Rab5 expression was linked to increases in the numbers of 
early endosomes or whether expression at additional intracellular locations distinct from EEA1 
positive membranes was also altered, co-staining for EEA1 and Rab5 was performed. Rab5 is 
associated with endocytic vesicles (Mousavi, Malerod et al. 2004), where it has been shown to 
control the level of clathrin-mediated endocytosis. While EEA1 is not found at these sites, it 
has been shown to interact with Rab5 in the early endosome and this interaction occurs upon 
fusion of Rab5 positive vesicles, serving to activate Rab5 GTPase activity (Woodman 2000). 
Thus co-staining facilitated investigation of the effect of LMP2A and LMP2B expression on 
the levels of Rab5 positive endocytic vesicles. Control, LMP2A and LMP2B expressing CNE2 
cells were subjected to immunofluorescence staining after fixation and permeabilisation using 
mAbs specific for Rab5 and EEA1, as described in section 2.4. Figure 5.3 shows confocal 
images of representative immunofluorescence staining. Comparing LMP2A and LMP2B 
expressing cells with control cells it is clear that the number of early endosomes, identified by 
the markers EEA1 and Rab5, is markedly increased in cells expressing LMP2A and LMP2B. 
As predicted a high degree of co-localisation was observed between EEA1 and Rab5. 
However, Rab5 expression was also observed in small punctate clusters that are EEA1 
negative, this corroborates the published data discussed previously, reporting that Rab5 is also 
localised to endocytic and trafficking vesicles. Although this increase in endosomal marker 
expression has been described above, the immunofluorescence staining also indicates an 
increase in smaller Rab5 vesicles, which have been shown to be responsible in mediating both 
the early events of endocytosis and later events in endosomal-lysosomal trafficking. 
Augmentation of endocytosis by Rab5 positive vesicles is likely to account, at least in part, for 
the reduction of signalling from certain classes of immunoreceptors in LMP2A and LMP2B 
expressing cells as previously reported (Shah, Stewart et al. 2009). 
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Figure 5.3  Immunofluorescent co-staining for early endosome associated proteins EEA1 
and Rab5 in the CNE-2 cell panel. 
 
CNE-2 cells expressing either a control neomycin resistance cassette, full length LMP2A of 
LMP2B were seeded at a density of 2 x 104 on to 12-well microdot Teflon coated slides and 
placed into a 37˚C incubator with 5% CO2 overnight to allow cell adherence. The following 
day immunofluorescent co-staining was performed for; the early endosome protein, Early 
Endosome Antigen 1 (EEA1) and the early endosome/endocytic vesicle associate Rab protein, 
Rab5. Representative confocal images are shown. Comparing the signals observed between 
control and LMP2 expressing cells, it can be seen that levels of each of the markers examined 
are increased with LMP2 expression. In tandem with this, although a high degree of co-
localisation is observed between each of the markers, Rab5 expression can also be observed in 
subcellular locations that are EEA1 negative, indicative of Rab5’s association with endocytic 
vesicles.  
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5.4 LMP2 expression on internal membranes: co-localisation with early endosomes  
When expressed in epithelial cells, LMP2A and LMP2B localise to internal perinuclear 
membranes, which constitute part of the endosome network (Dawson et al., 2001). To examine 
if LMP2A and LMP2B localise to the early endosome, which could account for the observed 
increase in the number of early endosomes, double immunofluorescence staining was 
performed for the endosome markers (EEA1, Rab5) and LMP2A or LMP2B. As described 
above CNE-2 cells stably expressing either LMP2A or LMP2B have increased levels of EEA1 
and Rab5, as assessed by immunoblotting and immunofluorescence staining, compared to 
control cells. Although the SK or Bala human sera could have been used to detect LMP2A and 
LMP2B in the CNE-2 cell panel, these sera may inhibit full and correct binding of other 
antibodies to epitopes on LMP2-associated proteins. However, the H103 and H157 cell panel 
have, as previously described, section 2.1, have been transduced with recombinant retrovirues 
to express HA-tagged versions of full length LMP2A or LMP2B. This HA-tagged epitope 
allows efficient detection of both proteins by immunofluorescence with minimal interference 
such as might be observed with polyclonal human sera. Cells grown in situ were fixed and 
permeabilised, as described in section 2.4, and probed with either antibodies specific for Rab5, 
EEA1 and the HA-tagged-epitope.  
 
Figures 5.4(A, B), show representative confocal images of double immunofluorescence 
staining. In agreement with the immunoblotting data in H103 cells, Figure 5.1, and mirroring 
findings from the immunofluoresence staining of the CNE-2 cell panel, Figure 5.2, Rab5 
expression in H103 and H157 cells expressing LMP2A and LMP2B was markedly increased 
compared to control cells. HA staining was visible as punctate peri-nuclear aggregates that 
were also positive for Rab5. However, expression of Rab5 was not limited to LMP2-positive 
vesicles and was also observed in smaller clusters nearer the plasma membrane, which are 
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believed to be endocytic vesicles. LMP2A and LMP2B therefore appeared to co-localise with 
Rab5 on early endosomes but not on vesicles closely localising with the plasma membrane. 
Figures 5.5A, B, show that EEA1 positive vesicles are also markedly up-regulated in cells 
expressing LMP2A and LMP2B compared with control cells in both the H103 and H157 cell 
lines. Extensive co-localisation is also observed between EEA1 and both LMP2A and LMP2B.  
 
5.5  LMP2A and LMP2B increase the numbers of lysosomes: live-cell imaging 
Although increases in protein levels of Ductin and CD63, Figure 5.1, by LMP2A and LMP2B 
indicate increases in acidification of a proportion of lysosomes, and immunofluorescent 
staining for LAMP1 revealed significant augmentation of this protein in LMP2A and LMP2B 
expressing cells, further investigation was necessary to fully elucidate LMP2’s effect on the 
these compartments. LysoTracker™ Red is a commercially available dye that identifies 
lysosomes in mammalian cells. Incubating living cells with the dye for up to two hours 
facilitates dye uptake for subsequent detection by fluorescent microscopy. The immunoblotting 
and immunofluorescent staining described above suggest that in tandem with an increase in 
numbers of early endosomes there is also an upregulation of acidified lysosomes in LMP2A 
and LMP2B expressing cells.  
 
To further analyse this, live cell confocal imaging was performed on the CNE-2, H103 and 
H157 epithelial cell panels, expressing full length LMP2A, LMP2B or control cells expressing 
a neomycin resistance cassette. Cells were seeded at a density of 2.5 x 104 onto each well of a 
glass bottomed 24-well microscopy plate, (MatTek©) and allowed to adhere overnight at 37°C 
and 5% C02. Serum free medium containing 150nM LysoTracker™ was added to each well 
incubated for 2 hours at 37oC and subsequently analysed using live cell confocal imaging. 
Representative images of a typical analysis are shown in Figure 5.6. In all cell lines examined 
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perinuclear aggregates of the dye were observed in control cells after 2 hours incubation. 
Comparing this with cells expressing LMP2A and LMP2B, it is clear that the number of 
lysosomal compartments was elevated in the presence of LMP2A and LMP2B. The 
distribution of lysosomes also appeared to be altered in LMP2A and LMP2B expressing cells, 
where they are spread throughout the cytosol in comparison to a more clustered localisation at 
one end of the nuclear compartment in control cells. Live cell imaging, rather than fixed 
staining allows analysis of samples without influencing the intracellular trafficking of vesicles. 
This allows for the fluid, dynamic nature of intracellular trafficking to be considered and 
observations of the same cells can be made over a period of time rather than a single snapshot. 
This method also ensures that the increased signal observed is not a result of build-up of 
unbound dye due to increased Rab5-Clathrin endocytosis, as unbound dye would be 
exocytosed from the cell upon further incubation of cell samples following initial confocal 
analysis (data not shown).    
 
5.6  LMP2A and LMP2B do not localise to lysosomal compartments 
From findings presented in the previous section, it was clear that a proportion of LMP2A and 
LMP2B localise to EEA1/Rab5 positive early endosomes, whilst also stimulating the numbers 
of lysosomes. As the intracellular trafficking of endosomal vesicles is a dynamic process, it is 
possible that LMP2A and LMP2B could migrate to other internal membranes including 
lysosomal compartments. To assess whether there is a direct interaction between LMP2, the 
lysosome and components of the V-ATPase machinery, immunofluoresence staining was 
performed staining for LysoTracker™ and LMP2A and LMP2B, using SK serum and a HA-
specific mAb to identify LMP2A and LMP2B in the CNE2 and H103 or H157 cells lines 
respectively. Cells were seeded at a density of 1 x 104 onto each well of a 12-well teflon coated 
microdot slide and incubated overnight at 37°C and 5% C02 to allow cellular adherence. The 
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following day the growth media was removed and replaced with serum free media containing 
150nM LysoTracker™ and incubated for 2 hours at 37oC. Cells were then fixed and 
permeabilised, using Acteone/Methanol to prevent disruption of LysoTracker™’s affinity for 
lysosomal compartments, as described in section 2.4. Samples were then probed with a mAb 
specific for the HA-tag or the SK serum to identify the localisation of LMP2A and LMP2B. 
Incubating the cells prior to fixation allows the dye to be taken into the cell and minimises 
signal interference by either addition of primary antibodies or the fixation procedure. 
 
 A representative analysis, shown in Figure 5.7(A), confirmed an increase in the number of 
lysosomes in LMP2A and LMP2B expressing cells. However, a significant level of co-
localisation between LMP2A and LMP2B and the lysosomes was not observed, indicating that 
these proteins do not associate with the lysosomal compartment but rather increase their 
number through interacting with components at an earlier stage in the endosomal-lysosomal 
network. Essentially identical results were obtained in H103 cells, Figure 5.7(B), and H157 
cells, Figure 5.7(C). These representative images show an increase in lysosome numbers and 
no significant level of colocalisation with LMP2A or LMP2B, as assessed by 
immunofluoresence staining using the HA-tag as a marker for LMP2A or LMP2B. Taking into 
consideration the degree of colocalisation between early endosome components and LMP2A 
and LMP2B, across all cell lines, it is hypothesised that LMP2A and LMP2B localise to 
endosomal-like compartments and that this interferes with normal trafficking mechanics, 
disrupting the correct sorting of membranes and their bound proteins to target these for 
degradation in the lysosome.   
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Figure 5.4  Immunofluorescent co-staining of Rab5 and LMP2 in the H103 and H157 cell 
panels.  
 
Cell panels were seeded at a density of 2 x 104 on to the wells of 12-well microdot Teflon 
coated slides and placed into a 37˚C incubator with 5% CO2 overnight to allow cell adherence. 
The following day immunofluorescent co-staining was performed for the early 
endosome/endocytic vesicle associated Rab protein, Rab5 and LMP2 using an antibody 
specific for Rab5 and a second antibody specific for the HA-tag of the LMP2 protein. 
Representative confocal images are shown of, (A) the H103 cell panel and (B) the H157 cell 
panel. Comparing the signals observed between control and LMP2 expressing cells in both (A) 
and (B), it can be seen that levels of Rab5 are increased with LMP2 expression in agreement 
with the images in Figure 5.2. Rab5 expression is observed as punctate clusters throughout the 
cytoplasm with some co-localisation with the LMP2 HA-tag signal.  
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Figure 5.5  Immunofluorescent co-staining of EEA1 and LMP2 in the H103 and H157 cell 
panels.  
      
Cell panels were seeded at a density of 2 x 104 on to the wells of 12-well microdot Teflon 
coated slides and placed into a 37˚C incubator with 5% CO2 overnight to allow cell adherence. 
The following day immunofluorescent co-staining was performed for the early endosome 
associated protein, EEA1 and LMP2 using an antibody specific for EEA1 and a second 
antibody specific for the HA-tag of the LMP2 protein. Representative confocal images are 
shown of, (A) the H103 cell panel and (B) the H157 cell panel. Comparing the signals 
observed between control and LMP2 expressing cells in both (A) and (B), it can be seen that 
levels of EEA1 are increased with LMP2 expression in agreement with the images in Figure 
5.2. EEA1 expression has a high degree of co-localisation with the HA-tag, demonstrating 
expression of LMP2 on the membrane of early endosomes.  
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Figure 5.6  Live-cell fluorescent imaging of lysosomes in the CNE-2, H103 and H157 cell 
panels.  
 
Cells panels were seeded at a density of 2.5 x 104 cells, onto wells of a 24-well uncoated, 
0.13mm, 13mm diameter glass bottomed plate and placed into a 37˚C incubator with 5% CO2 
overnight to allow cell adherence. Upon treatment with LysoTracker™ cells were 
photographed using live confocal microscopy. Representative images of each cell panel are 
shown. Across all cell types, comparing between control and LMP2 expressing cells it is 
observed that the number of lysosomes is increased with LMP2 expression. Distribution of 
lysosomal compartments is also altered in LMP2 positive cells, where signals are detected 
throughout the cytoplasm rather than in distinct peri-nuclear clusters. 
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Figure 5.7  Immunofluorescent co-staining of lysosomes and LMP2 in the CNE-2, H103 
and H157 cell panels.  
 
Cell panels, (A) CNE-2, (B) H103 and (C) H157, were seeded at a density of 2 x 104 on to the 
wells of 12-well microdot Teflon coated slides and placed into a 37˚C incubator with 5% CO2 
overnight to allow cell adherence. LysoTracker™ treatment was performed prior to fixation 
and permeabilisation of samples. Immunofluorescent staining was then performed using the 
SK human serum in (A) the CNE-2 cell panel or an antibody specific for the HA-tag in (B) 
H103 and (C) H157 cell panels to detect LMP2 expression. Increased numbers of lysosomes 
are observed in LMP2 expressing cells when compared with controls, across all cell types, in 
agreement with images from, Figure 5.6, and LMP2 expression is detected in the relevant 
cells. No significant co-localisation is observed between lysosomes and LMP2 indicating that 
LMP2 is not expressed in the membrane of this compartment. 
 
 
 
 
 
 
 
 
 
 
 
 
 260
CTRL
LMP2A
LMP2B
SK LysoTracker™                 Overlay
(A) CNE-2
10µm
10µm
10µm10µm
10µm
10µm
10µm
10µm
10µm
(B) H103
LysoTrackerTM HA-Tag                        Overlay
CTRL
LMP2A
LMP2B
10µm
10µm
10µm10µm
10µm
10µm
10µm
10µm
10µm
(C) H157
LysoTrackerTM HA-Tag                        Overlay
CTRL
LMP2A
LMP2B
10µm
10µm
10µm10µm
10µm
10µm
10µm
10µm
10µm
Chapter 5  Results 
 
5.7  Lysosome acidification and trafficking is altered by LMP2 expression
The above results show that the number of lysosomes is increased in cells expressing LMP2A 
and LMP2B and, given this, the immunoblotting results described in section 5.2.1, showing 
significant increases in the levels of CD63 and Ductin expression in LMP2A and LMP2B 
expressing cells is not surprising. To ascribe some functional significance to these observations 
it was necessary to investigate any effects on endosome acidification to determine whether 
LMP2A and LMP2B influence the kinetics of endosome acidification. An increase in the 
number of lysosomes, is suggestive of an intracellular trafficking network that has the potential 
to degrade receptors and endocytosed membrane proteins more effectively. To address this 
issue, LysoSensor ™ a commercially available dye (Invitrogen) was used to qualitatively 
measure the acidity of endosome and lysosomal compartments in LMP2A and LMP2B 
expressing cells relative to control cells. Unlike Lysotracker™, the signal intensity generated 
using Lysosensor™ is pH sensitive, with the extent of emission proportional to endosome pH; 
a decreasing pH results in stronger emission as read by the confocal microscope an viewed as a 
blue fluorescent signal.  
 
The CNE-2, H103 and H157 cell panels were incubated with LysoTracker™ as described in 
section 2.4 and, following confocal microscopic analysis to ensure that the lysosomes had been 
stained correctly, medium removed and replaced with serum free medium containing 1µM 
LysoSensor™. Time-capture laser scanning was then used to monitor the movement of the 
LysoSensor™ through the cell and to measure the signal emitted upon reaching the lysosome. 
Due to the increased numbers of lysosomes it was expected that the signal observed in LMP2A 
and LMP2B expressing cells would be greater compared to control cells, which was the case. 
Representative images from a typical analysis, taken 5 minutes and 15 minutes post incubation 
with the dye are shown in Figure 5.8(A, B, C). Here, an increase in lysosome number is 
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observed and thus a proportional increase in the occurrence of an acidified signal, what is most 
interesting to note however, is that the signal observed in control cells compared with LMP2A 
and LMP2B expressing cells was much stronger indicating an increase in acidification of these 
lysosomes. LMP2A and LMP2B appear to increase the number of lysosomes within the cell, 
by a mechanism that is independent of a direct LMP2:lysosome interaction, while also 
increasing the acidity of these lysosomes, compared with control cells.  
 
The increase in numbers of endosomes observed in response to LMP2A and LMP2B 
expression would increase the total amounts of internalised endosomal membranes, which 
require processing, either by degradation or through recycling to the plasma membrane. The 
concomitant increase in lysosomes could therefore be a result of LMP2 interaction with early 
endosomes. Further investigation is necessary to fully understand the exact mechanism of this 
modulation and what effects this has on the signalling capacity of affected cells.   
 
5.8  Effect of truncated forms of LMP2 on lysosome number 
The modulation of endosomal trafficking observed in LMP2A and LMP2B expressing cells is 
a feature common to both proteins. Given the lack of an N terminal signalling domain in the 
LMP2B protein, the transmembrane domains of the proteins are likely to contain the protein 
motifs, which dictate these functions. These membrane loops are responsible for the protein’s 
subcellular localisation on internal membranes and it is this tethering to membranes, which is 
postulated to facilitate LMP2’s disruption of endosomal traffic. To further investigate this and 
to characterise which domains of the protein are necessary for binding, the LMP2-Loop deleted 
mutants, chapter 3, were used. A similar study using mutant forms of the LMP2 protein (Rowe 
and Tomaszewski-Flick 2007) has shown that the regions preceding the fourth loop are 
responsible for membrane binding. This would suggest that expression of LMP2 mutant 
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proteins that express only the latter transmembrane domains of the protein would not display 
such modulation of intracellular traffic.  
 
CNE-2, H103 and H157 cells were transiently transfected with one of the following plasmids: 
pSG5, pSG5 LMP2A-HA-tag, pSG5 LMP2B-HA-tag, pLenti6 LMP2-L1Del, pLenti6 LMP2-
L3Del, pLenti6 LMP2-L4Del, pLenti6 LMP2-L5Del and pLenti6 LMP2-L6Del. 48 hours post-
transfection, cells were seeded onto each well of a 12-well teflon coated microdot slide and, 
following overnight incubation, treated for 2 hours with serum free media containing 150nM 
LysoTracker™, as described in section 2.4. Expression of LMP2A, LMP2B or mutant LMP2B 
proteins was visualised after probing with an antibody specific for the HA-tagged epitope and 
photographed on a Zeiss LSM 510Meta confocal microscope. Representative images of the 
staining are shown in Figures 5.9(A-F). 
 
Transient expression of full length, HA-tagged LMP2A and LMP2B for 72 hours resulted in 
increased numbers of lysosomes compared to cells transfected with the empty vector control 
plasmid, pSG5, in all cell types. In agreement with the co-staining performed with cells stably 
expressing LMP2A and LMP2B no significant overlap was observed between LMP2A and 
LMP2B and the LysoTracker™ positive signals; however, a degree of colocalisation was 
observed in the transient setting when compared with stable expression. This disparity may 
occur as a result of over-expression of the protein upon transient transfection and the degree of 
colocalisation may be diminished upon establishment of more stable expression. 
 
Cells transiently expressing the mutant forms of LMP2 deleted for domains up to and including 
transmembrane loop one, those expressing LMP2 deleted past transmembrane loop three and to 
a lesser extent those expressing LMP2 truncated beyond the fourth transmembrane loop, panels 
 266
Chapter 5  Results 
 
(v), (vi) and (vii) respectively, showed increased numbers of lysosomes when compared to null 
transfected controls, while maintaining a positive signal for the HA-tag, indicating expression 
of the indicated LMP2B deletion mutant. The HA-tag appeared to be lost from those cells 
expressing the two remaining truncated forms of LMP2, Loop5-deleted and Loop-6 deleted, 
panels (viii) and (ix). This may indicate a loss of membrane association and turnover of these 
proteins due to instability. The lack of a HA-staining is concomitant with a reduction in the 
number of lysosomes, indicated by a weaker LysoTracker™ signal, to levels comparable with 
null transfected controls, (i) and (ii).  
 
Here it is clear that even in a transient system, expression of LMP2A or LMP2B or truncated 
versions of LMP2, which include at least the fourth transmembrane domain, for 72 hours, is 
sufficient to augment formation of lysosomal compartments. It must also be noted that this is a 
novel finding, which for the first time puts forward a direct effect of LMP2B expression that 
mirrors the effect of LMP2A without acting as an antagonist or rheostat. The data also 
underpins the importance of the trans-membrane domains of both proteins and reveals this 
protein structure as a mediator of intracellular signalling.  
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Figure 5.8 Live-cell fluorescent imaging of acidified lysosomes in the CNE-2, H103 and 
H157 cell panels.  
 
Cells panels, (A) CNE-2, (B) H103 and (C) H157, were seeded at a density of 2.5 x 104 cells, 
onto wells of a 24-well uncoated, 0.13mm, 13mm diameter glass bottomed plate and placed 
into a 37˚C incubator with 5% CO2 overnight to allow cell adherence. Upon treatment with 
LysoTracker™ and LysoSensor™ cells were photographed using live time-capture confocal 
microscopy. Representative images of each cell panel are shown at the 5 minute and 15 minute 
time-points. Across all cell types, comparing between control and LMP2 expressing cells it is 
observed that the number of lysosomes is increased in cells expressing LMP2 and in agreement 
with Figure 5.6, distribution of these compartments is also altered. Signals for LysoSensor™, 
which detects the degree of acidification of these compartments, are also increased in cells 
expressing LMP2, indicating increased acidity of these compartments. Magnified versions of 
these images, (D) CNE-2, (E) H103 and (F) H157, demonstrate that the signal strength of 
LysoSensor™ is increased in individual lysosomes between control and LMP2 expressing 
cells, indicating that the increased acidification signal is not only a result of increased numbers 
of lysosomes. Comparing the movement of these dyes through the cell by time-capture 
between control and LMP2 positive cells, it is demonstrated, albeit simply, that the speed of 
this traffic is increased in LMP2 expressing cells. Arrows indicate movement of a smaller 
vesicle to a larger more acidified compartment.  
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Figure 5.9  Immunofluorescent co-staining for LysoTracker™ and transiently expressed 
LMP2 variants in CNE-2, H103 and H157 cell panels. 
 
(A, B) CNE-2, (C, D) H103 and (E, F) H157 parental cells were seeded at a density of 2.5 x 
105  cells per well of a 6-well plate and incubated overnight at 37˚C and 5% CO2 to allow cell 
adherence. The following day the cells were transiently transfected with the recombinant 
lentiviral plasmids or relative controls and grown for 48 hours to allow expression. Transfected 
cells were then seeded at a density of 2 x 104 on to 12-well microdot Teflon coated slides and 
placed into a 37˚C incubator with 5% CO2 overnight to allow cell adherence. All samples were 
treated with LysoTracker™ prior to fixation and permeabilisation. Immunofluorescent staining 
was performed for LMP2 using an antibody specific for the HA-tag. Representative confocal 
images are shown. In panels (A), (C) and (E), it is demonstrated that transient expression of 
LMP2 is sufficient to cause an increase in numbers of lysosomes when compared with null 
transfected controls. Compared with images shown in Figure 5.7, there is greater co-
localisation of signals in the transient setting when compared to stably expressed LMP2. Panels 
(B), (D) and (F) show representative images of the effect of expression of the loop deleted 
forms of LMP2. Here it is demonstrated that while deletion of the transmembrane loops 1, 1-3 
and 1-4 of LMP2, does not impair LMP2’s ability to increase lysosomal number. Deletion 
beyond Loop 5 results in loss of membrane binding and stability of the protein and a 
concomitant return to lysosome number that is comparable with control levels. This loss of 
membrane binding is also observed in Chapter 3, Figure 3.8 
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5.9  Discussion and future work. 
While the novel findings presented here show that LMP2A and LMP2B alter the endosome-
lysosome trafficking network in epithelial cells, the mechanism(s) by which this is achieved 
are unclear, and the physiological consequences of these effects are unknown. However, taken 
as a more “global” examination, findings presented here show that both LMP2A and LMP2B 
increase the number of early endosomes and endocytic vesicles, an effect which could facilitate 
increased endocytosis of plasma membrane-bound material such as receptors or integral 
membrane proteins. In tandem with this, the numbers of late endosomes and degradative 
lysosomes and are also increased, perhaps indicating that these viral proteins influence the rate 
at which receptors or signalling proteins are targeted for degradation. An important finding is 
the discovery that LMP2A and LMP2B increase the kinetics of endosome acidification, an 
effect that may have an effect on the signalling properties of receptors and other membrane-
associated proteins. Protein studies on the mechanism of Rab5 have shown that EEs can fuse to 
late endosomes (LE) and acidic compartments (Rink, Ghigo et al. 2005). Concomitant 
increases in lysosome number given increased levels of Rab5 are therefore not surprising.  
 
Increases in both Rab5 and EEA1 could indicate an increased level of endosomal fusion and 
thus an increase in merging of early endosomes into their Rab7 positive late endosomal 
counterparts. This would add weight to the hypothesis that LMP2 expression on internal 
membranes increases kinetics of traffic in the cell, rather than creating a bottleneck, where the 
level of one compartment severely outnumbers others. However this explanation cannot 
account for increases in acidification of individual lysosomal compartments, as assessed by 
imaging with LysoSensor™. It is postulated that LMP2A and LMP2B expression somehow 
interferes with functioning of vacuolar ATPases and as such decreases compartment pH, as 
shown by increases in Ductin expression in LMP2A and LMP2B expressing cells.   
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Thus far, the functional significance of this dysregulation has not been fully assessed, although 
it is hypothesised that an increase in the number of acidified compartments or increased 
kinetics of endosome acidification could prevent cell signalling via increased turnover and 
degradation of receptors and contribute to a down-regulation of receptor signalling. Initiation 
of signalling from certain receptors occurs in intra-cellular compartments where adaptor 
molecules, ligands and receptors form complexes and activate signalling cascades. Disrupting 
the external membrane architecture of these compartments, distorting the usual cellular ratios 
of compartment types and decreasing luminal pH would, in these cases, have detrimental 
effects on signalling networks. How LMP2A and LMP2B regulate this mechanism and the 
extent of this effect on receptors are as yet unknown. As localisation of the LMP2 proteins to 
internal membranes is integral to these processes, further analysis of stable expression of 
truncated forms of LMP2 on compartmental acidification will aid further understanding of the 
mechanism by which LMP2A and LMP2B exert these effects. It is shown that loss of 
membrane tethering through serial deletion of LMP2’s transmembrane loops alleviates 
increases in lysosome number and it is expected to also alleviate decreases in pH.  
 
Experimentally, further investigating these data would involve characterising the exact 
interaction of LMP2 with components of the early endosome cell membrane and assessing its 
relationship with Rab5 activity. Pulse chase experiments using labelled, radio-labelled or 
otherwise, versions of receptors would enable more robust proof that internalisation through 
clathrin-Rab5 mediated endocytosis is increased in LMP2 positive cells. Immuno-precipitation 
for tagged versions of LMP2 would allow characterisation of interacting intermediates and 
would determine relationships between LMP2 and, Rabex5, EEA1 and Rabapatin 5, effectors 
of Rab5 activity. Rab7 interaction with LMP2 would be assessed in a similar manner, to 
determine if LMP2 facilitates conversion of endosomes, or whether the kiss-and-run 
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hypothesis of vesicular trafficking enables a Rab7: LMP2 interaction. Tracing the path of 
internalised receptors by large-scale time-capture confocal microscopy would facilitate 
determining the postulated degradative fate of these molecules while also ascertaining the 
effect of LMP2 expression on recycling Rab4/Rab11 positive endosomes. In order to extend 
these findings it may also be prudent to examine the parallel effects of the E5 protein of HPV. 
In a similar manner this protein alters the pH of the GA but does not affect V-ATPase activity 
(Ashby, Meagher et al. 2001; Marchetti, Ashrafi et al. 2006), it is likely that the LMP proteins 
may act in a similar manner.  
 
Taken together the above data demonstrate a definitive effect of LMP2A and LMP2B on the 
endosome-lysosome trafficking network; however, this work is very much in its infancy and 
further more specific investigation is necessary to tease out the exact nature of this modulation.  
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CHAPTER 6 
                           General Discussion and Future Perspectives 
The association of EBV with malignancies of both B-cells and epithelial cells is well 
documented. Although there is some level of understanding of the role the virus plays in the 
development and progression of these diseases, many of the effects of viral protein expression in 
both B-cell and epithelial cells remains to be elucidated. In B-cells, LMP2A acts as a surrogate 
BCR allowing B-cell maturation and survival, ensuring viral latency whilst preventing lytic 
reactivation (Swanson-Mungerson, Bultema et al. 2006; Wang, Nicholas et al. 2006). During B-
cell infection, the potentiation of a surrogate BCR signal by LMP2A affords the virus a 
mechanism of persistent latent infection while also engaging with other signalling cascades to 
promote cell survival and preventing programmed cell death (Caldwell, Wilson et al. 1998). The 
“non-signalling” LMP2B protein is thought to function as a rheostat, antagonising LMP2A’s 
ability to maintain viral latency (Rovedo and Longnecker 2007; Rechsteiner, Berger et al. 2008; 
Rechsteiner, Bernasconi et al. 2008). Little, if any, information is available regarding specific 
signalling capabilities of LMP2B in this cell type. The tenet of LMP2A and LMP2B’s 
contribution to immune evasion in B-cells has been examined, and while their function in this 
cell type is becoming clearer, their role in epithelial cells is less well defined (Miller, Lee et al. 
1994; Wang, Nicholas et al. 2006).  
Although LMP2A and LMP2B are expressed in almost all NPC cases, their 
contribution to this epithelial malignancy remains elusive (Brooks, Yao et al. 1992). It has been 
shown that expression of the viral protein can alter epithelial cell adhesion and motility (Allen, 
Young et al. 2005; Lu, Lin et al. 2006), inhibit differentiation, and promote anchorage-
independent growth, (Scholle, Bendt et al. 2000)) through engagement of the PI3-kinase/Akt and 
Wnt/β-catenin signalling pathways (Morrison, Klingelhutz et al. 2003; Fukada and Longnecker 
2004; Pang, Lin et al. 2009). In terms of epithelial malignancy the majority of research has 
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focused on LMP2A and the effect of its amino-terminal signalling domain on cell function. Few, 
if any studies have addressed the role of LMP2B in epithelial cells. 
This thesis can be divided into two distinct but linked areas of research. Findings 
presented in Chapter 4 demonstrate an LMP2A-specific effect on Toll-like receptor (TLR) 
signalling, effects that can be attributed to the amino-terminal signalling domain given the 
inability of LMP2B to influence signalling from TLR receptors. These analyses were undertaken 
as part of a study to further explore the effects of LMP2A and LMP2B on attenuation of the type 
I interferon signalling in epithelial cells (Shah, Stewart et al. 2009). This previous study 
demonstrated that modulation of the type I IFN signalling response did not require the amino-
terminal domain of LMP2A, but rather, required domains common to both the LMP2A and 
LMP2B proteins. Findings presented in Chapter 5 have attempted to analyse the effects of 
LMP2A and LMP2B on intracellular trafficking and modulation of the endosomal/lysosomal 
network, with a view to exploring the possibility that LMP2A and LMP2B influence the fate of 
internalised receptors through mechanism(s) involving endosome acidification. Findings 
presented here suggest that although this may be true for the IFNRs (Shah, Stewart et al. 2009), 
the effects of LMP2A on TLR signalling must occur through as yet unidentified mechanism(s).  
Viral evasion of the host’s immune response can be achieved through a number of 
mechanisms, as outlined in section 1.8, many of which involve modulation of the innate immune 
response and disruption of the induction of cellular interferons. The idea that LMP2A could 
contribute to such an effect came from the study of epithelial cells infected with a recombinant 
EBV deleted for LMP2A (Stewart, Dawson et al., 2004). Unlike wild-type infected epithelial 
cells, cells carrying an LMP2A-deleted form of EBV displayed increased basal expression of 
NF-κB, STAT3 and IRF7, an effect which resulted in expression of the major viral transforming 
gene, LMP1 (Stewart, Dawson et al. 2004). In tandem with this expression of LMP2A and to a 
lesser extent LMP2B revealed that these proteins could modulate IFN signalling directly in the 
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NPC-derived cell lines, Hone-1 and Ad/AH. The pathways involved in innate immunity that 
control creation of an anti-viral state are initially mediated by the Toll-like receptors. Analyses of 
TLR signalling described in Chapter 4 revealed that cells expressing LMP2A were almost 
refractory to TLR agonist activation of these responses, whilst LMP2B had little, if any effect on 
TLR signalling. These findings build upon the previous observations reported by Shah and 
colleagues and demonstrate that whilst both LMP2A and LMP2B are capable of limiting the 
actions of interferon, LMP2A alone is capable of modulating TLR signalling responses. 
Five TLRs are known to control viral induction of the type I interferon response: TLR 3, 
4, 7, 8 and 9; the remaining family members are involved in recognition of bacterial and fungal 
PAMPs (Kawai and Akira 2006). Findings presented in this study showed that LMP2A did not 
alter the signalling capabilities of the latter, suggesting that their effects were specific to viral and 
bacterial-encoded PAMPs. LMP2A did however have a profound effect on expression and 
signalling from TLR family members that mediate anti-viral immune responses. IFNβ 
production is a vital component of initialising an immune response to viral infection and its 
promoter activity was used as a read-out for the activation of these TLRs (Samuel 2001). In all 
cases, IFNβ promoter activity was attenuated in LMP2A expressing cells compared to their 
control and LMP2B expressing counterparts in response to TLR agonist stimulation. While 
indicative of a global dampening of TLR responses, differences in the extent and level of 
modulation by LMP2A were observed. These variations are attributable to the various signalling 
pathways and adaptor intermediates utilised by each TLR in the induction of type I interferon 
expression. The effect of LMP2A was most pronounced in the cases of TLR3 and TLR4, which 
can both signal via the TRIF-dependent pathway to activate IRF complexes (Honda and 
Taniguchi 2006). IRF3 in particular is important for signalling from these receptors and findings 
presented here demonstrate that its activity was attenuated by LMP2A. Although the exact 
mechanism(s) involved in this attenuation remains to be uncovered, it may likely involve 
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interference of LMP2A with either dimerisation or phosphorylation events, both of which 
facilitate activation and nuclear translocation. Examination of the phosphorylation of IRF3 is an 
important future perspective for continuation of this research and initial data demonstrate that 
upon stimulation of TLR3, the levels of phosphorylated IRF-3 are reduced in LMP2A expressing 
cells compared to control and LMP2B expressing counterparts.  
Activation of TLR3 signalling was performed using poly (I:C) delivery to endosomes by 
liposome-mediated delivery, which ensured minimal cross-activation of the IFNβ promoter by 
signalling through the RLHs. It is thought however, that signalling through these receptors would 
be modulated in a similar manner given the effect of LMP2A expression on the activity of IRF-3. 
Analysis of the effect of LMP2A on EBER function demonstrates this. EBERs have been shown 
to modulate innate immunity via binding to the PKR and preventing activation of the eIF-2a 
transcription factor, (Nanbo and Takada 2002); however, they can also initiate signalling through 
RIG-1 activation (Samanta, Iwakiri et al. 2006) and more recently through activation of TLR3 
(Iwakiri, Zhou et al. 2009). Transient expression of the EBERs resulted in a robust stimulation of 
IFNβ promoter activity in control and LMP2B expressing cells, whereas this activation was 
attenuated in LMP2A expressing cells, demonstrating an ability of LMP2A to dampen EBER 
induction of IFNβ expression. This is important in the context of virus infection, where the 
EBER RNAs are always expressed. The interchangeable roles of IRF7 and IRF3 in TLR 
signalling pathways (Barnes, Richards et al. 2004) was not examined and as such it is shown that 
modulation of signalling by LMP2A is known to be contained to early signalling events prior to 
expression of IRF7. IRF7 expression however relies on type I interferon signalling and given that 
LMP2A modulates IGSF3 formation it is likely that IRF7 mediated TLR signalling would also 
be attenuated. Whether the activation of IRF7 is directly affected by LMP2A remains a future 
avenue of research.  
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NFκB activity was also examined by luciferase activity to further characterise the effect 
of LMP2A on TLR-mediated activation of the IFNβ promoter. Here it was surprising to see a 
primed NFκB response given the aforementioned effects on IRF3 activation and IFNβ promoter 
activity. These effects were most striking in the context of TLR3 stimulation in response to 
poly(I:C) stimulation, whereas stimulation with the remaining four TLR agonists (TLR 4,7,8,9) 
showed dampened responses in NFκB activity. Here, LMP2A appeared to augment the primed 
response. Indeed immunofluorescent staining for p65 pre- and post-stimulation shows that p65 
nuclear translocation is increased in the presence of LMP2A. Again this can only be attributed to 
the route by which these TLRs induce IκBα phosphorylation and degradation, with TLR3 
signalling only through TRIF-mediated pathways with the remaining receptors facilitating signal 
through MyD88 (Sandor and Buc 2005). This hypothesis holds up in the case of TLR4 signalling 
as this pathway preferentially activated IRF complexes via TRIF in early cascades and utilises its 
MyD88 adaptor capacity for additional signalling (Shen, Tesar et al. 2008). 
 Inactivation of IRF3 by LMP2A and hyper-activation of p65 are results that appear to be 
antagonistic to one another especially given the binding of both factors in the enhancesome 
complex (Panne 2008). EMSA analyses of two of the four domains of the IFNβ promoter 
element produced results in agreement with dampening of IFNβ production by LMP2A. IRF3-
IRF7 hetero/homo-dimers bind to PRDI while NFκB p65 subunits bind at PRDII. Upon 
stimulation with poly(I:C), binding of protein complexes to both sites were decreased in cells 
expressing LMP2A, whereas robust binding was observed in control and LMP2B expressing 
cells. These findings demonstrate the indispensable nature of IRF subunit binding in controlling 
this promoter and, although NFκB activity is increased, p65/p50 subunits cannot bind to PRDII 
domains without the co-operative binding of the remainder of activated IRF dimers. A general 
consensus sequence for NFκB activity did however demonstrate that binding of these subunits 
was effective elsewhere. 
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Physiologically in the context of cytokine release, LMP2A for the most part augments 
the production and secretion of pro-inflammatory cytokines. Basally this disparity is evident but 
it becomes much more pronounced upon analysis of cells post-stimulation with the TLR3 and 
TLR4 agonists, poly (I:C) and LPS. Production of these increased levels of cytokines fits nicely 
with a situation where NFκB activity is “primed” and becomes hyper-activated in LMP2A 
expressing cells. Two of the cytokines examined however displayed decreased levels in LMP2A 
expressing cells. These cytokines, RANTES/CCL5 and sICAM-1, are known to be under the 
control of IFNβ signalling through the type I response, and as such adds further weight to the 
ability of LMP2A to limit the induction of IFNβ. Taken as a whole, these findings suggest that 
LMP2A attenuates the induction of IFNβ-regulated cytokines, whilst augmenting the production 
of other pro-inflammatory cytokines. The observation that cytokine release is both augmented in 
some cases and decreased in others removes any ambiguity as to the specificity or efficacy of the 
experiment and indicates a situation where one signalling cascade is initiated and the other 
attenuated. The role of the lymphocyte infiltrate of NPC is a topic under current investigation 
and scrutiny and results such as these indicate that the situation may be more complex than first 
considered (Niedobitek, Young et al. 1992; Agathanggelou, Niedobitek et al. 1995; Wu, Chien et 
al. 2005), that the tumour cell may attract the infiltrate to promote an environment that is more 
permissive to tumourigenesis.  
Another aspect of this model of signalling modulation by LMP2A is the role of PI3K 
signalling. This pathway is engaged by LMP2A, section 1.5.3.2, which results in constitutive 
phosphorylation and activation of Akt. PI3K also plays a role in TLR signalling, in particular 
mediating the response through TLR3 (Schroder and Bowie 2005). Modulation of this signalling 
pathway could indirectly prevent IRF3 phosphorylation downstream of TLR3. Interference of 
TLR signalling by LMP2A would afford the virus a cellular context incapable of mounting or 
maintaining an “anti-viral” state. The contribution of LMP2A to NFκB signalling observed here 
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is at odds with previous data showing that the protein decreased the levels of IL-6 secretion, 
although these findings were based on deletion of LMP2A from the whole virus (Stewart, 
Dawson et al. 2004). Also experiments were performed in the adenocarcinoma cell line Ad/Ah, 
while here the cell lines used are either derived from squamous carcinoma of the head and neck, 
H103, or derived from NPC itself, CNE2. In the context of whole virus infection, the 
augmentation of LMP1 induced NFκB activity by LMP2A has been reported and the data 
presented here further implicate LMP2A in this signalling cascade (Dawson, George et al. 2001). 
Results of analyses using the EBERs reveal that although these RNAs can mount RIG-1 induced 
IFNβ activity, this is attenuated in the presence of LMP2A, facilitating EBER action without 
establishment of an innate immune response. 
The second area of investigation regarding the effect of viral protein expression on 
intracellular trafficking was undertaken to bridge the gap between the exclusive signalling 
modulation of the TLR network by LMP2A and the function of both proteins in controlling 
signalling through IFNαβR. The endosomal lysosomal network controls the endocytosis, 
degradation and recycling of signalling receptors, (Bonnerot, Briken et al. 1997; Lorenzo, Ploegh 
et al. 2001; Boulan, Kreitzer et al. 2008). Distortion of this network could account, in part, for 
the dampening of signalling allowing the virally infected cells to evade immunosurveillance. 
Although effects of LMP2A and LMP2B on modulation of the endosome/lysosomal network 
have been uncovered, the mechanism(s) involved have yet to be elucidated. It was thought that 
the effect of the viral proteins on endosomal traffic may also play a role in modulation of TLR 
signalling, given that the receptors investigated, with the exception of TLR4, bind to, signal from 
and are activated by ligands recognised within the endosome (Colonna 2007). However although 
the numbers and apparent activities of these compartments are altered, the fact that LMP2B 
expressing cells displayed no differences in levels of TLR signalling discount this possibility. In 
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these cells although movement of compartments is augmented it is hypothesised that this does 
not distort ligand:TLR binding and activation. 
Early endosomes are responsible for the endocytosis and sorting of membrane bound 
receptors in order to facilitate signalling and receptor turnover (Woodman 2000). 
Characterisation of endosomes has been aided by the identification of markers specific to 
compartments involved in different stages of vesicular trafficking enabling early and late 
endosomes to be distinguished (Stenmark and Olkkonen 2001; Barnekow, Thyrock et al. 2009). 
Rab5 is a marker of the early endosome, immuno-blotting using whole cell lysates showed an 
increase in expression in the presence of LMP2A and LMP2B. Immunofluoresence staining and 
confocal imaging revealed that this was due to an increase in the numbers and/or formation of 
early endosomes. A similar scenario emerged when analysis of Rab7 was undertaken, indicating 
that late endosome numbers also appeared to be increased. Rapid endocytosis from the 
membrane of MHC molecules is a mechanism utilised by many viruses in evading immune 
surveillance (Ishido, Wang et al. 2000), section 1.9.6. The K3 and K5 proteins of KSHV, section 
19.6.2, are known to exert this effect on both MHC molecules and the IFNγ receptor (Li, Means 
et al. 2006). It is hypothesised that the increased number of early endosomes observed in 
LMP2A and LMP2B expressing cells may increase the turnover of cell-surface receptors or 
membrane associated proteins, which may include the IFNRs or TLRs. Pulse-chase experiments 
using fluorescently-labelled ligands would provide an indication that the level of endocytosis in 
these cells is increased, thus accounting for increases in the number of membrane-associated 
early vesicles.    
As described in section 1.9, binding of Rab GTPase effector proteins is necessary and 
important for compartmental conversion events. This machinery is adaptable and significant 
overlap exists between the Rab proteins involved in its regulation (Rink, Ghigo et al. 2005) 
allowing Rab5 positive endosomes to progress to sorting Rab4 positive endosomes and switch to 
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Rab7 positive late endosomes (Barnekow, Thyrock et al. 2009). Findings presented here show 
that LMP2A and LMP2B localise to early endosomal rather than in late endosomal 
compartments. Increases in expression of EEA1 a Rab5 effector protein (Simonsen, Lippe et al. 
1998; Christoforidis, McBride et al. 1999) indicates that Rab5 activity may also be increased 
which could facilitate compartmental conversion more rapidly, increasing the movement of 
cargo through the cell. The sorting endosome or MVB is designated by the expression of both 
Rab4 and Rab11 and future work will focus on this as one possible site for LMP2’s interference 
with the pathway (McCaffrey, Bielli et al. 2001), with a putative role for the Nedd4-like 
ubiquitin ligase binding domain of LMP2A possibly influencing sorting of proteins by 
ubiquitination (Longnecker, Merchant et al. 2000; Winberg, Matskova et al. 2000; Piper and 
Luzio 2007). It is suggested that disruption of activity here could redirect cargo to be degraded 
rather than recycled, accounting for an attenuation in receptor signalling.  
Rab7 is as mentioned a marker for late endosomes but is also expressed on the 
membranes of lysosomes (Bucci, Thomsen et al. 2000). The lysosome is the degradative vacuole 
of the cell, the acidic luminal environment coupled with the presence of acid hydrolases 
facilitate, ligand-receptor de-coupling and degradation of endocytosed particles (Eskelinen, 
Tanaka et al. 2003). Live cell confocal microscopy demonstrated that lysosomal number was 
increased in LMP2A and LMP2B expressing cells and that the lysosomes of these cells were also 
more acidic. The nature of these experiments allowed identification of the lysosome using one 
dye and the concomitant identification of acidification using another. The dyes are endocytosed 
and thus follow the pathway through the trafficking network, using time capture it was 
demonstrated that movement of the dye is markedly faster in LMP2 expressing cells. There are 
two main theories accounting for this, firstly the overabundance of lysosomes may facilitate 
uptake of the dye more quickly or given the increases in early endosome number that the 
shuttling of endocytosed material in LMP2 expressing cells is augmented. Techniques using this 
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type of live imaging are being optimised to allow comparison of the traffic of labelled receptors 
between LMP2 positive and negative cells.  
Increases in lysosomal acidity may also in part be attributed to self-aggregation of the 
viral proteins on internal membranes. Interaction of these aggregates with the vacuolar ATPase 
machinery could account for such increases, or indeed the aggregates themselves could act as 
porin-like structures. It is shown here that expression of a component of this complex, Ductin, is 
increased upon LMP2A and LMP2B expression, although this can be attributed to an increase in 
lysosomal number, rather than an increase in numbers and activity of endogenous vacuolar 
ATPase complexes. While it is tempting to hypothesise that LMP2 could exert such effects, a 
significant degree of co-expression was not observed between the viral protein and the lysosomal 
markers. This could be due to the detection system currently used for LMP2 but it is more likely 
to be indicative of an indirect LMP2 effect. While initially these analyses were performed to 
define a mechanism for dampening of innate immune signalling, increased intra-cellular traffic 
could have far reaching effects on signalling responses controlled by other receptors, such as the 
EGFR (epidermal growth factor receptor). This receptor initiates signalling via MAPK and Akt 
to control cell motility and proliferation (Miller and Raab-Traub 1999; Repetto, Yoon et al. 
2007), is regulated through tyrosine kinases and is a target or viral oncoproteins including, E5 of 
papilloma viruses BPV and HPV16, which has been shown to alter trafficking to prevent MHC 
presentation, (Thomsen, Deurs et al. 2000; Marchetti, Ashrafi et al. 2006). The ability of LMP2A 
to sequester tyrosine kinases and the ability of LMP2A and LMP2B to alter membrane traffic 
may play a role in distortion of EGFR signalling, which may promote tumorigenesis (Lu, Lin et 
al. 2006; Sandilands and Frame 2008).  
The necessity of the internal membrane localisation of the LMP2 proteins in order to 
exert these effects is demonstrated clearly upon generation and expression of the loop deleted 
mutants of this transmembrane region, Chapter 3. Expression of these proteins reversed the 
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increase in lysosome formation once membrane attachment was lost. Little is known about the 
activity of the transmembrane domains apart from membrane anchoring, (Tomaszewski-Flick 
and Rowe 2007). Here it is shown that proteins appear increasingly unstable after deletion of 
loop 4 and that this unstable unbound protein exerts little or no effect on lysosome formation. 
Previous published data revealed that these transmembrane domains were necessary for internal 
membrane anchoring and that the carboxyl-terminus domain was responsible for self-aggregation 
of the protein, (Rowe and Tomaszewski-Flick 2007). Most of the current research of these 
proteins focuses exclusively on the role of the signalling domain unique to LMP2A, while 
investigations into the role of LMP2B in the B-cell context have focused on its apparent ability 
to modulate these signals (Rovedo and Longnecker 2007; Rechsteiner, Berger et al. 2008; 
Rechsteiner, Bernasconi et al. 2008). Generation of the loop-deleted mutants of the proteins 
allows in depth analysis into the role of the LMP2B protein while also highlighting the 
importance of certain transmembrane domains for the function of LMP2A. Although these 
studies remain in their infancy it is believed that generation of cell lines stably expressing these 
truncated proteins will underpin the importance of certain domains within the transmembrane 
portion of the protein in controlling the localisation of the protein and its ability to induce its 
effect on endomembrane dynamics. While not presented here, a bioinformatic examination of 
these domains has revealed putative myristylation consensus sequences, which could account for 
the binding of LMP2A and LMP2B to lipid rafts on intracellular membranes of epithelial cells. 
Such a location allows the proteins to alter the endosomal to lysosomal trafficking network, 
which as demonstrated results in modulation of signal from certain classes of immune receptors. 
In B-cells, the association of LMP2A with lipid rafts allows this viral protein to act as a surrogate 
BCR; indeed, recent studies show that this ability is dependent on cholesterol (Ikeda and 
Longnecker 2007). Similar cholesterol depletion experiments are currently being performed to 
characterise whether lipid rafts in epithelial cells are the sites of LMP2 action. Interactions 
 295
Chapter 6  Discussion 
between phospho-lipids and proteins are a fundamental part of intracellular traffic and signal 
transduction. PI3K pathways have been shown to be involved in Rab5 activation, further 
implicating LMP2A’s modulation of this pathway as a possible mechanism of endosomal 
distortion (Horiuchi, Lippe et al. 1997; Hirota, Kuronita et al. 2007). The Tip protein of HSV 
may also illuminate a potential mechanism for this interaction as it also binds to lipid rafts and 
modulates cell signalling, specifically TCR by interaction with STAT3 (Cho, Kingston et al. 
2005). It is known that these lipid rafts serve as a base for creation of “signalosome” complexes 
and immunological synapses, it is possible that distortion of these raft structures by the presence 
of the LMP2 proteins could modulate formation and disassociation of receptors, ligand and 
adapter proteins. It is possible that the signalling effects seen upon LMP2A expression result 
from the interaction of its amino-terminal domain upon distortion of lipid rafts, possibly 
explaining the apparent disparity in function of these two viral proteins. Further analyses with 
these mutants would allow a clearer understanding of the influence binding of these proteins to 
lipid rafts have on membrane mechanics. 
In conclusion, novel functions of the LMP2 viral proteins have been identified 
highlighting the function of these proteins in promotion of latency and tumourigenesis by innate 
immune evasion. Signalling through TLRs is modulated upon expression of LMP2A but is not 
affected by LMP2B, while endosomal trafficking and the putative effect of this on receptor 
signalling is altered by both transmembrane proteins. Taken together these data demonstrate the 
unique signalling potential of the amino-terminal signalling domain of LMP2A while also 
illustrating the result of intracellular membrane binding by the transmembrane regions of both 
proteins. 
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